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Abstract 
 
Erythrocyte invasion is a key step in the Plasmodium life cycle. This process is tightly 
regulated, involving the sequential release of specialised apical secretory organelles – 
the micronemes, rhoptries and dense granules. These organelles contain proteins 
required for invasion and establishment of the parasitophorous vacuole, but most of the 
proteins remain uncharacterised. 
 
The aim of this project was to uncover novel proteins with a role in invasion by the 
human malaria parasite Plasmodium falciparum merozoites. I identified proteins using 
the following selection criteria: a) expression in the schizont/merozoite form of the 
parasite; b) conservation across the genus; c) the presence of a signal peptide and d) one 
or more transmembrane (TM) domains. A list of 64 proteins was identified, and filtered 
further based on novelty, presence in the merozoite proteome, expression in other life 
cycle stages, and difficulty of study.  
 
Five proteins were selected, and I produced recombinant protein and raised antibodies 
against three, which I used to identify the sub-cellular location of the protein within the 
parasite. The proteins appear to reside in either the rhoptries or the endoplasmic 
reticulum of the merozoite. Attempts were made to epitope-tag and delete all 3 genes, 
with a focus on one protein, the type IV Hsp40, PF11_0443. This protein contains two TM 
domains and is expressed during schizogony. By immunofluorescence it is present in the 
ER of early schizonts, before accumulating at the apex of merozoites in a rhoptry 
location. Immunoprecipitation experiments indicated that the protein binds known 
rhoptry proteins and other chaperones. The protein has been epitope-tagged but 
attempts to delete the gene by genetic recombination were unsuccessful. The gene is 
conserved in Plasmodium spp. and there are orthologues in higher eukaryotes, but it is 
absent from other Apicomplexa. Current studies are focused on the role of this protein 
in erythrocyte invasion. 
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1. Introduction 
 
1.1 Malaria and global health 
 
With an estimated 655,000 deaths, 216 million clinical episodes and over 3 billion people 
at risk in 2010 (WHO, 2011), malaria has a devastating impact on global health.  
Harrowing as these figures are, a recent study by Murray et al. (2012) suggests the actual 
number of annual deaths may be double that published in the WHO report, estimating 
the total number of global deaths due to malaria in 2010 at 1,238,000 (Murray et al., 
2012). Malaria is primarily a disease of the tropics due to the habitual constraints of the 
definitive host and vector, the Anopheles mosquito, and its effects are more drastic in 
developing nations. An estimated 81% of clinical episodes and 91% of mortalities were 
in the African continent in 2010 however 99 countries worldwide present ongoing 
transmission (figure 1.1), including many regions across South America, India and South 
East Asia. Children under 5 years of age are most at risk of fatal outcome, accounting for 
86% of deaths due to malaria (WHO, 2011). Other major risk groups include pregnant 
women and ‘non-immune’ adults or travellers. The disease varies in severity and can be 
categorised according to the symptoms the patient presents: uncomplicated malaria 
patients present fever and mild malaria anaemia; complicated and severe malaria 
symptoms additionally include severe anaemia, respiratory distress, metabolic acidosis, 
organ failure, mortality; and Cerebral Malaria, which is the most fatal presentation of the 
disease, and results in severe neurological symptoms, coma and death (WHO, 2000).  As 
well as morbidity and mortality, there is a socio-economic cost associated with the 
disease. With the expense of treatment and the loss of a workforce through sick-leave, 
countries where malaria is endemic rarely attract foreign investment and face reduced 
economic growth as a result (Gallup and Sachs, 2001), which is precisely what these 
countries need to implement the necessary infrastructure which will ameliorate the 
burden of malaria. 
 19
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Global likelihood of death due to malaria in 2010. World map depicts the 
cumulative probability of death due to malaria in the absence of other cause from birth 
until aged 80 years in each country in 2010. Countries are colour coded based on 
percentage probability: 0-0.1% - deep blue; 0.1-1% - mid-blue; 1-5% - pale blue; 5-10% - 
pale purple; 10-20% - pale pink. No countries presented greater than 20% chance of 
death due to malaria. Countries with no transmission are pictured in white. While the 
majority of deaths occur in sub-Saharan Africa, large parts of South and South East Asia 
as well as Indonesia and south pacific islands face a substantial threat. Although South 
America experiences a large volume of cases of malaria, it is more usually caused by P. 
vivax which is rarely fatal. Adapted from (Murray et al., 2012). 
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1.2 Malaria: a history in brief 
 
Malaria has been the scourge of the tropics for millennia and was most likely present in 
the earliest human populations (Brier, 2004). Paleopathological studies of mummified 
human remains from ancient Egypt identified several specimens exhibiting porotic 
hyperostosis (cranial thickening which is indicative of severe anaemia) and 
splenomegaly (enlarged spleen), common symptoms of malaria (Brier, 2004). As the field 
advanced, molecular biology techniques were able to validate the presence of malaria in 
ancient Egypt: a genetic study by Hawass et al. (2010) revealed King Tutankhamun (c. 
1333-1324 BC) suffered from malaria although whether this caused his early death 
remains controversial (Hawass et al., 2010; Timmann and Meyer, 2010).  Malaria is 
thought to have spread out of Africa along shipping routes to India, South East Asia, 
China and also parts of Europe. Hypocrates (460 – 370 BC) of ancient Greece and Celsus 
(25 BC – 54 AD) of ancient Rome both provided written accounts of the clinical 
presentations of what we now know as malaria. It was the Romans who named the 
disease ‘mal aria’ meaning ‘bad air’, as they attributed the fevers to noxious vapours 
arising from the stagnant waters of the marshlands surrounding Rome. The draining of 
the marshes and consequent reduction of malaria episodes gave weight to their 
hypothesis but it would be nearly 2 millennia before the true cause of the disease was 
uncovered [reviewed in (Cunha and Cunha, 2008)]. 
 
Although several theories were put forward since the fall of the Roman Empire, few 
major scientific break-throughs were made regarding malaria until 1880, when a French 
clinician named Alfonse Laveran working in Algeria noted the presence of black 
pigment in the spleen and brain of his patients that died of malaria. He consequently 
studied the blood of malaria patients until finally witnessing the exflagellation of a 
gametocyte. This confirmed his suspicion that the disease was of parasitic origin, and 
not bacterial as had previously been suggested (Garnham, 1966). The observation of 
what was termed ‘filariae of the blood’ until later classified under the genus Plasmodium, 
as the causative agent of malaria, kick-started a new age of malaria research. The 
discovery of the parasite led to the question of transmission and research into the vector 
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responsible was top priority. Although suspected throughout history by doctors and 
philosophers from different nations, there was no evidence to link the occurrence of 
malaria with the mosquito. That was until Surgeon-Major Ronald Ross, aided in his 
observations by Dr. Patrick Manson, in 1897 identified the presence of the malarial 
parasite in the midgut of a particular and rare form of mosquito (later ascribed to the 
genus Anopheles) fed on the blood of malaria patients. The parasite was absent in the 
more common, grey coloured mosquito fed on malarial blood and also in Anopheles 
mosquitoes fed on healthy individuals. Ross also observed the presence of ‘germinal 
rods’ (sporozoites) in the salivary glands of mosquitoes and concluded the mosquito 
bite to be the method of host transfer of the parasite (Ross, 1897; Manson, 1898; Ross, 
1898). Although Ross was able to demonstrate transmission from insect to host in birds 
with avian malaria, the first experimental evidence of mosquito-to-man transmission 
was provided in 1899 in Rome by Bignami and Grassi who were able to follow the 
parasite’s lifecycle to completion and their experiments were repeated and confirmed 
by Dr. Patrick Manson in London a year later (Grassi and Noe, 1900; Manson, 1900).   
Since then, efforts in mosquito control including destruction of mosquito breeding 
grounds, distribution of bed nets and insecticide sprays, have resulted in a reduction of 
incidents of malaria in the developing world and eliminated malaria from much of the 
developed world where countries boast the infrastructure and capital to effectively 
control the spread of disease. Major break-throughs in scientific research such as the 
adaptation of Plasmodium falciparum to long term in vitro culture (Trager and Jensen, 
1976), the sequencing of the P. falciparum genome (Gardner et al., 2002) and 
development of various animal models have aided drug and vaccine research 
immensely. Despite all this, malaria persists and devastates the tropics to this day.  
 
1.3 How do you solve a problem like malaria? 
 
Any strategy for control and eventual eradication of such a complex and multifaceted 
disease as malaria must encompass multiple and complementary methods, and should 
be approached with extreme caution. The WHO’s Global Malaria Eradication Program, 
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adopted in 1955, saw the mass application of DDT to eliminate mosquitoes (WHO, 1956). 
The program succeeded in eliminating the disease from Europe, North America and 
Australia however, due to the publicly controversial and adverse environmental side 
effects as well as the eventual emergence of resistance to the insecticide, the 
programme was abolished in 1972. As a result of the failure to completely disrupt 
transmission in sub-Saharan Africa, malaria returned to equivalent or greater levels than 
before the control strategy was implemented.  
 
With an injection of funding from the Bill and Melinda Gates Foundation, there has been 
a renewed drive for eradication of malaria in recent years from charities and other 
organisations, primarily focussing on controlling the mortality and morbidity of the 
disease. In 2011, after a 2 year consultation period, the newly established Malaria 
Eradication Research Agenda (malERA) set out to complement the ongoing work of 
charitable organisation and government initiatives but with the goal of reducing the 
reproductive rate of Plasmodium to less than 1 and ultimately removing it form the 
human population (Alonso et al., 2011) These programs exist to consolidate and 
strategise the best use of all the anti-malarial weapons in our armoury and to ensure 
new tools are being developed where needed. Current methods of malaria prevention 
and treatment include vaccines, anti-malarial drugs, vector control and improving 
infrastructure and monitoring. 
 
1.3.1 Vaccines 
Regardless of its aptitude for immune evasion, natural immunity to Plasmodium is 
acquired over time, increasing in efficiency with each exposure (Day and Marsh, 1991). 
This non-sterile immunity allowing a low level or parasitaemia to persist in the absence 
of symptoms is called premunition. Passive transfer of anti-Plasmodium antibodies from 
hyper-immune individuals ameliorates disease and confers protection to non-immune 
adults (Sabchareon et al., 1991). Taken together, this suggests a successful vaccine 
against the parasite is feasible and would represent a beneficial boost to our immune 
defence. Despite being commercially unattractive, a malaria vaccine could be one of the 
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most cost effective methods of eradicating malaria. Developing a successful vaccine is 
the major goal of several laboratories worldwide and has been for over 40 years; 
however this has proved to be more difficult than first anticipated. Vaccine candidates 
can be split into three groups: those aimed at blocking infection targeting the 
sporozoite stage parasites before they enter the host liver; disease blocking vaccines 
targeting blood stage parasites which are responsible for disease symptoms; and 
transmission-blocking vaccines that target the sexual stage of the parasite, preventing 
development in the mosquito. Transmission blocking vaccines are the least developed 
and ethically difficult to promote as the vaccine will not benefit the vaccinee in the short 
term as it will not protect from disease. It also requires high coverage of community 
participation to break the transmission cycle from the human to the mosquito. Disease 
blocking vaccines targeting the blood stage aim to prevent severe malaria and death 
without preventing the initial infection. A large number of potential antigens have been 
put forward as vaccine candidates for a disease blocking vaccine. Merozoite surface 
proteins, in particular merozoite surface protein (MSP)-1 were initially of interest due to 
their abundance. Other candidate antigens include MSP-2, -3, -4, -5, -8, -9, serine repeat 
antigens (SERAs), apical membrane antigen (AMA)-1, glutamate rich protein (GLURP), 
the erythrocyte binding antigens (EBAs) and the Rh family proteins.  Although 
promising, due to polymorphisms, strain variability, multiple invasion pathways and the 
lack of correlation between animal models and protection in the field, few of these 
candidates have progressed in clinical trials. Infection blocking vaccines are by far the 
most successful to date. As early as 1967, Nussenzweig et al.demonstrated in mice that 
immunisation with irradiated sporozoite stage parasites conferred protection from 
subsequent infection (Nussenzweig et al., 1967). Today, the infection blocking vaccine 
RTS,S, produced by GlaxoSmithKline (GSK) and the Walter Reed Army Institute of 
Research, is the world’s leading vaccine candidate. Comprised of the C-terminus of the 
circumsporozoite protein (CSP) fused to hepatitis B surface antigen in the form of virus 
like particles (VLPs), it is at present in phase III clinical trials however early results suggest 
it is delivering an efficacy of only around 50% in first time episodes (Agnandji et al., 
2011).  
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1.3.2 Anti-malarial drugs 
In a disease that has been around since antiquity, the discovery and development of 
effective remedies over time is to be expected. Quinine, extracted from the bark of the 
cinchona tree, was used by native South Americans to relieve fever and has been used in 
anti-malarial therapy since its introduction to Europe in the 17th century. Although 
effective, quinine produced undesirable side effects and after a long period of use, the 
parasite finally developed resistance in 1910 (Achan et al., 2011)). The drug chloroquine, 
a quinine derivative, was developed in the early 20th century and quickly replaced 
quinine as the drug-of-choice in the treatment of malaria. Not only was it an extremely 
effective anti-malarial, it was cheap to manufacture and therefore suitable for 
distribution amongst the developing world. Its success also led to its downfall, as heavy 
application eventually led to the emergence of resistance, first detected in P. falciparum 
around the Thailand-Cambodia border and in Colombia in the late1950s before 
spreading throughout the world over a 20 year period (Payne, 1987). Several drugs have 
been developed and distributed since then, however in time resistance has arisen to 
almost all of them. The current drug-of-choice in the treatment of malaria is artimisinin, 
derived from the white flowering plant Artemisia annua. It was first noted to display anti-
malarial properties in 340 B.C. by the alchemist Ge Hong of the East Jin Dynasty. Over 2 
millennia later, the active ingredient derived from this plant was identified and 
produced in tablet form. In order to delay the emergence of resistance to the drug, 
Professor Zhou Yiquing of the Chinese Academy of Military Medical Sciences developed 
the first artemisinin-based combination therapy (ACT), Coartem, which incorporates an 
artemisinin derivative, artemether in combination with lumefantrin (Weiyuan, 2009). 
Unfortunately the first case of artemisinin resistance was reported in Cambodia in 2009 
(Dondorp et al., 2009). Although the WHO, local governments and charities endeavoured 
to prevent it, artemisinin resistance has reached Myanmar (Phyo et al., 2012), and 
authorities now fear its dispersal through to India and the rest of the world is inevitable.  
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1.3.3 Vector control 
Vaccines boost natural immunity to a disease and drugs treat the disease which has 
already taken its toll on the body, but perhaps the most thorough method of preventing 
the problem of malaria is to remove the agent of its dispersal. A programme of indoor 
residual spraying (IRS) with pyrethroid insecticides in households combined with long 
lasting insecticide-impregnated nets (LLINs) has been employed in a number of malaria 
endemic countries (WHO, 2010). Although this may be effective in controlling malaria in 
areas of low-moderate transmission, areas of high transmission will require additional 
control mechanisms to prevent the disease (Control, 2011; 
malERA_Consultative_Group_on_Vector_Control, 2011). These control mechanisms are 
preventative only in areas where pyrethroid susceptible mosquitoes predominate, 
several species of Anopheles are now resistant to these insecticides (Ranson et al., 2009). 
Also, a number of Anopheline species feed and rest outdoors and are therefore not 
targeted by IRS and LLINs. Research and development of new insecticides as well as 
application strategies to include outdoor feeders should be a priority if malaria 
transmission is to be controlled in areas of high endemicity. In such areas, it would be 
prudent to employ additional, long term approaches to decrease or halt transmission. 
Genetic approaches are being developed to reduce the capacity of natural Anopheles 
populations to act as vector for the parasite. This includes vector replacement strategies 
using mosquitoes which are resistant to Plasmodium  or those which are killed upon 
infection with Plasmodium spp. (Terenius et al., 2008). Other novel approaches to vector 
management target the mosquito environmentally (e.g. eliminating breeding grounds), 
biologically (e.g. niche competitors, insect pathogens, plasmodicidal symbiotic 
organisms) and chemically  (e.g. new effective insect repellents,).  
 
1.3.4 Infrastructure, Monitoring and Diagnostics 
Frustrating though it may be to a scientist, the sad fact remains that the countries worst 
affected by malaria are those which lack the proper infrastructure to deal with it; a 
problem antagonised by tyrannic regimes, corruption and civil war. Something as simple 
as better housing design that limits mosquito entry would have a dramatic impact on 
transmission. Access to antimalarial drugs is another limiting factor.  In rural areas of sub-
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Saharan Africa patients are required to travel miles to reach a clinic and clinics struggle 
to keep up drug reserves due to problems with delivery.  Patients require rapid diagnosis 
and application of treatment if they are to survive the infection; efficient health systems 
need to be in place across all malaria endemic countries in order to support a permanent 
block in malaria transmission. As the economies of the worst effected countries are 
unlikely to change while malaria is rife, charitable organisations and international aid 
must be relied upon to introduce the necessary infrastructure to combat malaria.  
 
1.3.5 Combine and conquer?  
Elimination is not achievable at the individual country level; if eradication was achieved 
in one country, any bordering countries with moderate malaria transmission would 
inevitably re-introduced malaria via migrants and travellers. Eradication must be a global 
effort, using strategic combinations of tools to permanently interrupt transmission of 
the parasite. Education and training regarding drug administration as well as schemes to 
ensure drug supplies remain stable will enable early diagnosis and treatment, limiting 
the transmission of sexual stage parasites to mosquitoes and therefore the spread of 
malaria. Attacking both indoor and outdoor feeding mosquitoes with insecticide will 
limit the transmission to humans however finding a long term solution to Plasmodium 
susceptible mosquitoes is important. In the event of insecticide or antimalarial drug 
resistance, a now non-immune population would be exposed to a pathogen they are no 
longer prepared to fight. Vaccines will be necessary here, as if malaria resurges in 
insecticide resistant mosquitoes or with the reintroduction of susceptible mosquitoes, 
vaccination will ensure a certain amount of immunity persists. Animal reservoirs are 
difficult to control and must also be eliminated if a complete block in transmission is to 
be achieved. Although western lowland gorillas in Africa are capable of transmitting P. 
falciparum evidence suggests this is not a regular occurrence. The simian malaria P. 
knowlesi is readily transmitted to humans in SE Asia from Macaques however there is 
limited evidence of human to human transmission.  With thorough monitoring, it is 
hoped that these zoonoses will not present a significant threat to global malaria 
eradication.  
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Research into the parasite, vector and host biology is absolutely necessary to develop 
the highest quality tools to combat malaria. Thus far, the development of an effective 
vaccine remains elusive. With the continuing spread of drug and insecticide resistance, 
research into novel vaccine candidates is vital to the success of eradicating the disease. 
 At present and until artemisinin resistance spreads, ACTs are the best method of 
treatment for those who have access or can afford it, however for the areas most in need 
cost is a major issue and inexpensive alternatives must be found. Current anti-malarial 
drugs are based a small number of chemical structures that act on a relatively few 
targets and further research should aim to expand this list. The ideal drug, as set out by 
the malERA initiative, should be: able to provide a single encounter radical cure and 
prophylaxis (SERCaP); effective against all human infecting species of Plasmodium 
including P. vivax long-lived hypnozoites; kill 100% of parasites in an infected person; 
suitable for mass administration (includes cost effectiveness and safety record); and able 
to be used as prophylaxis for a period that will see the effects outlive the mosquito stage 
of Plasmodium lifecycle (minimum of1 month post treatment) 
(malERA_Consultative_Group_on_Drugs, 2011). This mythical drug may seem like the 
stuff of fiction but with continuing research into the right target, who is to say that it will 
not be brought to life? 
 
1.4 Introducing the protozoan problem parasite, Plasmodium 
 
Malaria is caused by the protozoan micro-parasite Plasmodium, belonging to the phylum 
Apicomplexa, within the superphylum Alveolata (depicted in figure 1.2). This group of 
unicellular eukaryotes contains a number of perilous pathogens of medical and 
veterinary (and therefore economic) importance. One such Apicomplexan, Toxoplasma 
gondii, commonly infects humans following contagion from the faeces of feline house-
pets or by consumption of infected livestock. Due to their penchant for under-cooked 
meats, up to 60% of the inhabitants of Southern Europe are positive for T. gondii (Pappas 
et al., 2009). This infection has no obvious side effects unless contracted during 
pregnancy (Desmonts and Couvreur, 1974); or contracted by the immuno-compromised 
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and is therefore a major complication during the onset of acquired immunodeficiency 
syndrome (AIDS) (Luft et al., 1993). T. gondii has been referred to as the ‘model’ 
Apicomplexan due to its superior genetic tractability compared with Plasmodium and is 
therefore easier to study (Kim and Weiss, 2004). Much of what we know of Plasmodium in 
terms of molecular biology was first discovered in Toxoplasma. Humans also play host to 
Cryptosporidium spp., causing a severe gastroenteritis. Neospora caninum presents a very 
similar infection to Toxoplasma albeit with slightly different host preference – a canine 
instead of feline definitive host and where Toxoplasma is common is sheep, and N. 
caninum is prevalent in cattle and no infections have been recorded in humans unlike 
Toxoplasma (Dubey, 2003). Fellow coccidian Eimeria causes a gastro-intestinal infection 
in chickens (reviewed in (Allen and Fetterer, 2002). Theileria and  Babesia spp. are a 
particular pest to agriculture, causing serious disease in cattle and resemble Plasmodium 
in as much as  merozoite stage parasites infect erythrocytes, (Shaw, 2003; Yokoyama et 
al., 2006) 
 
There are in existence approximately 450 species of Plasmodium, each infecting a 
diverse group of organisms (Perkins and Schall, 2002). Numerous genera of mammals, 
birds and reptiles are susceptible to particular species of Plasmodium. While avian 
malaria can be transmitted by several different genera of mosquitoes, Anopheles 
mosquito is solely responsible for transmission and spread of the parasite in mammals. 
In humans, Anopheles gambiae, An. arabiensis, An. melas and An. merus are the 4 main 
dominant vector species responsible for the majority of transmission in sub-Saharan 
Africa and consequently the most devastating species of mosquito in terms of human 
life (Sinka et al., 2010). Four species of Plasmodium primarily infect humans; P. vivax, P. 
ovale, P. malariae and P. falciparum; the latter being responsible for the majority of 
fatalities due to malaria worldwide. The other species cause considerable morbidity 
however infections are rarely fatal although P. vivax malaria is particularly rife in South 
America and can cause recurrent bouts of disease from a single infection. A fifth human-
infecting species, the simian malaria P. knowlesi, has been discovered in rural areas of 
Malaysia and other parts of SE Asia to infect humans and although only recently 
revealed to be a human pathogen, it has most likely been misdiagnosed in the past, 
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mistaken for P. malariae due to morphological similarities despite failing to test positive 
for P. malariae by PCR (Singh et al., 2004). Unlike the other Plasmodium spp., P. knowlesi 
has a 24 hour lifecycle therefore parasite burden will increase more rapidly and febrile 
episodes associated with red blood cell rupture and parasite exit will become more 
frequent, resulting in a more aggressive infection. Although P. knowlesi research is in its 
infancy, early evidence suggests the mortality rate is comparable to that of P. falciparum 
of those positively diagnosed (Cox-Singh et al., 2008).  
 
 
 
 
Figure 1.2: Alveolate phylogenetic tree. The Phylogenetic tree is based on amino acid 
sequence alignments from 17 ribosomal proteins. The 3 major alveolate lineages – 
Ciliates, Dinozoa and Apicomplexa are highlighted with brackets. Adapted from 
(Bachvaroff et al., 2011). 
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1.4.1 What’s the problem with Plasmodium? 
A parasite should not kill its host.  It should keep its host alive for as long as possible in 
order to increase its transmission potential and spread, and therefore its success. So why 
is a disease that has been around since antiquity responsible for such a large number of 
deaths? Homo sapiens take at least 16 years to reach reproductive age therefore 
evolution on the side of the host is comparatively slow. Mutations in host haemoglobin 
are common in areas of high transmission however they, with the possible exception of 
the Haemoglobin E trait, confer a health disadvantage to the human host with varying 
severities of anaemia. Living with these haemoglobinopathies is almost as much of a 
burden as malaria itself, with 300,000 babies born with these genetic disorders every 
year (Weatherall et al., 2010). Erythrocyte surface proteins are also subject to selection. 
Heterozygotes for band 3 mutation that causes ovalocytosis are protected from cerebral 
malaria however homozygotes are non-viable and result in miscarriage (Jarolim et al., 
1991; Genton et al., 1995; Allen et al., 1999). Approximately 95% of the West African 
population are homozygous for a point mutation in the promoter of the Duffy antigen 
that results in a complete block of its expression. Given that the presence of this antigen 
is essential to permit P. vivax infection, West Africa is free from Plasmodium vivax malaria 
(Miller et al., 1976). 
 
The laws of natural selection would suggest the parasite would evolve to become less 
virulent and although P. vivax, P. ovale and P. malariae cause significant morbidity they 
rarely result in death, in contrast to P. falciparum which is often fatal. P. falciparum must 
possess an additional virulence factor not present in the other species. One possible 
reason for this difference in disease severity is thought to be the phenomenon of 
cytoadherence of parasite-infected erythrocytes to the blood vessel endothelium. 
During the intra-erythrocytic stage of the P. falciparum lifecycle the parasite exports its 
own proteins onto the red blood cell surface and in the case of P. falciparum the major 
surface molecule is erythrocyte membrane protein (PfEMP)-1. The parasite uses this 
ligand to cytoadhere to the blood vessel endothelium, allowing it to avoid clearance by 
the spleen. In doing so Plasmodium prolongs its life but also clogs the microvasculature, 
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restricting blood flow to organs of the body. Parasites can cytoadhere to the brain 
endothelium which is believed to contribute to cerebral malaria. In the worst cases this 
results in coma and death.  P. falciparum is capable of attachment to any of eleven 
endothelial receptors identified to date. This binding capacity varies between different 
strains and seems to be responsible for strain virulence - attachment to CD36 is common 
to all parasites and associated with uncomplicated malaria whereas binding of 
intercellular adhesion molecule (ICAM)-1 is elevated in severe and cerebral malaria 
(Newbold et al., 1997; Silamut et al., 1999; Ochola et al., 2011). PfEMP-1 also binds 
multiple uninfected red blood cells, cloaking itself from immune detection and shielding 
itself from immune clearance as well as keeping fresh rbc targets in close proximity. This 
phenomenon is known as rossetting and the ability to form rosettes is associated with 
severe disease (Rowe et al., 1995). P. falciparum contains around 60 copies of the var 
genes which encode PfEMP-1 and is able to switch which singular one is expressed on 
the erythrocyte surface, evading host immunity (Roberts et al., 1992; Smith et al., 1995). 
Antibodies to one PfEMP-1 molecule will not necessarily protect against another 
therefore natural acquired protective immunity will only build up after repeated 
exposure (Bull et al., 1998).  Cytoadherence is clearly an important virulence determinant 
in P. falciparum but what about other human-infecting species? Although P. vivax 
appears to possess sub-telomeric multi-gene families (Carlton et al., 2008), there is 
limited evidence of cytoadherence in vivax malaria and the molecular basis for 
pathology is poorly understood (reviewed in (Costa et al., 2011). Due to lack of fatal 
cases, in vitro culture and incomplete genome sequence; there is a lack of evidence to 
prove or deny cytoadherence of P. ovale and P. malariae however cerebral symptoms 
have not been reported for these malarias. There is one variant multi-gene family in P. 
knowlesi: the schizont-infected cell agglutination variant antigen (SICAvar) genes (al-
Khedery et al., 1999).  P. knowlesi infected erythrocytes have been demonstrated to 
cytoadhere ex vivo and there has been one fatal case where parasites were found in the 
brain however no cerebral malaria symptoms were reported (Fatih et al., 2012). This, 
taken together with the fact P. knowlesi may result in a comparable number of fatalities 
as P. falciparum, implies there is a correlation between cytoadherence ability and 
parasite virulence. 
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1.4.2 Plasmodium Life Cycle 
 
Plasmodium has a complex lifecycle involving the invertebrate definite host, the 
mosquito, and a vertebrate intermediate host which can range from reptiles and birds to 
mammals. Focusing on human infecting species of Plasmodium, the parasite is 
transferred to its host by the female Anopheles mosquito.  The sporozoite form of the 
parasite, temporarily lodging in the mosquito salivary glands, is deposited onto the skin 
with the mosquito’s saliva during a blood meal. The sporozoite uses gliding motility to 
traverse the various layers of the dermis and actively penetrates into the 
microvasculature (Amino et al., 2006). The parasite travels with the blood stream, stalling 
at the liver where it exits the blood vessel passing through sinusoidal cells of the liver 
capillaries, and glides through several layers of hepatocytes before selecting one to 
actively invade (Mota et al., 2002).  Host cell invasion requires the secretion of proteins 
from apical secretory organelles - the micronemes and rhoptries – and proteins 
contained in these organelles are required for attachment to, active invasion of, and 
establishment within the hepatocyte, forming a parasitophorous vacuole (PV) upon 
entry, in which it resides throughout this stage of the lifecycle. The parasite undergoes 
several rounds of asexual replication in hepatocytes, producing a hepatic schizont where 
large numbers of merozoites are produced. Merozoite stage parasites are able to invade 
red blood cells but first must be released safely from the liver. Although it was initially 
thought that merozoites were release upon hepatic schizont rupture, evidence from the 
murine malaria model, P. berghei reveals the formation of merosomes - large merozoite-
packed vesicles - which bud-off from the infected hepatocyte after the PV has broken 
down (Sturm et al., 2006). This has never been confirmed in any of the human malarias 
due to ethical and experimental difficulty. P. vivax and P. ovale produce a dormant stage 
hypnozoite during liver development that can result in relapse of the disease, however 
this is not seen in the other malarias (Krotoski et al., 1982; Cogswell et al., 1983). 
 
Merozoites released from hepatocytes enter the blood stream where the parasite must 
rapidly invade a new host cell to escape immune detection (discussed in detail in section 
1.5). The parasite selects which host cell to invade via interactions of merozoite surface 
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proteins (MSPs) with red blood cells (rbcs). Similar to invasion of hepatocytes by 
sporozoites, apical secretory organelles release proteins required for invasion onto the 
surface of the merozoite as well as into the rbc. A parasite molecular motor drives 
invasion, creating a PV upon entry through secretion of the contents of the rhoptries. P. 
falciparum develops within its vacuole over a period of 48 hours in visually discrete 
stages. The young trophozoite or ‘ring’ stage parasite, named after its appearance on a 
Giemsa-stained blood smear, describes the period of the intra-erythrocytic lifecycle 
immediately post-invasion (p.i.) and the following 24 hours where the parasite will begin 
feeding and establishing itself within the rbc, exporting a number of proteins and 
membranous structures into the rbc cytoplasm and onto the rbc surface. Once the 
parasite is established within its host, it undergoes a period of aggressive feeding and 
growth. This is typically around 24-32 hours post-invasion in P. falciparum and is known 
as the trophozoite stage. As increasing amounts of haemoglobin are digested, the haem 
by-products within the parasite’s food vacuole form haemozoin crystals that darken the 
appearance of the infected cells. The parasite will also begin to replicate its DNA at this 
stage, ready for later cell division. Schizont stage parasites are initially observed at 
around 32-34 hours post-invasion when nuclear division takes place. Daughter cell 
segmentation occurs at 45-48 h, completing cell division and producing up to 32 (more 
typically 16) merozoites (Bannister and Mitchell, 2003). Completion of replication is 
followed by a process known as egress, in which both PV and rbc membranes must be 
broken down in order to release daughter merozoites into the blood stream.  Prior to 
release, organelles referred to as the exonemes discharge the subtilisin-like serine 
protease (SUB)-1 into the parasitophorous vacuolar space (Yeoh et al., 2007) which is 
responsible for the necessary proteolytic processing of MSP-1, 6 and 7 precursor 
proteins (Koussis et al., 2009). This ‘priming’ of merozoite proteins is not sufficient for 
release; a cascade of kinases has proven to be essential in this process including calcium-
dependant protein kinase 5 (CDPK5) potentially acting first (Dvorin et al., 2010), followed 
by cGMP-dependant protein kinase (PKG) (Taylor et al., 2009) however the initial source 
of increased calcium levels required to activate CDPK5 is undefined and the effector 
molecule responsible for membrane rupture remains elusive. Upon release into the 
blood stream, primed and ready merozoites quickly identify new target cells via there 
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surface proteins and invade within 2 min of egress (Gilson and Crabb, 2009), completing 
one round of asexual development.   
 
It is the blood stage of the Plasmodium lifecycle that is responsible for disease 
symptoms. The intra-erythrocytic cycle is synchronised to host circadian rhythm thus 
schizonts will rupture within hours of each other (Hawking et al., 1968). A bombardment 
of foreign material bursts into the blood stream resulting in an acute pro-inflammatory 
response and consequential fever.  Fevers occur in multiples of 24h depending on the 
infecting species of Plasmodium. In more severe presentations of the disease, rbc 
rupture and diserythropoesis give rise to anaemia while cytoadherent infected rbcs 
obstruct bloods vessels, restricting blood flow to organs or parts of the brain (Marsh and 
Snow, 1997).  
 
Continuation of the lifecycle following the trophozoite stage of intra-erythrocytic 
parasite development can take an alternative route to schizogony, producing female 
(macro) and male (micro) gametocytes. This commitment is prompted in the mother 
schizont, producing sexually committed merozoites which will invade the host 
erythrocyte as usual but intracellular development is now geared towards sexual stage 
production (Bruce et al., 1990; Silvestrini et al., 2000; Smith et al., 2000). P. falciparum 
gametocytes develop through stages I-V over a period of 8-12 days within the human 
host. Early gametocytes (stage I) are difficult to distinguish from the asexual trophozoite 
thus stage specific markers, such as the protein Pfs16 which is expressed 24 hours p.i. in 
sexually committed parasites, are extremely valuable (Bruce et al., 1994).  Later stage 
gametocytes form the characteristic crescent shaped parasites, commonly associated 
with malaria in the late 19th century (Garnham, 1966). The ‘trigger’ for commitment to 
gametocytogenesis remains unclear although several stress stimuli from the 
surrounding environment such as host immune factors, haematological disruption, high 
parasite density, low nutrient levels and antimalarial drugs have all been implicated, 
reviewed in (Baker, 2010). Gametocytes are arrested at G0 until taken up by the 
Anopheles mosquitoes during blood meals where the change of environment 
(temperature, pH, salt concentration etc.) leads to rapid development in gametes. 
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Differentiated male and female gametes are released from the safety of the rbc, and are 
vulnerable to mosquito digestive enzymes and acids, as well as human immune factors 
injested with the blood meal. Gametes fuse to form a diploid zygote, which will develop 
into the invasive ookinete and traverse the midgut epithelium to escape the hostile 
environment it now finds itself in.  This traversal is achieved by gliding motility and relies 
on microneme secretion for release of key adhesins essential for this process. The 
parasite traverses through various layers of the epithelium until reaching the basal 
lamina of the gut where it forms an oocyst (Vlachou et al., 2004). Sporogony occurs 
within the oocyst, developing and releasing thousands of sporozoites into the 
haemocoel (Canning and Sinden, 1973). Migration to, and active invasion of the salivary 
glands ensues, where sporozoites remain until deposition onto the skin of their human 
host, completing one round of the lifecycle. The lifecycle is summarised in figure 1.3 and 
each invasive stage is illustrated in figure 1.4. 
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Figure 1.3 Plasmodium lifecycle. (A)Sporozoites are deposited in the skin during the 
mosquito’s blood meal and from this site the parasite rapidly makes its way through the 
blood stream to the liver (B) where it invades and multiplies in hepatocytes, producing a 
large number of liver merozoites which eventually break free and re-enter the blood 
stream, where the parasite is now able to infect erythrocytes (C). The infecting merozoite 
develops through ring, trophozoite and schizont stages where it asexually produces up 
to 32 new daughter merozoites which are released back into the blood stream. 
Gametocytes are also produced in the blood stream and are taken up by Anopheles 
mosquito in a blood meal (D), where they are able to produce gametes that fuse and 
develop into ookinetes which traverse the midgut, forming an oocyst in the basal 
lamina. Thousands of sporozoites are produced which travel to and invade the salivary 
glands (E). These sporozoites will be deposited in the skin of the human source of the 
mosquito’s next blood meal, continuing the cycle. Adapted from (Bannister and Mitchell, 
2003).  
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1.5 Erythrocyte invasion 
 
Plasmodium belongs to a group of Apicomplexa of the blood, order Haemosporidia. The 
‘choice’ of the erythrocyte is a smart tactical move by the parasite. Plasmodium spends 
the majority of its stay in its mammalian host inside this immune-privileged cell and is 
therefore ‘invisible’ to a large faction of the immune system.  Although a crucial step in 
propagation of the parasite, exiting the erythrocyte creates cell damage and immune 
‘danger’ signals therefore it is critical that the parasite be removed from the treacherous 
extra-cellular environment of the blood stream and that re-invasion of a new erythrocyte 
occurs rapidly to limit the exposure of the parasite’s surface proteins to the immune 
system, prolonging its life within the host.  Control of erythrocyte invasion is tightly 
regulated and involves the sequential release of the apical organelles. Based on 
videomicroscopy of P. knowlesi (Dvorak et al., 1975) and several structural and electron 
microscopy studies (Ladda et al., 1969; Bannister et al., 1975; Aikawa et al., 1978), the 
invasion process is complete within minutes and can be broken down into distinct 
stages: initial attachment, apical reorientation, junction formation followed by rhoptry 
secretion and formation of the parasitophorous vacuole (PV) and finally active motor-
driven entry into the host cell (illustrated in figure 1.5).  
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Figure 1.4: Erythrocyte Invasion. (A) The free merozoite initially forms a weak, reversible 
attachment with the erythrocyte surface Erythrocyte Invasion via merozoite surface 
proteins. (B, F) The merozoite reorientates so that the apical end of the parasite is in 
contact with the erythrocyte surface. Once the apical end is aligned perpendicular to the 
erythrocyte surface, a depression forms in the erythrocyte membrane (G) and a close 
irreversible attachment occurs, acting as a junction between parasite and host cells. (C, 
D, H) The junction then moves, by way of the actin/myosin motor, engulfing the 
parasite, shedding its surface proteins as the parasite enters the erythrocyte. During the 
junction’s posterior progression, the merozoite’s electron dense proteinacious coat is 
shed by proteolytic cleavage. (E+I) When the moving junction reaches the merozoite’s 
posterior surface, the adhesion between the cells is removed and the parasite remains 
inside its own vacuole, separate from the erythrocyte cytoplasm. Transmission electron 
microscopy shows a thickening of the membrane around the formation of the junction. 
The junction remains intact until reaching the posterior end. Rhoptries are secreted into 
the rbc as the parasite enters, creating the parasitophorous vacuole in which the 
internalised parasite resides (adapted from (Aikawa et al., 1978; Cowman and Crabb, 
2006; Riglar et al., 2011).
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1.5.1 Initial Attachment 
Once released into the blood stream from their parent schizont, free merozoites must 
find a new erythrocyte host. The selection of host cell represents a specific molecular 
interaction as P. knowlesi merozoites attach to simian and human rbcs but not those of 
non-susceptible hosts such as chicken and guinea pig (Miller et al., 1977). The interaction 
is weak, reversible and can take place at any position of the merozoite surface (Dvorak et 
al., 1975; Bannister and Dluzewski, 1990). Merozoite surface proteins (MSPs) are 
undoubtedly involved in initial rbc binding although there is very limited evidence for it 
thus far. MSP-1, 2, 4, 5, 8 and 10 are attached to the parasite membrane by way of GPI-
anchor.  Interestingly MSP1, 4, 5, 8 and 10 all share one or more epidermal growth factor 
(EGF)-like domain at their C-terminus . EGF-domains are involved in protein-protein 
interactions in other biological system however this has yet to be demonstrated 
experimentally in Plasmodium.  Merozoite surface protein (MSP)-1 is one of the most 
abundant protein on the surface of the merozoite. The MSP-1 protein precursor is c. 200 
kDa, which is cleaved by the P. falciparum PfSUB-1 within the parasitophorous vacuole 
into 83, 30 and 38kDa fragments which are non-covalently linked to the C-terminal 
42kDa fragment that remains attached to the membrane by its GPI anchor (Holder et al., 
1987; McBride and Heidrich, 1987; Gerold et al., 1996). MSP-1 is found in a high 
molecular weight complex with soluble merozoite surface proteins MSP-6 and MSP-7 
(Kauth et al., 2006).  The soluble MSP-9 has been reported to associate with MSP-1(42), 
which in complex bind the rbc surface glycoprotein Band 3 (Goel et al., 2003; Li et al., 
2004a). A study by Ranjan et al. (2010) suggests MSP-1 forms a complex with Rhoptry 
bulb proteins which have been described by some to have rbc binding properties 
(Ranjan et al., 2010). This is however unlikely due to temporal and spatial isolation within 
the merozoite. Although the MSPs are the most studied molecules of the merozoite, the 
role of these proteins and complexes has yet to be experimentally proven and the key 
event of host cell selection upon initial attachment remains poorly understood. 
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1.5.2 Apical reorientation 
After attaching to the correct cell, the merozoite must re-orientate so that the apical end 
of the merozoite is in contact with the rbc surface. The molecular mechanisms behind 
this process are as yet unknown however Mitchell et al (2004) demonstrated that apical 
membrane antigen (AMA)-1 specific monoclonal antibodies are able to block re-
orientation of P.knowlesi merozoites, suggesting an essential role for AMA-1 in this 
process (Mitchell et al., 2004). AMA-1 is conserved throughout Apicomplexa and was first 
described as part of the apical complex of blood stage merozoites (Peterson et al., 1989). 
Since then it has been shown to be essential for blood stage growth (Triglia et al., 2000). 
This protein is a type 1 membrane protein expressed in late schizogony, localising to a 
subset of the apical organelles called the micronemes (Healer et al., 2002; Bannister et 
al., 2003). These organelles secrete their contents from the apex prior to invasion and 
AMA-1 can be seen diffused out onto and diffused around the free merozoite cell 
surface by indirect immunofluorescence assay (IFA) (Healer et al., 2002). It was proposed 
by Mitchell et al (2004) that a gradient of AMA-1 existed that allowed the parasite to roll 
towards the apex where the highest concentration of AMA-1 is present although this has 
never been proven.  
 
A role in apical re-orientation implies AMA-1 is capable of host cell binding and there is 
experimental evidence that demonstrates the erythrocyte adhesive properties of AMA1. 
The protein expressed in COS cells leads to rbc agglutination (Fraser et al., 2001) and 
AMA-1 derived peptides bind to human erythrocytes (Urquiza et al., 2000). Domain III of 
AMA-1 has been shown to bind to the rbc surface protein Kx (Kato et al., 2005), however 
AMAI derived from Babesia divergens bound to wild type and Kx null rbcs in equal 
measure (Montero et al., 2009). As AMA1 is expressed in zoites of all apicomplexa it 
would be surprising if the major role of AMA1 involved any kind of erythrocyte specific 
receptor. An alternative role for AMA1 in invasion is discussed in the following sections 
(1.5.4). 
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1.5.3 Interactions at the apex  
With the apex in juxtaposition to the erythrocyte cell membrane, the parasite forms a 
closer interaction with its host. Upon reorientation, released micronemal proteins are 
able to interact with their host cell binding partners. The micronemal erythrocyte 
binding proteins of the Duffy-binding-like (DBL) superfamily are released onto the 
surface of the merozoite and appear to remain around the apical end of the parasite 
unlike their fellow microneme inhabitant, AMA-1, which is diffused around the surface 
(Singh et al. 2010). Proteins EBA-175, EBL-1 and EBA-140 (BAEBL) bind sialic acid residues 
of the rbc surface proteins glycophorin A (Sim et al., 1994), glycophorin B (Mayer et al., 
2009) and glycophorin C (Maier et al., 2003), respectively.  Other gene family members 
include the rbc binding protein EBA-181 (JESEBL), for which the receptor remains to be 
determined (Gilberger et al., 2003), and the transcribed pseudogene EBA-165 (PEBL) 
(Triglia et al., 2001). A sixth member of this family, MAEBL, is expressed in merozoites and 
sporozoites however it possesses an atypical DBL-domain, more like the rbc binding 
region of AMA-1 (Kappe et al., 1998), and is essential for salivary gland, not erythrocyte 
invasion (Fu et al., 2005; Saenz et al., 2008).  
 
A second family of invasion molecules are 5 members of the reticulocyte-binding-like 
(RBL) superfamily, the PfRh proteins. Unlike the EBA proteins the Rhs are located in the 
rhoptries/ rhoptry neck of the mature blood stages. PfRh1 has erythrocyte binding 
activity and localises to the apex of merozoites (Rayner et al., 2001), presumably to the 
rhoptry neck based on the presence of family members PfRh2a and PfRh2b which also 
exhibit erythrocyte binding capacity however the exact receptor has yet to be identified 
(Rayner et al., 2000; Taylor et al., 2002; Duraisingh et al., 2003). PfRh4 is also a rhoptry 
neck protein which binds to complement receptor 1 (CR-1) on the rbc surface (Tham et 
al., 2010). PfRh3 is not translated due to a frameshift mutation in the 5’ end of the gene 
(Taylor et al., 2001). Interestingly, as also previously shown for the EBAs, it is possible to 
individually delete the Rh genes with the exception of PfRh5 (Duraisingh et al., 2003; 
Triglia et al., 2005; Baum et al., 2009a; Tham et al., 2010). The smallest of the Rh proteins 
lacking a transmembrane domain, PfRh5 has recently been shown to bind to the 
erythrocyte surface protein basigin (Crosnier et al., 2011).  
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The multiple host cell binding antigens imply that a certain amount of redundancy in 
the erythrocyte invasion process is required to safeguard successful invasion.  If one 
invasion pathway is unavailable P. falciparum seems to be able to switch invasion 
pathways e.g. from sialic acid dependant to sialic acid independent (Dolan et al., 1990). 
In laboratory adapted strains of P. falciparum, genetic deletion of eba-175 results in 
upregulation of Rh4 (Stubbs et al., 2005). A large diversity of invasion phenotypes can be 
found in field isolates however the sialic acid dependant pathway appears to be the 
most prevalent invasion pathway, particularly in young children, based on dominant 
transcript expression of eba175 and eba140 (Gomez-Escobar et al., 2010). This 
redundancy in invasion recepters not only allows the parasite to invade a wide variety of 
human erythrocytes of all ages but facilitates immune evasion, since targeted deletion 
of eba-175 and Rh4 results in decreased susceptibility of parasites to growth inhibition 
from antibodies from semi-immune serum (Persson et al., 2008). It has been suggested 
that the binding of these antigens triggers commitment to invasion, in particular the 
binding of EBA-175 to glycophorin A or Rh4 to CR1 , after which rhoptry secretion will 
occur, even in the absence of a moving junction (Singh et al., 2010; Riglar et al., 2011).  
 
1.5.4 Junction formation 
Protein-protein interactions here are not restricted to parasite-host, but in fact a 
parasite-parasite protein interaction may be the most important complex in the invasion 
process, forming an anchoring ring for a molecular motor, driving the internalisation of 
the merozoite. First discovered in T. gondii tachyzoites (Alexander et al., 2005; Lebrun et 
al., 2005) and later shown in P. falciparum (Riglar et al., 2011), on secretion from the 
rhoptry neck, proteins RON2, RON4 and RON5 are translocated across and inserted into 
the erythrocyte membrane where they follow the moving junction from apex to the 
posterior end of the invading zoite.  The micronemal protein AMA-1 co-
immunoprecipitates with RON2, RON4, RON5 and RON8 in tachyzoites (Alexander et al., 
2006) - directly interacting with RON2 (Besteiro et al., 2009; Straub et al., 2009; Lamarque 
et al., 2011; Tyler and Boothroyd, 2011). A similar complex exists in P. falciparum without 
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the presence of RON8 which has no orthologue in Plasmodium (Cao et al., 2009; Richard 
et al., 2010). Antibodies and peptides that inhibit this complex formation also block 
invasion, highlighting its importance in host cell invasion (Collins et al., 2009; Richard et 
al., 2010; Lamarque et al., 2011). In light of this evidence the proposed model for moving 
junction interaction places RON4 on the cytoplasmic face of the erythrocyte membrane, 
interacting with transmembrane protein RON2, of which the C-terminus is to be found 
on the extracellular face of the erythrocyte membrane. This complex binds to AMA-1 
which is anchored in the parasite membrane via a single transmembrane domain.  
 
Although there are no established methods of genetic conditional knock-down in P. 
falciparum, AMA-1 cannot be deleted in blood stage parasites implying its function is 
essential (Triglia et al., 2000). Giovannini et al. (2011) show through conditional KO in T. 
gondii tachyzoites and P. berghei sporozoites that AMA-1 is not essential at these stages 
for invasion of host cells but invasion is impaired - tachyzoites invade at an angle and 
‘corkscrew’ into the cell as opposed to their normal linear internalisation (Giovannini et 
al., 2011). RON4 is an essential component invasion of T. gondii tachyzoites and P. berghei 
sporozoites, and this dissociated phenotype implies separate roles in invasion. 
Importantly, AMA-1 was shown to be essential for P. berghei merozoite invasion of rbcs 
in vivo however, as the invasion process and machinery is shared among all apicomplexa 
zoites, a functionally diverse role is unlikely. AMA1, unlike RON4, seems to have its role 
on the parasite site of the invasion junction but might therefore be involved in 
stabilising correct orientation and distance between parasite and host cell rather than 
the junction itself. This stability may be more important in the fast-flowing, fluid 
environment of the blood stream. 
 
1.5.5 The molecular motor – driving invasion 
This junction moves with respect to the invading parasite, from the apex at which it is 
formed to the extreme posterior, engulfing the merozoite in rbc and parasite-derived 
membrane. This movement is powered by an actin-myosin motor which resides 
between the plasma membrane and an inner membrane complex (IMC), a series of 
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flattened membranous vesicles lining the interior of the cell membrane. The motor 
complex is highly conserved and is responsible for motility and invasion throughout the 
Apicomplexan family. The complex consists of membrane-anchored glideosome 
associated protein GAP50, GAP45, myosin A tail-interacting protein (MTIP), myosin A, F-
actin and aldolase (Baum et al., 2006; Green et al., 2006b; Baum et al., 2008), illustrated in 
figure 1.5. An additional component of the motor complex, GAP40, has been discovered 
in T. gondii (Frenal et al., 2010), however its Plasmodium homologue remains 
undiscovered. Upon binding of the merozoite apex and rbc surface, an unknown trigger 
transmits the binding signal across the membrane and kick-starts the motor in which 
myosin A and F-actin interaction drive the parasite forward. In merozoites, the link 
between surface adhesion and activation of the motor remains to be defined. In 
sporozoites, thrombospondin related anonymous protein (TRAP) binds both hepatocyte 
membrane and aldolase (fructose-1,6-bisphosphate aldolase), an enzyme involved in 
glycolysis but that also is capable of binding filamentous F-actin and therefore linking 
host cell binding with the parasite’s invasion machinery (Buscaglia et al., 2003). TRAP is a 
member of a family of thrombospondin repeat antigens which contain combinations of 
human thrombospondin type I-related (TSR) and von Willeband factor type A-related 
(vWA) adhesive domains. Family members include  TRAP of Babesia, TRAP-C1 of 
Cryptosporidium, MIC2 of Toxoplasma and Neospora, and MIC1 and ETFP250 of Eimeria 
(Morahan et al., 2009).  The Plasmodium merozoite equivalent of TRAP (MTRAP) is 
thought to fulfil this role and binds aldolase (Baum et al., 2006) however no red cell 
binding activity had ever been described until recently. A study by by Uchime et al 
(2012) showed for the first time in vitro that MTRAP but not fellow TSR domain-
containing family member Plasmodium thrombospondin-related apical merozoite 
protein (PTRAMP), exhibited rbc binding activity, validating a potential role for this 
protein in linking rbc binding with activation of the motor (Uchime et al., 2012). Aldolase 
has been implicated in connecting the cytoplasmic tails of erythrocyte-binding surface 
molecules to actin, linking the surface interaction and triggering of the parasite 
molecular motor. It has been reported that aldolase is found on the cytoplasmic face of 
micronemes in sporozoites and Toxoplasma tachyzoites suggesting an interaction with 
MTRAP even before microneme release (Buscaglia et al., 2003; Jewett and Sibley, 2003). 
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Figure 1.5: The motor complex. 
(1) MyoA anchored in detergent resistant 
membranes of the IMC and interacts with 
MTIP, GAP45 and GAP50 as well as IMC 
constituent alveolin or GAPMs (2). When 
signalled, formin and profilin polymerise 
actin (3) and MyoA drives actin (4) and 
TRAP (connected by aldolase) towards 
the merozoite posterior (5). Adhesions 
are shed to allow internalisation (6). Actin 
depolymerises and monomers are 
recycled (7,8) (adapted from (Baum et al., 
2008)) 
 
 
 
1.5.6 A close shave 
In order to facilitate smooth parasite entry into the rbc, its bulky surface proteins/protein 
complexes should be lost and interactions between parasite and host proteins must be 
uncoupled. This action can be seen by EM and is performed by two different families of 
proteases. The first is a member of the subtilisin-like serine protease family, PfSUB2, 
which is responsible for the juxta-membrane shedding of MSP-1, AMA-1 and PTRAMP 
(Harris et al., 2005; Green et al., 2006a). The 42 kDa fragment of MSP-1 is cleaved leaving 
a 19 kDa membrane-bound fragment to enter the parasitophorous vacuole (Blackman et 
al., 1990, 1991, 1996). A recent TEM study by Riglar et al (2011) demonstrated that 
cleavage by SUB2 and actual shedding may be temporally independent and occur at 
different sites. A second protease family have a role in merozoite membrane-protein 
shedding. Rhomboid proteases are involved in the disengagement of adhesive 
interactors between the rbc and the parasite. They are also serine proteases and cleave 
within the transmembrane domain of susceptible proteins (Freeman, 2008). ROM1 and 
 48
ROM4 cleave a number of adhesins involved in rbc attachment such as EBA-175, the 
cleavage of which by ROM4 is an essential process to the parasite (O'Donnell et al., 
2006).  Interestingly, although the majority of AMA-1 is shed by SUB2, a small amount of 
the protein is cleaved by a rhomboid protease (Howell et al., 2005), perhaps indicating a 
disparate role of AMA-1 concentrated at the junction and that observed around the 
circumference of the cell.  
 
1.5.7 Parasitophorous vacuole formation and completion of invasion 
As the merozoite enters the rbc, the electron-lucent, lipid-rich contents of the rhoptries 
are discharged into the erythrocyte, aiding the creation of a parasitophorous vacuole in 
which the merozoite is to reside throughout the intraerythrocytic stage of its lifecycle 
(Bannister et al., 1986). TEM shows the rhoptry associated protein (RAP)1moves to the 
apex mid-invasion, the position that rhoptry neck proteins previously occupied, before 
finally taking up residence in the PVM (Riglar et al., 2011).  Rhoptry secretion is 
concomitant with merozoite entry into the erythrocyte through the junction. As the 
moving junction reaches the posterior of the merozoite, the PVM fuses so that the 
merozoite is contained within its own vacuole, out of the rbc cytosol, and the invasion 
process is complete (Lingelbach and Joiner, 1998).  The dense granules remain intact 
throughout the invasion process but are secreted immediately following the completion 
of invasion so that the contents may fulfil their role in the PV, PVM or cytosol of the 
newly invaded rbc (Bannister et al., 1975; Torii et al., 1989; Culvenor et al., 1991; Riglar et 
al., 2011). 
 
 
1.6 The Merozoite 
 
The merozoite stage of the Plasmodium lifecycle is responsible for the obligatory process 
of erythrocyte invasion and entry into the lifecycle stage that gives rise to malaria 
disease symptoms. Understanding the molecular biology of this cell is therefore crucial 
in designing vaccines and new drug targets. Plasmodium is a eukaryotic pathogen and 
this is reflected in the merozoite cellular architecture (figure 1.6). The nucleus resides at 
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the posterior of the cell and contains the 14 chromosomes and 23Mb of DNA that make 
up the Plasmodium nuclear genome. The mitochondrial genome holds another 6kb 
while an Apicomplexan-specific organelle, the apicoplast, contains a 35kb circular 
genome (Gardner et al., 2002). All Apicomplexa, excepting Cryptosporidium spp., possess 
this ancient relic of a red algal, secondary endosymbiont, the acquisition of which 
changed the course of their evolution. The resulting non-photosynthetic plastid 
organelle is reduced in size and activity, however it is an indispensible part of the zoite 
cellular architecture. It is involved in the biosynthesis of fatty acids, isoprenoids and the 
digestion of haem, providing the parasite with metabolites which are essential to its 
survival (reviewed by (Striepen, 2011)).  Although in possession of its own genome, the 
majority of apicoplast proteins are encoded by the nuclear genome and must be 
trafficked through the classic eukaryotic secretory pathway. In order to reach the correct 
destination, proteins contain an N-terminal signal sequence for entry into the ER 
followed by a transit peptide which drives correct trafficking to the apicoplast via 
vesicular transport (Waller et al., 1998; Foth et al., 2003). 
 
Surrounding the merozoite nucleus resides the membranous network of the 
endoplasmic reticulum (ER). Due to the cell’s polarity this network can extend in the 
apical direction but is distinct from the apex. As with all eukaryotic cells, the merozoite 
ER plays host to newly synthesised transmembrane and soluble proteins destined for 
cellular compartments or secretion from the cell. Proteins require a classic signal 
sequence at the N-terminus in order to enter the ER and protein translocation machinery 
appears to be conserved, although this observation is reliant on sequence similarity and 
not experimental data (Tuteja, 2007). Proteins are retained in the ER by the conventional 
XDEL motif which retrieves escaped resident ER proteins from the Golgi (Elmendorf and 
Haldar, 1993; van Dooren et al., 2005). A Golgi apparatus of sorts exists and cis- and 
trans-Golgi compartments have been identified using the markers ERD2, Rab6 and 
GRASP respectively (Elmendorf and Haldar, 1993; de Castro et al., 1996; Van Wye et al., 
1996; Noe et al., 2000). There is however limited evidence for the characteristic Golgi 
stacks seen in higher eukaryotes. The function of these stacks is to compartmentalise, 
facilitating processing and sorting of newly synthesised proteins and lipids. Since 
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Plasmodium has limited N-glycosylation and lacks an O-linked glycosylation pathway 
(Templeton et al., 2004) this level of compartmentalisation may not be necessary. One 
post-translational modification that does occur is the addition of 
glycosylphosphatidylinositol (GPI) to the cleaved C terminus of would-be surface 
proteins, to allow membrane insertion. The merozoite surface is coated in a thick layer of 
GPI-anchored proteins which include the abundant MSP-1 and are believed to facilitate 
attachment to red blood cells. Immediately underneath the merozoite membrane lies a 
series of flattened vesicles known as the inner membrane complex (IMC). This double 
membranous structure is common among many Chromalveloates including all 
Apicomplexa. On the cytosolic face of the IMC lies a network of cytoskeletal 
intermediate filament-like proteins and sub-pellicular microtubules, providing structural 
support to the cell. The sub-pellicular microtubules are also thought to be involved in 
the trafficking of secretory vesicles, particularly to the apical end of the cell (Bannister et 
al., 2003). One of the defining features of the phylum Apicomplexa is the presence of a 
unique set of organelles at the apex of the zoite form of the parasite. The protein 
contents of these apical organelles are arguably the most important proteins in the cell 
as their secretion is absolutely necessary to permit host cell invasion. These proteins, as 
well as surface proteins, are described in Table 1.1. 
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Figure 1.6: The Merozoite. All major organelles are highlighted. Note the polarity, with 
the secretory organelles at the apex and nucleus at the posterior. Trafficking routes from 
the ER and Golgi to the rhoptries, micronemes and dense granules are labelled 1, 2 and 3 
respectively [adapted from (Bannister et al., 2003)]. 
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Table 1.1: P.falciparum merozoite proteins important in erythrocyte invasion. 
 
Name Features/Function 
GPI-anchored Surface Proteins 
MSP-1 2 EGF domains, shedding upon invasion essential, cannot KO, putative Band 3 
ligand 
MSP-2 highly polymorphic, cannot KO 
MSP-4 EGF domain, cannot KO 
MSP-5 Non-essential paralogue of MSP4 
MSP-10 cannot KO, surface AND apical staining, 2 EGF domains 
Pf12 6-cys family member, similar to SAG of T. gondii 
Pf38 6-cys family member, surface and apical location 
Pf92 Cysteine-rich protein, cannot KO 
Pf113 Putatively GPI anchored , putative surface protein, cannot KO 
Peripheral Surface Proteins 
MSP-3 redundant member of MSP-3 family locus, coiled coil domain 
MSP-6 MSP-3 family member, in complex with MSP-1+7 on the surface, not essential 
MSP-7 non-essential in complex with MSP-1+6; deletion causes reduced invasion 
MSP-9(ABRA) essential, putative association with MSP-1 and potential Band 3 ligand 
SERA5 serine repeat antigen, putative serine protease, high expression levels; essential 
S-antigen Cannot KO, function unknown 
GLURP glutamate-rich protein, targeting antibodies associated with protection from 
clinical symptoms in the field 
H101 non-essential MSP3 family member 
MSP11 non-essential MSP3 family member 
Pf41 6-cys family member, apical surface protein 
PfDBLMSP redundant MSP-3 family member, DBL domain 
Micronemal proteins 
AMA-1 essential merozoite invasion protein, antibodies inhibit apical 
reorientation/invasion, binds RON2 in complex with RON4 at moving junction 
EBA-140 redundant erythrocyte binding protein, binds glycophorin C 
EBA-175 redundant erythrocyte binding protein, binds glycophorin A 
EBA-181 redundant erythrocyte binding protein, binds unknown rbc receptor 
EBL-1 redundant erythrocyte binding protein, binds glycophorin B 
MTRAP essential rbc adhesin, also binds aldolase, putative motor function 
SUB2 subtilisin-like protease or surface sheddase, cleaves MSP-1 and AMA-1 upon 
merozoite internalisation 
Rhoptry Neck Proteins 
RH1 redundant erythrocyte binding antigen, receptor unknown 
RH2a redundant erythrocyte binding antigen, receptor unknown 
RH2b redundant erythrocyte binding antigen, receptor unknown 
RH3 pseudogene 
RH4 redundant erythrocyte binding antigen, binds to CR1 on rbc surface 
RH5 essential invasion ligand, binds basigin on rbc surface 
 53
RON1 aka apical sushi protein (ASP), contains 'sushi' domain and GPI anchor 
RON2 essential component of moving junction, target of invasion inhibitory 
antibodies, translocated to rbc surface, binds AMA-1 
RON4 essential component of moving junction, target of invasion inhibitory 
antibodies, translocated to rbc cytoplasmic face 
RON5 6 transmembrane protein, conserved in Plasmodium spp, homologue in T. 
gondii 
RON6 cannot KO, soluble, cysteine rich domain, conserved in T. gondii  
Rhoptry Bulb Proteins 
RAMA Early expressed, GPI-anchored rhoptry protein, putative role in binding protein 
complexes 
RAP1 non-essential member of low-molecular weight rhoptry protein complex 
RAP2 non-essential member of low-molecular weight rhoptry protein complex, 
attaches to rbc surface upon aborted invasion 
RAP3 non-essential member of low-molecular weight rhoptry protein complex 
RhopH1(2) high molecular weight rhoptry protein complex, redundant member, encoded 
by clag multigene family 
RhopH1(3.1) high molecular weight rhoptry protein complex, redundant member, encoded 
by clag multigene family 
RhopH1(3.2) high molecular weight rhoptry protein complex, redundant member, encoded 
by clag multigene family 
RhopH1(9) high molecular weight rhoptry protein complex, redundant member, encoded 
by clag multigene family 
RhopH2 high molecular weight rhoptry protein complex, cannot KO 
RhopH3 high molecular weight rhoptry protein complex, cannot KO 
RON3 P. falciparum orthologue of T. gondii RON3 is  located in the rhoptry bulb not 
neck, in complex with RON2+4 but not AMA-1 
    
 
Table 1.1:  P.falciparum merozoite proteins important in erythrocyte invasion. The table 
represents a summary of proteins of the merozoite surface and apex described in detail 
and referenced in the text or otherwise references can be found in (Cowman and Crabb, 
2006) from which the table was adapted. 
 54
1.6.1 The apical organelles 
The apical organelles are a defining feature of apicomplexa and their secretion facilitates 
motility and invasion of host cells. Plasmodium merozoite apical organelles are formed 
de novo during schizogony in the last 10-12 hours of the parasites intraerythrocytic 
development. In order to reach the apical organelles, proteins contain an N-terminal 
signal sequence in order to utilise the classical secretory pathway, trafficking through 
the ER and Golgi before reaching their apical destination. 
 
1.6.1.1 Dense Granules 
Dense granules form around the periphery of the Golgi but little is known of their 
trafficking other than timing of protein expression is key (Rug et al., 2004).  Their name is 
derived from their appearance in electron microscopy – electron dense, granular vesicles 
which reside slightly behind the micronemes and rhoptries (Bannister et al., 1975). Less 
is known about the role of dense granules although their secretion appears to be 
coordinated and they diffuse laterally into the PV after invasion has taken place (Torii et 
al., 1989; Carruthers and Sibley, 1997; Riglar et al., 2011). As would be predicted from the 
timing of their secretion, proteins of the dense granules have a role in ring stage 
parasites, particularly in host cell remodelling. The best characterised dense granule 
protein is Ring-infected Erythrocyte Surface Antigen or RESA which is released from 
dense granules (Culvenor et al., 1991), exported into the rbc cytoplasm where it binds 
spectrin (Foley et al., 1991) and is involved in resistance to heat shock (Silva et al., 2005) 
and decreasing rbc deformability (Mills et al., 2007). 
 
1.6.1.2 Rhoptries 
The rhoptries are large, club or bulb shaped organelles which occur in pairs at the apex 
of the merozoite. Rhoptries are formed through the accumulation of vesicles trafficked 
from the Golgi (Jaikaria et al., 1993; Bannister et al., 2000). It seems the first 24 amino 
acids, including signal peptide, of RhopH2 is adequate to target to the rhoptries after 
transport through the secretory pathway (Ghoneim et al., 2007). A C-terminal tyrosine 
motif as well as a cytoplasmic dileucine motif has been described for the targeting of 
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rhoptry membrane proteins of T. gondii and although several Plasmodium rhoptry 
proteins also possess these motifs, a role in trafficking has not been elucidated (Hoppe 
et al., 2000; Ngo et al., 2003).  Adaptor protein complex 1 (AP-1) and dynamin-related 
protein B (DrpB) have also been implicated in rhoptry targeting in T. gondii (Ngo et al., 
2003; Breinich et al., 2009).There also appears to be a mechanism of secretory pathway-
independent targeting to the rhoptries since the P. falciparum armadillo repeats-only 
(PfARO) protein can be targeted to rhoptry membranes by myristoylation and 
palmitoylation within the first 20 aa of the protein (Cabrera et al., 2012). Ghoneim et al 
(2007) suggest RhopH2 is post-translationally inserted into the ER, however the 
necessary machinery for this translocation has not been identified in Plasmodium 
(Tuteja, 2007). They also suggest a role for chaperones in identifying rhoptry targeting 
sequences however experimental evidence is lacking.  
 
Each individual rhoptry is divided into 2 distinct compartments, the electron-dense 
rhoptry bulb and electron-lucent rhoptry neck.  The thin neck regions of the rhoptries 
appear in close proximity at the extreme apical tip of this invasive cell (Bannister et al., 
2000). The bulb compartment contains lipids which are responsible for the lucidity of 
the rhoptry bulb in TEM studies (Bannister et al., 1986). These lipids have a role in 
establishment of the PVM within the rbc. 
 
Rhoptry exocytosis has been shown in vitro to occur following host cell interaction with 
EBA-175, EBA-140 or EBA-181 when previously elevated intracellular calcium levels are 
supposedly restored to basal levels (Singh et al., 2010), although the precise signalling 
mechanisms involved have yet to be demonstrated. The requirement for committed 
invasion as defined by binding of EBL- and also RBL- antigens was confirmed Riglar et al 
(2011), demonstrating by TEM, 3D SIM, IEM and IFA, rhoptry contents will be secreted 
irrespective of whether an intact junction forms at the apex, with an incomplete junction 
resulting in the secretion of rhoptry contents onto the surface and culture media but not 
into the host cell and without successful invasion. In parasites with intact junctions but 
chemically treated to block either the actin/myosin motor (cytochalasin D) or shedding 
(PMSF), rhoptry contents are secreted in ‘whorls’ into the rbc cytoplasm instead of 
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surrounding the invading merozoite (Miller et al., 1979; Bannister et al., 1986; Riglar et al., 
2011).  
 
Proteins contained in each compartment are separated based on temporal and 
functional differences since the rhoptry neck protein will be secreted first, followed by 
the rhoptry bulb contents (Bradley et al., 2005). Rhoptry neck proteins play an important 
part in erythrocyte attachment via the RH family (discussed in 1.5.3) and junction 
formation where RON2 and RON4 play essential roles (described in section 1.5.4). The 
specific role of other rhoptry neck proteins is less clear. The bulb is thought to contain 
protein constituents of the PV or PVM. Several rhoptry bulb proteins have been 
described to date, with perhaps the most studied being members of the high molecular 
weight rhoptry (or RhopH) protein complex. This complex consists of the proteins 
RhopH1, RhopH2 and RhopH3 and is formed in the schizont’s secretory pathway, 
remains intact within the newly infected erythrocyte and is conserved in other 
Plasmodium species (Campbell et al., 1984; Holder and Freeman, 1984b; Cooper et al., 
1988; Hienne et al., 1998).  While RhopH2 and RhopH3 are encoded by single genes 
which are refractory to genetic deletion (Holder, unpublished data; Cowman et al., 
2000), RhopH1 is encoded by at least 5 members of the clag (cytoadherence linked 
asexual gene) multi-gene family (Kaneko et al., 2001) and different clones express 
different clag genes - expression of clag3.1 and clag3.2 is mutually exclusive (Cortes et 
al., 2007). The first of these genes to be characterised, clag9, was implicated in 
cytoadherence (Trenholme et al., 2000), although the protein was demonstrated to 
localise and interact with the RhopH complex, which is present in the merozoite rhoptry 
bulb and translocated into the PVM upon invasion, where it remains throughout the ring 
stage (Hiller et al., 2003; Ling et al., 2003; Ling et al., 2004), calling this role into question. 
There has been much controversy regarding the role of rhoptry proteins since this 
complex also exhibits erythrocyte-binding properties and antibodies to the complex 
inhibit invasion (Sam-Yellowe and Perkins, 1991; Doury et al., 1994; Wang et al., 2006). 
Given that rhoptry bulb proteins are internal in the free merozoite and are passed 
through what is thought to be a molecular seal (the moving junction) during host cell 
invasion, it is not clear how the antibodies access the complex in order to hinder 
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merozoite entry. It is also unclear how the RhopH complex will come in contact with the 
rbc surface during ‘successful’ invasion, other than the portion of the rbc membrane that 
is internalised during the formation of the PVM where the complex resides in ring stage 
parasites (Ling et al., 2004).  A similar situation is true of the low molecular weight 
rhoptry protein complex consisting of rhoprty associated proteins RAP1, RAP2 and RAP3. 
Although located in merozoite rhoptries and transferred into the PV during the invasion 
process, the complex can readily be observed on the surface of infected and non-
infected erythrocytes (Sterkers et al., 2007; Awah et al., 2011). Destruction of uninfected 
red bloods cells is a major contributing factor to malaria-induced anaemia (Mendez et 
al., 2000). Erythrocytes coated with sticky rhoptry proteins are the target for immune-
mediated clearance (Layez et al., 2005; Evans et al., 2006; Awah et al., 2009).  
Since that we cannot assume that all invasion attempts are ‘successful’ and given that 
committed invasion is triggered by the binding of apical erythrocyte binding proteins 
resulting in the release of rhoptry contents irrespective of the presence of an intact 
moving junction (Singh et al., 2010; Riglar et al., 2011), it is probable that rhoptry 
proteins contact the rbc surface during aborted invasion. Deposition of these protein 
complexes onto erythrocytes that aren’t invaded will tag them as ‘foreign’ nonetheless, 
rendering the rbc liable to immune destruction.   
 
1.6.1.3 Micronemes  
Micronemes are small, elongated vesicles with an electron dense membrane, found at 
the apex, in front of the rhoptry bulb as well as peripheral and slightly posterior to the 
rhoptry neck. The organelles bud off from the Golgi and are transported along sub-
pellicular microtubules to the apical end of the merozoite (Bannister et al., 2003). 
Evidence from the ookinete microneme proteome suggests this trafficking may deliver 
motor components to the apex via attachment to micronemal proteins’ cytoplasmic tails 
(Lal et al., 2009). This is consistent with reports of aldolase on the cytoplasmic face of 
micronemes in sporozoites and Toxoplasma tachyzoites (Buscaglia et al., 2003; Jewett 
and Sibley, 2003). Most micronemal proteins are single-pass transmembrane proteins 
with large extracellular domains and short cytoplasmic tails. In T. gondii, a tyrosine motif 
and patch of acidic residues in this C-terminal cytoplasmic tail targets transmembrane 
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proteins to the micronemes (Di Cristina et al., 2000), however this does not seem to be 
the case for the P. falciparum EBL family (Gilberger et al., 2003), which instead require a 
cysteine-rich region present in the ectodomain as well as correcting timing of expression 
(Treeck et al., 2006). Soluble microneme proteins have been described in ookinetes 
(Langer et al., 2000; Yuda et al., 2001) as well as coccidian apicomplexa (Eschenbacher et 
al., 1993; Fourmaux et al., 1996; Tomley et al., 1996). There is evidence from Toxoplasma 
that a family of micronemal EGF-domain containing proteins function as escorts, 
directing microneme soluble residents to the correct destination (Meissner et al., 2002), 
however no functional homologue has been discovered in Plasmodium.  
 
Microneme exocytosis has been shown to occur upon egress, where the low potassium 
concentrations found in the blood stream trigger an intracellular rise in calcium, 
resulting in the micronemal protein AMA-1 being translocated to the surface (Singh et 
al., 2010). An intracellular calcium increase is also implicated in microneme release in 
Toxoplasma, with low intracellular potassium-induced release of calcium from 
intracellular stores resulting in the surfacing of invasion-essential micronemal protein 
MIC2 (Carruthers et al., 1999; Carruthers and Sibley, 1999; Lovett et al., 2002). Microneme 
membrane fusion that facilitates secretion is thought to occur at the rhoptry neck. 
Proteins contained in micronemes appear to have different specific roles however all 
micronemal proteins characterised to date contribute towards the same goal – the 
removal of the free merozoite from the inhospitable environment of the blood stream 
into the sanctuary of the erythrocyte.  Despite being assigned a micronemal location, 
EBA-175 and AMA-1 do not co-localise. Upon release, AMA-1 is dispersed over the whole 
surface of the merozoite, colocalising with MSP-1, however EBA-175 is only ever found at 
the apical tip, suggesting some level of spatial compartmentalisation. This has been 
described in Toxoplasma tachyzoites with distinct proteins shown to localise only to the 
apex.  Two distinct subsets of micronemes have been described in P. falciparum. One 
subset contains the protease SUB1 which is required for egress, hence these organelles 
have  been termed the exonemes (Yeoh et al., 2007). Unlike classic micronemes they are 
believed to secrete their contents during schizogony by fusion with the plasmalemma 
and not using the apical organellar duct in a fashion reminiscent of dense granules. The 
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second subset, named mononemes, contain the rhomboid protease PfROM-1 and are 
distinct in location from other micronemal markers, as determined by fluorescent 
microscopy (Singh et al., 2007). 
 
An ookinete microneme proteome was published by Lal et al (2009) however this has 
not been possible for other invasive stages due to difficulty in separating micronemes 
from rhoptries and dense granules, which are absent in ookinetes. In this study, a group 
of 24 proteins were classed as invasive or surface proteins. Other significant groups 
included chaperones and signalling molecules (and ribosomal contaminants), but by far 
the largest group of proteins produced by this study were unknown proteins, 
highlighting the importance of characterising new proteins in the search for new drug 
and vaccine candidates. Although this study involved ookinete micronemes, it is 
reasonable to presume the case is similar for merozoite micronemes and other 
organelles. Transcriptome data from P. falciparum merozoites shows a poignant 
induction of gene expression of known micronemal proteins late in schizont stage 
development. Of the 262 open reading frames (ORFs) that shared their expression 
pattern, 189 had no assigned function (Bozdech et al., 2003). Given that micronemal 
proteins are required for invasion and are the target of invasion-inhibitory antibodies, 
they represent important vaccine candidates. Characterisation of the unknown, late 
expressed proteins could uncover a whole host of new vaccine candidates or drug 
targets that are badly needed in the fight against malaria.  
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1.7 Project Aims 
 
The aim of this project is to uncover novel proteins that play a part in the invasion of red 
blood cells by merozoites. Identifying components of this essential process will not only 
lead to a better biological understanding of the parasite, but may well identify potential 
drugs targets and perhaps even vaccine candidates. 
 
Comparing the P. falciparum 3D7 genome with other sequenced genomes predicted the 
function of only c. 40% of the 5400 genes, leaving the remaining 60% with no identified 
orthologue in any other sequenced species and hence no assigned function (Gardner et 
al., 2002). In order to identify which of these proteins are important for invasion of rbcs, 
the list must be refined utilising the wealth of genomic, transcriptomic, proteomic and 
bioinformatic data available. I intend to characterise a small number of proteins of the 
malaria parasite Plasmodium falciparum using the following criteria for selection: 
 
 a) The protein is expressed late during schizogony in the blood stage cycle  
From previous studies it appears that if we are to find proteins that are essential for 
invasion of erythrocytes, we need to look to apical organelles. AMA-1 is a micronemal 
protein essential for invasion. The selection process aims to identify proteins expressed 
at a similar time during the asexual cycle as AMA-1, in late schizogony just before 
merozoite release, in the hope they might be trafficked to the micronemes, rhoptries or 
the cell surface.  
 
b) The protein should have a signal peptide/anchor sequence 
Signal sequences direct emerging or newly synthesised proteins to the endoplasmic 
reticulum (ER), and into the eukaryotic secretory pathway. Proteins destined for the 
apical organelles utilise the secretory pathway in order to reach their destination.  
Therefore the proteins  of interest to be studied must contain signal peptide/anchor 
sequences in order for them to be directed to the apical organelles.  
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c) The protein should have a transmembrane domain or a GPI anchor 
Glycosylphosphatidylinositol (GPI) anchored proteins are abundant on the merozoite’s 
surface and many are thought to have a role in host cell selection and attachment of the 
merozoite to the rbc. Recentlly MTRAP, a micronemal transmembrane protein has been 
identified as one of the ligands linking the adhesion receptor on the host cell surface 
with the parasite motor complex. Other as yet unidentified molecules however might be 
able to fulfil a similar function. Therefore we are looking into proteins containing 
transmembrane domain(s), in which the cytoplasmic tail could be involved in signalling 
pathways or directly in motor complex binding. Indeed many proteins known to be 
involved in invasion such as AMA-1 and the DBL-EBP and PfRH protein families, contain a 
single transmembrane domain. 
 
d) The protein must be conserved across other Plasmodium species 
The erythrocyte invasion process is common among all Plasmodium species, and indeed 
across all Apicomplexa, thus one would expect genes critical for invasion to be 
conserved throughout the genus. 
 
Utilising a variety of experimental techniques, I aim to characterise the selected proteins, 
uncovering features that provide clues to their role within the parasite. 
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2. Materials and Methods 
 
2.1 Molecular Biology Techniques 
2.1.1 Protein Selection and Bioinformatic analysis 
Proteins for study were selected by searching the P. falciparum genome using the 
database PlasmoDB (plasmodb.org) and the following parameters: maximal expression 
at 42 ± 2 hours post invasion, minimal expression 24 ± 8 hours, presence of a signal 
peptide, minimum of one  transmembrane domain and presence in genomes of all other 
annotated Plasmodium spp. Signal peptide predictions were confirmed using the 
program SignalP (http://www.cbs.dtu.dk/services/SignalP/) and transmembrane regions 
verified using TMHMM (http://www.cbs.dtu.dk/services/TMHMM-2.0/). Protein sequence 
alignments were performed using ClustalW Multiple Alignment software.  
2.1.2 Primers 
Primers were designed based on the published genomic sequence of 3D7 available on 
PlasmoDB (plasmodb.org) and ordered from Sigma-Aldrich. Primer sequences are 
detailed in the table 1. 
2.1.3 Polymerase Chain Reaction (PCR) 
AmpliTaq DNA polymerase (Applied Biosystems) was used with 1 mM dNTPs, 2 mM 
MgCl2 and 0.5 pM primer set to amplify gene fragments from genomic or cDNA for 
vector construction, PCR reactions were carried out in a Mastercycler Gradient PCR 
machine (Eppendorf). The amplified DNA was purified using QIAquick® PCR purification 
kit (Qiagen) according to manufacturer’s instructions. 
2.1.4 DNA-modifying enzymes 
Restriction digests were carried out using endonucleases from New England Biolabs 
(NEB). Digested plasmid DNA was phosphatase treated using calf intestine alkaline 
phosphatase (Roche). Digested DNA fragments were purified using Qiaex® II gel 
extraction kit (150) or QIAquick® Gel Extraction kit (both from Qiagen) according to 
manufacturer’s instructions.  The resulting DNA fragments were ligated using T4 DNA 
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ligase (Roche). For ligation independent cloning into pET30- or pET32-Xa/LIC vectors, T4 
DNA polymerase (Novagen) was used according to the manufacturers’ instructions. 
2.1.5 Purification of plasmid DNA 
E.coli was grown in Luria-Bertani broth (LB) (Bertani, 1951). Plasmid DNA was purified 
using QIAprep® Spin Miniprep Kit or HiSpeed® Plasmid Maxiprep kit (both from Qiagen) 
according to the manufacturers’ instructions. DNA yields were analysed using a 
Nanodrop spectrophotometer (Thermoscientific) or by running an aliquot on a 1% 
agarose (Roche) gel. 
2.1.6 Nucleotide Sequencing 
Plasmid DNA was sequenced by Geneservice Ltd, now renamed Source Bioscience, 
Cambridge. 
2.1.7 Transfection vector construction 
Parasite vectors for both single homologous genomic integration and episomal 
expression were based on the pHH3 transfection plasmid (Knuepfer and Holder, 
unpublished). These plasmids contain the Blasticidin resistance cassette. For C terminal 
epitope tags, regions of homology to the gene of interest were cloned into pHH3 using 
EcoRI and SacII. FLAG and TY tags were introduced to the vector backbone on the primer 
and amplified with the region of homology. Codons were optimized for P. falciparum as 
based on previous research (Peixoto et al., 2003). Each tag was flanked with AvrII and 
SacII restriction sites. Truncation of functional gene product was attempted by single 
homologous recombination.  Nucleotide regions of homology were amplified and 
cloned in between EcoRI and BamHI sites of pHH3. This restriction enzyme digest 
removes the existing promoter and terminator region within pHH3 so that after 
homologous integration either no stable RNA would be produced or if expression of the 
gene occurred a truncated product would result in a functional knockout. Double 
homologous recombination vectors were based on the pHTK transfection vector 
(Duraisingh et al., 2002). This plasmid contains the human dihydrofolate reductase 
(hdhfr) selection cassette, conferring resistance to the antifolate drug WR99210 (Jacobus 
Pharmaceuticals). This vector was used to attempt to knock out PF11_0443 by double 
homologous recombination. A region form the 5’UTR and ORF were cloned into MCS 1 
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using SacII and BglII and a region of 3’end of the ORF and 3’UTR were cloned into MCS 2 
using EcoRI and AvrII. Vector backbones were generously provided by Ellen Knüpfer. 
Transfection vectors, cloning and transfection strategy are illustrated in figure 2.1. 
Primers used to amplify flanking regions are described in table 2.1. 
2.1.8 Southern Blot 
DNA preparation, separation and transfer 
Genomic DNA was prepared from WT 3D7 and transgenic parasite lines and digested 
using suitable restriction enzymes. The resulting fragments were separated by agarose 
gel electrophoresis  containing 0.5μg/ml ethidium bromide at 30V overnight. The gel 
was agitated in 0.25mM HCl for ten minutes, washed with H20, then incubated in 
denaturing buffer (1.5M NaCl, 0.5M NaOH) for 1 hour, followed by 2x30 minute 
incubations with neutralising buffer (1.5M NaCl, 0.5M Tris, 1mM EDTA pH 8.0). The DNA 
was transferred onto a Gene Screen Plus membrane (Whatman) in 10x SSC (1xSSC: 
150nM NaCl, 15mM Na Citrate pH7.0) by capillary transfer (Sambrook J., 1989). Following 
transfer the DNA on the membrane was denatured in 0.4M NaOH for 1 min before 
neutralisation, dried then UV crosslinked using a UV-Transilluminator (UVITEC 
Cambridge). 
Hybridisation 
The membrane was pre-hybridised in hybridisation buffer (6x SSC, 5x Denhardts [0.1% 
BSA, 0.1% Ficoll, 0.1% polyvinylpyrrolidone), 0.5% SDS, 0.2mg/ml salmon sperm DNA) 
rotating for 1 hour at 62°C. The hybridisation probe was labelled with α-[ 32 P] dATP 
(Perkin Elmer®) by random priming using the Decaprime II kit (Ambion) according to 
manufacturer’s instructions. Unincorporated labelled nucleotides were removed using 
ProbeQuant
TM
 G-50 Microcolumns (Amersham Biosciences). The membrane was 
incubated overnight at 62°C with the labelled probe in hybridisation buffer. The 
membrane was washed twice with 6x SSC , 0.1% SDS for 20 minutes at 62°C. The blot 
was visualised by autoradiography using Kodak BioMax
TM
 MR film (Kodak®) following 
incubation at -80°C. If necessary, the probe was stripped off the membrane by boiling in 
0.05x SSC, 0.01M EDTA, 0.1% SDS which allowed reprobing. 
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2.1.9 Site-Directed Mutagenesis (SDM) 
SDM was used to introduce single amino acid changes into the transfection constructs 
with the intent to remove phosphorylation sites within the protein of interest. SDM was 
carried out using QuikChange II Site-Directed Mutagenesis Kit (Agilent Technologies) 
according to the manufacturer’s instructions. 
 
2.2 Recombinant proteins and Immunochemistry 
2.2.1 Protein expression vectors 
DNA fragments from genes of interest were amplified by PCR (section 2.1.3) and cloned 
into protein expression vectors pET30-Xa/LIC, pET32-Xa/LIC or pET46-Ek/LIC (Novagen) 
according to the manufacturers’ instructions. 
2.2.2 Competent cells and transformations 
E. coli Giga single cells (Novagen) were used for propagation of plasmid DNA. E. coli 
BL21-DE3 and BL21-DE3 pLysS (Stratagene) were used for protein expression. 
Transformations with plasmid DNA were carried out according to the manufacturers’ 
instructions. 
2.2.3 Expression of Recombinant Proteins 
Protein expression vectors containing the correct sequence were transformed into 
either BL21 DE3 or BL21 (DE3) pLysS E.coli . Multiple colonies were picked and grown in 
10ml of LB with antibiotic overnight at 37°C. To test expression, 100μl of overnight 
culture was added to 5 ml LB with antibiotic and grown to OD 600 =0.6. Protein expression 
was induced using 1mM Isopropyl β-D-thiogalactopyranoside (IPTG) for 4hrs at 37°C or 
22°C in an attempt to increase solubility. To rapidly screen for solubility, 2ml of culture 
was pelleted at 9600xg for 2 minutes. The pellet was lysed in 300 μl Bugbuster 
(Novagen) plus 1x complete, EDTA-free protease inhibitors (Roche) and 1μl Benzonase 
nuclease (Novagen) to reduce the viscosity and incubated for 20 minutes at room 
temperature with shaking. After centrifugation at 17000xg for 10 minutes at 4°C soluble 
(supernatant) and insoluble (pellet) proteins were collected and analysed by SDS-PAGE. 
 
 66
2.2.4Sodium Dodecyl Sulphate Polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE was performed using pre-cast NUPAGE gels from Invitrogen in MES or MOPS 
running buffer (Invitrogen). Samples were run in either reducing or non-reducing two 
times Laemmli sample buffer (Sambrook J., 1989). Gels were stained with either 
coomassie blue (Sambrook J., 1989), the Mass Spectrometry-compatible Novex® 
Colloidal Blue Staining Kit (Invitrogen) or silver stain following a previously described 
method (Blum et al., 1987). 
2.2.5 Protein purification 
6xHis tagged proteins were purified on a Nickel resin. Bacterial lysate supernatant was 
incubated with Nickel-NTA beads (Qiagen) at 4°C for 1 hour. This was transferred into a 
disposable 10ml polypropylene column (Thermo-Scientific) and the resin washed in 
50mM sodium dihydrogen orthophosphate, 300mM sodium chloride and 10mM 
imidazole, pH8.0. Protein was eluted by washing with the same buffer but containing 
250mM imidazole. For insoluble protein, inclusion bodies were purified as described in 
the pET systems manual (Invitrogen), solubilsed in 8M urea and purified on a Nickel-NTA 
column by the same method but with the addition of 8M urea to the wash and elution 
buffers. 
2.2.6 Antibody production 
Antibodies to each recombinant protein were raised in either rabbits or rats by Harlan, 
UK, following standard protocol. The resulting antibodies and their working dilutions are 
listed in table 2.4. 
2.2.7 Purification of antibodies by affinity chromatography 
An affinity column was generated using CNBr activated sepharose 4B (Pharmacia). For 
each column, 0.5g of sepharose was reconstituted and washed in 1mM HCl, dried under 
vacuum and incubated with 20mg of purified recombinant protein in 0.1M sodium 
bicarbonate pH8.3, 0.5M sodium chloride, rotating overnight at 4°C. The resin was 
transferred into a column and the flow through tested by Bradford assay to ensure the 
protein had bound. Free CN-Br arms were blocked in 10 column volumes of 0.2M glycine 
pH8.0 then washed with 10 column volumes of 0.1M sodium bicarbonate pH8.3, 0.5M 
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NaCl followed by 0.1M sodium acetate pH4.0, 0.5M NaCl followed by 0.1M sodium 
bicarbonate pH8.3, 0.5M NaCl and finally in two column volumes of PBS. To bind  
antigen-specific antibodies, rabbit serum was diluted 1:1 in 10mM Tris pH7.5 and passed 
over the column 5 times. Then the column was washed with 20 column volumes of 
10mM Tris pH7.5 and 10mM Tris pH7.5, 0.5mM NaCl. Antigen-specific antibodies were 
eluted with 15ml of 100mM glycine pH2.5 and collected in a tube containing 1 bed 
volume of 1M Tris pH8.0 to neutralise. The column was washed with 10mM Tris pH7.5 
returning the column to pH7.5 and stored at 4°C in PBS containing sodium azide. 
2.2.8 Antibody purification by immunoblot strip purification 
Antigen solubilised in 8M urea was diluted 1:1 in reducing Laemmli sample buffer and 
resolved by SDS-PAGE in a 1 well NUPAGE 12% Bis-Tris polyacrylamide gel 
(Invitrogen).The protein was then transferred onto a Whatman Protran nitrocellulose 
transfer membrane in a western blotter at 13V overnight. The membrane was stained 
with Ponceau S and a strip containing the protein was cut out of the membrane, washed 
in PBS + 0.2% Tween 20 (PBST) and blocked in PBST containing 5% (w/v) non-fat milk 
powder for 1 hour. The membrane was then washed 3 times in PBST then incubated 
overnight in rabbit serum diluted 1:1 in PBS, rotating at 4°C. The membrane was again 
washed 3 times in PBST. To elute the bound antibodies, the membrane strip was placed 
into a 2 ml tube containing 100mM glycine pH2.5 for no more than 2 minutes after 
which the solution was neutralised by addition of 1/10 volume of 1M Tris pH8.0. The 
membrane was removed and washed 5 times in PBST. This was repeated several times. 
Purified antibodies were combined and concentrated using a Vivaspin 20 concentrator 
with 10kDa molecular weight cut off (Sartorius Biolab Products). The antibody 
concentration was estimated using the OD 280  on a spectrophotometer. 
2.2.9 IgG purification 
To purify IgG, antibodies/serum were diluted in 10mM Tris pH7.5 and incubated with 
protein G sepharose 4B (Sigma-Aldrich) overnight, rotating at 4°C. The sepharose was 
transferred into a column and washed with 10 column volumes 100mM Tris pH8.0 then 
10mM Tris pH8.0. IgG antibodies were eluted with 10 column volumes of 100mM glycine 
pH2.5 and collected in a tube containing 1 bed volume of 1M Tris pH8.0 to neutralise. 
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The column was washed with 10mM Tris pH7.5 until the column was pH7.5 and stored at 
4°C in PBS containing sodium azide. 
2.2.10 His-Antibody depletion 
Similar to the affinity chromatography described above. CN-Br activated sepharose 4B 
(Pharmacia) was bound to the Txr and His-tag expressed as soluble protein from pET32-
Xa/LIC (glycerol stock provided by Dr. Judith Green - NIMR) and antibodies were 
depleted of His-reacting antibodies by batch incubation with resign and collection of 
flowthrough. 
2.2.11 Western Blot 
Proteins from SDS-PAGE were transferred onto Whatman Protran nitrocellulose transfer 
membrane in a western blotter in transfer buffer (Invitrogen) for 3hrs at 35V or overnight 
at 13V.  Blots were blocked in blocking buffer (5% milk powder in PBS, 0.2% Tween 20) 
for 1h or overnight. Primary antibodies were diluted in the blocking buffer and 
incubated at room temperature for 1 h. Blots were washed 3 times in PBST and 
incubated with HRP-linked secondary antibodies diluted in blocking buffer for 1h. The 
blots were then washed 3 times in PBST. Enhanced chemoluminescence (ECL) detection 
reagents (GE Healthcare) were used for visualisation on Biomax™ MR film (Kodak®). 
2.2.12 Solubility Assay 
Percoll-purified schizonts or early ring stage parasites were hypotonically lysed in 10 
times the pellet volume of 10mM Tris pH8.0 plus 1x complete protease inhibitors 
(Roche) for 1 h at 4°C, with vortexing every 10 minutes. Parasite DNA was sheared using 
a 25G needle. Soluble and insoluble materials were separated by centrifugation at 
100000xg for 30 minutes. The supernatant was collected and the pellet washed in the 
same volume of hypotonic lysis buffer to ensure all soluble material was removed. The 
pellet was resuspended in 0.1M sodium carbonate pH11 and incubated at 4°C for 1 h, 
with vortexing every 10 minutes. Again, to separate the soluble and insoluble 
membrane bound fractions, centrifugation at 100000xg for 30 minutes was performed. 
The pellet was washed in carbonate lysis buffer before solubilsation in Laemmli sample 
buffer and boiled for 5 min. The samples were then analysed by Western Blot. 
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2.2.13 Immunofluorescence Assay (IFA) 
2.2.13.1 Fixed IFA 
Thin films of P. falciparum stage specific parasite material were air dried then fixed in 4% 
paraformaldehyde for 30 minutes, permeabilised in 0.1%Triton X-100 in PBS for 10 
minutes, blocked in 3% bovine serum albumin (BSA) in PBS and stored at 4°C. Primary 
antibodies, diluted in 3% BSA in PBS, were incubated for 1h at room temperature. The 
slide was washed 3 times in PBS before adding secondary antibodies (Invitrogen) in 3% 
BSA. For nuclear staining samples were stained with 5μg/μl of 4,6-diamidino-2-
phenylindol (DAPI), then using Vectashield (Vector Labs) on a coverslip were mounted 
and the slide was stored at 4°C. Images were acquired using a Zeiss Axioplan 2 Imaging 
system (Carl Zeiss, Germany) and AxioVision 3.1 software. 
 
2.2.13.2 Unfixed or live IFA 
Highly synchronized, rupturing 3D7 schizonts were allowed to burst in RPMI 1640 
medium, pelleted at 1500xg for 3 minutes at 4°C then resuspended in 3% BSA in PBS. 
Primary antibody was added at the correct dilution (see Table 2.1 for antibody dilutions) 
and incubated for 30 minutes at room temperature. The samples again were pelleted as 
before and resuspended in the correct dilution of secondary antibody in 3% BSA in PBS, 
incubating for 30 minutes after which samples were pelleted and resuspended in 50μl 
3% BSA in PBS. 2μl of this suspension was transferred to glass slide and mounted with a 
coverslip. Images were acquired using a Zeiss Axioplan 2 Imaging system (Carl Zeiss, 
Germany) and AxioVision 3.1 software. 
2.2.14 Immunoprecipitation of schizont stage parasites 
Schizonts were lysed in 10 x pellet volume with lysis buffer (1% Triton X-100, 50mM Tris-
HCl pH8.0, 5mM EDTA, 5mM EGTA, 150mM NaCl, 1x complete protease inhibitors 
[Roche]) and incubated on ice for 1hr, vortexing every 10 minutes. A 25G needle was 
used to shear the parasite DNA. The samples were centrifuged at 17000xg for 30mins at 
4°C and the supernatant was transferred into a new tube. To reduce background and 
non-specific binding, the sample was pre-absorbed with 150μl of protein G sepharose 
(Sigma-Aldrich) and 20μl of pre-immune rabbit serum (Harlan) for 1 hour, rotating at 4°C. 
The samples were centrifuged at 17000xg at 4°C. The supernatant was collected and 
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split between 2 tubes; to the first 5μl of purified specific antibody was added and to the 
second 5μl of pre-immune serum. Incubation lasted overnight, rotating at 4°C. To pull-
down the antibody/protein complexes, 50μl of protein G sepharose was added and 
rotated at 4°C for 1 hour. The samples were centrifuged at 17000xg for 2 minutes at 4°C. 
Supernatant was discarded and the pellet washed 6 times in lysis buffer with the 
addition of 300mM NaCl. The pellet was resuspended in 50μl reducing Laemmli sample 
buffer, boiled for 5 minutes and the supernatant analysed using SDS-PAGE.  
2.2.15 Immunoprecipitation of 35 S radiolabelled schizonts 
35 S labelled schizonts were prepared by M. Grainger. The immunoprecipitation protocol 
was identical to 2.2.14 above. After protein separation on SDS-PAGE the gel was fixed in 
10% acetic acid and 25% isopropanol in water for 30 minutes, then the signal amplified 
using Amplify (GE Healthcare) for 30 minutes before drying the gel under vaccum at 
70°C for 2 hours. To visualise, the dried gel was exposed to Biomax MR film (Kodak) for 1-
21 days.  
2.2.16 Large-scale Immunoprecipitation for Mass Spectrometry analysis 
To identify binding partners 5ml of purified, pelleted schizont, (46 ± 2 hour p.i. prepared 
by M. Grainger) were lysed and prepared as in 2.2.15.  The cleared lysate was firstly 
passed through a pre-immune antibody affinity column, after which the flowthrough 
was applied to a specific antibody affinity column. Both columns were washed with 20 
column volumes of wash buffer 1 (lysis buffer:1% Triton X-100, 50mM Tris-HCl pH8.0, 
5mM EDTA, 5mM EGTA, 150mM NaCl, 1x complete protease inhibitors [Roche]) followed 
by 20 column volumes of wash buffer 2 (lysis buffer minus NaCl: 1% Triton X-100, 50mM 
Tris-HCL pH8.0, 5mM EDTA, 5mM EGTA, 1x complete protease inhibitors [Roche]) before 
eluting protein from the column with 10 column volumes of 100mM glycine pH2.5, 
0.01% Triton X-100. The eluate was neutralised by addition of 1/10 volume of 1M Tris-
HCl pH 8.0. Samples were concentrated using Vivaspin 500 concentrator with 10kDa 
molecular weight cut off (Sartorius Biolab Products) and resolved by SDS-PAGE, staining 
with either Instant Blue™ or silver-nitrate (2.2.4).  Visible bands were excised and 
analysed by Liquid Chromotography-tandem Mass Spectrometry (LC-MSMS) at PNAC, 
University of Cambridge. 
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2.2.17 Large-scale Immunoprecipitation with PF11_0443-FLAG schizonts 
Approximately 3ml of purified (section 2.3.1), pelleted PF11_0443-schizonts, were lysed 
and prepared as in 2.2.15.  The cleared lysate was bound in batch to anti-FLAG M2 
affinity gel (Sigma Aldrich). The same volume of WT 3D7 schizonts were treated the 
same way and bound to FLAG affinity gel to control for non-specific binding. Both 
samples were applied to a spin column (Sartorius Biolab Products)and were washed with 
20 column volumes of TBS (Tris Buffered Saline: 50 mM Tris, 150 mM NaCl) before eluting 
protein from the column with 5 column volumes of 150 nM 3xFLAG peptide in TBS. 
Samples were concentrated using Vivaspin 500 concentrator with 10kDa molecular 
weight cut off (Sartorius Biolab Products) and resolved by SDS-PAGE, staining with the 
fluorescent stain SYPRO® Ruby according to manufacturer’s instructions.  Visible bands 
were excised and analysed by Liquid Chromotography-tandem Mass Spectrometry (LC-
MSMS) in house by Dr. Steve Howell, Division of Molecular Structure. 
 
2.3 Parasite cell culture 
2.3.1 Maintenance and synchronisation 
P. falciparum 3D7 was cultured in RPMI-1640 with Albumax medium (GIBCO™), with the 
addition of 2 mM L-Glutamine, at 2-4% haematocrit and gassed with a mixture of 7% 
CO
2
, 5% O
2
, and 88% N
2
(Trager and Jensen, 1976). Mature stage parasites were isolated 
on a 70% (v/v) Percoll (GE Healthcare) density gradient as described (Rivadeneira et al., 
1983; Dluzewski et al., 1984).  Further synchronisation using 5% D-sorbitol was 
performed as previously described (Trager and Jensen, 1976; Lambros and Vanderberg, 
1979). Frozen stocks were prepared from 200-300μl of pelleted cultures (828xg 
[2100rpm, Heraeus Megafuge 16, Thermo Scientific], 4 minutes, room temperature) 
containing ~5% ring stage parasites by the drop-wise addition of 700μl Freezing 
solution (111mM NaCl, 166mM D-sorbitol, 28% glycerol). Samples were transferred to 
cryovials (Nunc™) and stored in liquid nitrogen. In order to revive frozen samples, stocks 
are thawed quickly in a 37°C water bath and transferred to a larger tube. One volume of 
thawing solution (3.5% NaCl) was added drop-wise to the stock, which was then 
centrifuged at 270xg (1200rpm in the same centrifuge as above) for 4 minutes at room 
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temperature and the supernatant discarded. The addition of one volume thawing 
solution and following centrifugation was repeated twice more, before adding warmed 
culture medium and transferring to a culture flask. 
2.3.2 Preparation of parasite DNA 
 P.falciparum cell culture with parasitaemia > 5% of any stage was pelleted (828xg 
[2100rpm, Heraeus Megafuge 16, Thermo Scientific], 4 minutes, room temperature) and 
resuspended in 4 pellet volumes of room temperature Buffer A (50mM sodium acetate 
pH5.2, 100mM NaCl, 1mM EDTA). Cells were lysed by the addition of 1 pellet volume of 
18% SDS, inverting the tube to mix, then incubated at room temperature for 2 minutes. 
An equal volume of phenol/chloroform (Sigma Aldrich) was added, mixed and the 
sample was centrifuged at 1028xg (2100rpm, Heraeus Megafuge 16, Thermo Scientific) 
for 14 minutes at room temperature. The parasite DNA was removed from the aqueous 
phase of the lysate to a 15ml Corex glass tube then precipitated with 2.5 pellet volumes 
of cold EtOH plus 1/10 volume of 3M sodium acetate, pH5.2, overnight at -20°C. The 
DNA was pelleted (12000xg, 15 minutes, 4°C) and the pellet air dried. The sample was 
then resuspended in 500ml TE (10mM Tris, 1mM EDTA, pH8.0) and the 
phenol/chloroform step repeated. The DNA was removed to a fresh Eppendorf tube and 
precipitated by addition of an equal volume of isopropanol plus 1/10 volume of 3M 
sodium acetate, pH5.2,. The DNA was pelleted (17000xg, 10 minutes, 4°C) then washed 
with 80% EtOH before air drying and resuspension in an appropriate volume of TE, 
depending on pellet size. 
2.3.3 Preparation of parasite RNA and cDNA 
P.falciparum 3D7 RNA was prepared as previously described (Kyes et al., 2000). In brief 
parasitized erythrocytes were  pelleted (828xg [2100rpm, Heraeus Megafuge 16, Thermo 
Scientific], 4 minutes, room temperature) and resuspended in 10-20 volumes (10 
volumes for early rings, 20 for late schizonts) of pre-warmed (to 37°C) TRIzol (Gibco Life 
Technologies) and agitated until clumps dissolved. Samples were stored at -80°C at this 
stage. To continue with RNA preparation, samples were thawed on ice and 2 pellet 
volumes of chloroform added. Samples are agitated vigorously for 15 seconds and 
incubated at room temperature for 3 minutes after which the sample was centrifuged at 
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4700xg (7000rpm, Heraeus Fresco 17, Thermo scientific) for 30 minutes at 4°C. The 
aqueous supernatant was removed to a fresh tube, avoiding the interface and possible 
DNA contamination. To this, 0.5 times the original TRIzol volume of ice cold isopropanol 
was added, mixed and left to incubated on ice for 2 hours before pelleting the RNA at 
4°C, 12000xg for 30 minutes. The supernatant was removed and the pellet washed in 
75% ethanol, pelleting as before. The RNA pellet was air dried before resuspending in a 
small volume of DEPC treated water. The concentration of the RNA was estimated by 
spectrophotometry. To remove salt and DNA contamination and concentrate the RNA, 
RNeasy® Minielute™ Cleanup kit (Qiagen) was used, following manufacturer’s 
instructions. The Reverse Transcription System (Promega) was used to produce cDNA, 
according to the manufacturer’s instructions. 
2.3.4 Time-course Analysis 
P. falciparum 3D7 blood stage parasites were tightly synchronised so that egress and re-
invasion within the culture would complete in 1-2 hours. Upon re-invasion (time point 
zero) protein samples were taken and thin smears were made from the culture for 
Giemsa staining and use in indirect immunofluorescence assays. Further samples were 
taken every 4 hours until schizont egress/reinvasion which took place at approximately 
46.5 h p.i. Each protein sample contained 50μl of pelleted cells and the number of cells 
per sample was counted using a haemocytometer. Parasitaemia was counted for each 
time point and averaged (as each time point came from the same starter culture) and 
this was used to calculate the number of parasites per sample. Due to the abundance of 
haemoglobin from the rbcs, samples were hypotonically lysed in 10mM Tris, pH8.0 and 
the hypotonic pellet was resuspended in 2x reducing Laemli sample buffer to a 
concentration of 2x105 parasites/μl. Protein samples were separated by SDS-PAGE with 
2x106 parasites (10μl) per well. Hypotonically lysed rbcs were included in the western 
blot to control for parasite versus rbc specific band recognition. Protein expression was 
analysed by western blot using the polyclonal antibodies raised againt the recombinant 
proteins. A glycophorin A/B antibody was used as a loading control. Antibodies against 
the parasite ER resident protein BiP were used to confirm the presence of parasites in 
each lane and MSP-2 was used as a late stage marker. Images of Giemsa stained 
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parasites from each time point were taken to demonstrate parasite morphology at each 
stage. 
2.3.5 Transfection 
Ring-stage P. falciparum 3D7 parasites were transfected using previously described 
methods (Wu et al., 1996; Crabb et al., 1997). In brief, 100μg of transfection construct 
DNA was previously ethanol precipitated and dissolved in 15μl TE (10mM Tris, 1mM 
EDTA, pH8.0). On the day of transfection 385μl of sterile cytomix (120mM KCl, 0.15mM 
CaCl 2 , 2mM EDTA, 5mM MgCl 2 , 10mM K 2 HPO 4 /KH 2 PO 4 pH7.6, 25mM Hepes pH 7.6) 
was added to the 100μg of DNA. 200 ul of ring stage parasitized RBCs (parasitaemia 8-
10%) were collected by centrifugation at 800 xg and mixed with the dissolved DNA in 
cytomix before transferring to a Gene Pulser® Cuvette, 0.2cm (Bio-Rad) and 
electroporation at 0.31kV, 950μF, ∞ resistance. Transfected cells were immediately 
transferred to a dish with10ml RPMI-Albumax containing 3% rbcs.  The appropriate drug 
for selection was added with the medium 24 hours post transfection and medium 
containing selection drug was replaced every day for 7 days, prior to replacing it every 
48h (10nM WR99210; Jacobus Pharmaceuticals, Princeton, New Jersey, United States) for 
pHTK or pHH4 vectors, 2.5μg/ml Blasticidin-S (Calbiochem®) for the pHH3 vector – see 
transfection vector table, Table 2.2). Parasitaemia was checked every 2 days by thin 
blood smear stained with Giemsa and typically 2-4 weeks after transfection viable 
parasites appeared. Parasites were frozen as described in 2.3.1 and genomic DNA was 
prepared as in 2.3.2. For cultures containing episomal construct, drug pressure was 
continuous so the parasite maintains the plasmid DNA. For integration constructs 
parasites are cycled on-and-off drug. Drug selection pressure was removed for 3 weeks 
before reapplication, when frozen stocks and genomic samples were prepared. This was 
repeated for 3 to 5 cycles and integration status was analysed by PCR, Southern Blot or 
immunoblotting . For transfectants with double-crossover homologous recombination 
constructs (pHTK), after each drug cycle on WR99210 the culture was additionally put 
onto 10 μM gancicolvir (Sigma Aldrich). Any parasite containing the thymidine kinase 
(TK) cassette (parasites with episome or integration of a single flank) will be susceptible 
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to the drug. Integration was analysed by Southern blot. Any integrated lines were 
cloned by limiting dilution (Rosario, 1981; Kirkman et al., 1996). 
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Table 2.1: List of primers  
 
 Primer  Purpose Sequence 
A MAL13P1.94fwd Protein 
expression 
5’-GGTATTGAGGGTCGCCGCTTATGCTTGGAA 
GATTTAAGACATC-3’ 
B MAL13P1.94rev Protein 
expression 
3’AGAGGAGAGTTAGAGCCTTATACTTTAATTAGATAT
TCTTTTTCGTC-5’ 
C PF11_0443fwd Protein 
expression 
5’- GGTATTGAGGGTCGCGAAGATTATGATGAA 
CATGATAAG-3’ 
D PF11_0443rev Protein 
expression 
3’- AGAGGAGAGTTAGAGCCCTAATCGTTGTAA 
TTAAAACTTAAAC-5’ 
E PF14_0045fwd Protein 
expression 
5’-GGTATTGAGGGTCGCAACAAAATATCGAGT 
GCTAGAGATGATATTC-3’ 
F PF14_0045rev Protein 
expression 
3’-AGAGGAGAGTTAGAGCCTTAGGAACCTTAT 
TGTCTGTCAATACCTTC-5’ 
G PF02_0040fwd 
(optimised gene) 
Protein 
expression 
5’-GGTATTGAGGGTCGCAATGAAATAAAAAAC 
GCAATGAGTTC-3’ 
H PF02_0040rev 
(optimised gene) 
Protein 
expression 
3’- AGAGGAGAGTTAGAGCCTTATTTCAGTTTCA 
CCACATCTTC-5’ 
I MAL13P1.94_KO
flank1FWD 
Transfection: 
Integration 
5’-CATCATGAATTCGATTTATTATGAATATTTTA 
GAAAATGACATC-3’ 
J MAL13P1.94_KO
flank1REV 
Transfection: 
Integration 
3’-CATCATGGATCCAGCTAAATAATCCCCAATA 
GTCC-5’ 
K MAL13P1.94_pH
H3tagFWD 
Transfection: 
Integration 
5’-CATCATGAATTCTTATAGAATATAAACAGAA 
GAGGACATG-3’ 
L MAL13P1.94_pH
H3TYrev 
Transfection: 
Integration 
3’-CATCATCCGCGGATCTAATGGATCTTGGTT 
GGTGTGAACTTCCCTAGGTACTTTAATTAGATATTCTT
TTTCGTCG-5’ 
M MAL13P1.94_pH
H3x3FLAGrev 
Transfection: 
Integration 
3’-CATCATCCGCGGTTTATCATCATCATCTTTG 
TAATCAATATCGTGATCTTTGTAATCACCATCGTGATC
TTTGTAATCTACTTTAATTAGATATTCTTTTTCGTCG-5’ 
N PF11_0443_KOfl
ank1FWD 
Transfection: 
Integration 
5’-CATCATCCGCGGTTTATTATAATAAATGTATA 
TATTAGAAAAGG-3’ 
O PF11_0443_KOfl
ank1REV 
Transfection: 
Integration 
3’-CATCATAGATCTCTTGTACTTTTATTTACTAA 
TACGTTG-5’ 
P PF11_0443_KOfl
ank2FWD 
Transfection: 
Integration 
5’-CATCATGAATTCAATAGAAGAACAAATTGAA 
GAAGAGG-3’ 
Q PF11_0443_KOfl
ank2REV 
Transfection: 
Integration 
3’-CATCATCCTAGGTATTTACTCTTGTGTTGTC 
GAGC-5’ 
R PF11_0443_pHH
3tagFWD 
Transfection: 
Integration 
5’-CATCATGAATTCATTAAAAAGGGTAATACAG 
AAATCATC-3’ 
S PF11_0443_pHH
3tyREV 
Transfection: 
Integration 
3’- CATCATCCGCGGATCTAATGGATCTTGGTTGGTGT 
GAACTTCCCTAGGATCGTTGTAATTAAAACTTAAACC-
5’ 
T PF11_0443_pHH
3x3flagREV 
Transfection: 
Integration 
3’-CATCATCCGCGGTTTATCATCATCATCTTTGTAATC 
AATATCGTGATCTTTGTAATCACCATCGTGATCTTTGT
AATCCCTAGGATCGTTGTAATTAAAACTTAAACC-5’ 
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U PF02_0040fwdK
O 
Transfection: 
Integration 
5’-CATGAGGAATTCCCTATTCATTAGCTAG 
CCAAA-3’ 
V PF02_0040revKO Transfection: 
Integration 
3’-CTCAGCGGATCCGTGATAATATTTGTAG 
GATGTATTTG-5’ 
W PF02_0040fwdT
AG 
Transfection: 
Integration 
5’-CATGAGGAATTCCCTATTCATTAGCTAG 
CCAAA-3’ 
X PF02_0040revTY
tag 
Transfection: 
Integration 
3’-CACTAGCCGCGGTTAATCTAATGGATCTTGGT 
TGGTGTGAACTTCCCTAGGTTTGCTTTTTTTCTTTT
TCTTC-5’ 
Y PF02_0040revFL
AGtag 
Transfection: 
Integration 
3’-CACTAGCCGCGGTTATTTATCATCATCATCTTTGTA 
ATCAATATCGTGATCTTTGTAATCACCATCGTGATCTT
TGTAATCCCTAGGTTTGCTTTTTTTCTTTTTCTTC-5’ 
Z PF02_0040gfpF
WD 
Transfection: 
Episomal 
expression 
5’-CATGGACCTAGGATGTTCATATTATACA 
TAATTTTTGTTGTTATTCC-3’ 
AA PF02_0040gfpRE
V 
Transfection: 
Episomal 
expression 
3’-CATGGACCTAGGTTTGCTTTTTTTCTTTT 
TCTTCTTCGAATTC-5’ 
 
BB MAL13P1.94_5_
UTR 
Diagnostic 
primer 
5’-GTAGTTTTCTCAATAAATAGATATTATCA 
TGGC-3’ 
CC MAL13P1.94_3_
UTR 
Diagnostic 
primer 
3’-CTATAGAAAATATGCTCATTCCTGTCAT 
G-5’ 
 
DD PF02_0040_5_U
TR 
Diagnostic 
primer 
5’-AATTCCATAAAGCATTTCTCTTAAAATGT 
GTC-3’ 
EE PF02_0040_3_U
TR 
Diagnostic 
primer 
3’-TAGAAAATAAAAATAAGAAAATTAAATTA 
TGATTGAAGTGAC-5’ 
FF PF11_0443diagn
ostic1FWD 
Diagnostic 
primer 
5’-ATCTTTTAATCCCTTATTAAATTGTTACAT 
ATC-3’ 
 
GG PF11_0443diagn
ostic2FWD 
Diagnostic 
primer 
5’-TAGAAAAGGATTAAAAAAAGGGACATT 
G-3’ 
HH PF11_0443FLAG
senseStoA 
Site directed 
mutagenesis 
5'-AAAACAAATAAGAATGAAGAAAAAAGGTTTA 
GCTTTTAATTACAACGATCCTAGGGATTACAAA-3' 
II PF11_0443FLAG
antisenseStoA 
Site directed 
mutagenesis 
5'-TTTGTAATCCCTAGGATCGTTGTAATTAAAA 
GCTAAACCTTTTTTCTTCATTCTTATTTGTTTT-3' 
JJ PF02_0040signal
anchorGFPfwd 
Transfection: 
Episomal 
expression 
5’-CTAGAATGTTCATATTATACATAATTTTT 
GTTGTTATTCCATTTTTAATATTTGCTTATATCATA
TATAAAAATGTCC-3’ 
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KK PF02_0040signal
anchorGFPrev 
Transfection: 
Episomal 
expression 
3’-CTAGGGACATTTTTATATATGATATAAGC 
AAATATTAAAAATGGAATAACAACAAAAATTATG
TATAATATGAACATT-5’ 
LL PF11_0443TM2f
wd 
Transfection: 
Episomal 
expression 
5’-CATGGACCCGGGCAAGAAATTGTTATGATTA 
ATAATCAGAAGACTAAG-3’ 
 
MM PF11_0443TM2f
wd 
Transfection: 
Episomal 
expression 
5’-CATGGACCCGGGATCTTCATTTAATATATTA 
TATTTAATAACCCATTTTATATTCC-3’ 
 
NN Hrp2 sequence 3 
(E. Knüpfer) 
Diagnosis GATTCATTATTCTATATTTATAAGGAAGATTAC 
OO Hsp86 sequence 
2 (E. Knüpfer) 
Diagnosis CTTAATTTCTCACGTTGTTAAAA 
 
Legend:  ___ : Restriction enzyme site 
     Text: Mutagenesis site 
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Table 2.2: Table of Transfection Constructs 
Construct name Product Purpose 
pHH3MAL13P1.94ko Truncated  
MAL13P1.94  
Integration by single homologous 
recombination resulting in truncation of 
MAL13P1.94 and possible loss of function 
pHH3MAL13P1.94ty C terminally Ty1 
tagged 
MAL13P1.94 
Integration by single homologous 
recombination resulting in tagged 
MAL13P1.94 line 
pHH3MAL13P1.94flag C terminally 3x 
FLAG tagged 
MAL13P1.94 
Integration by single homologous 
recombination resulting in tagged 
MAL13P1.94 line 
pHH3MAL13P1.94_3’ WT 3D7 
MAL13P1.94 gene 
Integration by single homologous 
recombination demonstrating accessibility 
of genomic locus 
pHTK_PF11_0443ko Deleted 
PF11_0443 
Integration of hDHFR cassette into the 
genomic locus by double homologous 
recombination resulting in the removal of 
PF11_0443 
pHH3PF11_0443ty C terminally Ty1 
tagged PF11_0443 
Integration by single homologous 
recombination resulting in PF11_0443-Ty1 
pHH3PF11_0443flag C terminally 3x 
FLAG tagged 
PF11_0443 
Integration by single homologous 
recombination resulting in tagged 
PF11_0443 line 
pHH3PF11_0443_3’ WT PF11_0443 
gene 
Integration by single homologous 
recombination demonstrating accessibility 
of genomic locus 
pHH3PF02_0040ko Truncated  
PF02_0040  
Integration by single homologous 
recombination resulting in truncation of 
PF02_0040 protein and possible loss of 
function 
pHH3PF02_0040ty C terminally Ty1 
tagged PF02_0040 
Integration by single homologous 
recombination resulting in tagged 
PF02_0040  
pHH3PF02_0040flag C terminally 3x 
FLAG tagged 
PF02_0040 
Integration by single homologous 
recombination resulting in tagged 
PF02_0040  
pHH3PF02_0040_3’ WT PF02_0040 
gene 
Integration by single homologous 
recombination demonstrating accessibility 
of genomic locus 
pHH3PF11_0443flagS316A C terminally 3x 
FLAG tagged 
PF11_0443 S316A 
Integration by single homologous 
recombination resulting in tagged 
PF11_0443 plus the exchange of serine 
316 to alanine 
pHH3PF11_0443gfp PF11_0443-GFP Integration by single homologous 
recombination resulting in tagged 
PF11_0443 line 
pHH3MSP3prom_SP0040_gfp GFP tagged 
PF02_0040 signal 
anchor 
Episomal expression PF02_0040 signal 
anchor sequence fused to a GFP reporter 
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Figure 2.1: Integration Strategy. Parasite vectors for single homologous genomic 
integration (A+B) were based on the pHH3 transfection plasmid. A) Regions of 
homology to the gene of interest were cloned into pHH3 using EcoRI and SacII. FLAG 
and TY tags were introduced to the vector backbone on the primer. Each tag was 
flanked with AvrII and SacII restriction sites. B) Regions of homology were cloned using 
EcoRI and BamHI.  C) Double homologous recombination vectors were based on the 
pHTK transfection vector. Regions of homology from the N-terminus and 5’ UTR region 
was inserted into multiple cloning site (MCS) 1 using SacII and BglII and from the C-
terminus and 3’ UTR into MCS 2 using EcoRI and AvrII.  
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Table 2.3 Table of Protein Expression Constructs 
 
Protein Region (amino acids) Vector Purpose 
 
MAL13P1.94 154 – 191 pET30-Xa/LIC Raising antibodies
PF11_0443 237 – 321 pET30-Xa/LIC Raising antibodies
PF14_0045 391 – 600 pET30-Xa/LIC Raising antibodies
PF14_0045 391 – 600  pET32-Xa/LIC Raising antibodies
PF02_0040 41 – 121  pET30-Xa/LIC Raising antibodies
PF02_0040 28 – 276 pET30-Xa/LIC Raising antibodies
PF02_0040 28 – 276 pET32-Xa/LIC Raising antibodies
PF11_0443 34 – 98 (J domain) pET30-Xa/LIC Raising antibodies
PF11_0443 135 – 232 pET30-Xa/LIC Raising antibodies
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2.4 Table of Antibodies 
 
Primary 
antibodies 
Type Animal Target Conc. 
IFA 
Conc. 
Western 
Supplier 
αMAL13P1.94 Polyclonal Rabbit MAL13P1.94 1:200 1:200 This study 
αPF11_0443 Polyclonal Rabbit PF11_0443 1:500 1:2000 This study 
αPF14_0045 Polyclonal Rabbit PF14_0045 1:100 1:200 This study 
α PF02_0040 Polyclonal Rabbit PF02_0040 1:1000 1:5000 This study 
1E1 Monoclonal Mouse MSP1.19 1:3000 - (Blackman et 
al., 1994) 
αMSP1 Polyclonal Rabbit MSP1.83 1: 20000 - (Arnot et al., 
2008) 
αRhopH2 Polyclonal Rabbit RhopH2 1:4000 - (Ling et al., 
2003) 
61.3 Monoclonal Mouse RhopH2 1:200 - (Holder and 
Freeman, 
1984a) 
24C6 Polyclonal Mouse RON4 1:1000 - (Alexander et 
al., 2006) 
αAMA-1 Polyclonal Mouse AMA-1 1:400 - (Collins et al., 
2007) 
αAMA-1 Polyclonal Rabbit AMA-1 1:2000 - (Arnot et al., 
2008) 
EBA-175VI Monoclonal Mouse EBA-175 1:100 - MR4 
EBA-175VI Polyclonal Rabbit EBA-175 - 1:500 MR4 
MSP3 Polyclonal Rabbit MSP3 - 1:3000 (Mills et al., 
2002) 
113.1 Monoclonal Mouse MSP2 1:500 1:1000 (Gerold et al., 
1996) 
28.2 Monoclonal Mouse RESA 1:500  (Anders et al., 
1986) 
αBiP Polyclonal Rat BiP 1:500  E. Knüpfer, 
unpublished 
M2 Monoclonal Mouse FLAG tag 1:7500 1:20000 Sigma Aldrich 
αTy1  Polyclonal Rabbit Ty1 tag 1:500 1:1000 antibodies 
online.com 
       
Secondary 
antibodies 
      
αrabbit/mouse 
/ratAlexa Fluor 
488 
Polyclonal Goat Rabbit/mouse 
/rat Fc 
1:5000 - Invitrogen 
αmouse/rabbit 
/rat Alexa Fluor 
594 
Polyclonal Goat Rabbit/mouse 
/rat Fc 
1:5000 - Invitrogen 
αrabbit/mouse 
/rat HRP 
Polyclonal Goat Rabbit/mouse 
/rat Fc 
- 1:2500 Biorad 
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Chapter 3: The selection process and bioinformatic 
analysis of eligible proteins 
 
 
3.1 Introduction 
 
With the rapid spread of drug and insecticide resistance and the failure to discover an 
effective vaccine from the limited number of candidates, the urgent need for new 
antigens and drug targets is increasingly apparent. The completion of the Plasmodium 
falciparum 3D7 genome sequence gave the field of molecular parasitology the boost it 
needed to address these problems. Functional genomics has had a dramatic impact on 
the way in which stage-specifically expressed genes are identified and selected for 
further study. Genome comparisons revealed 60% of the P. falciparum genome was 
unique with little or no homology between Plasmodium genes and those from a wide 
range of previously sequenced organisms (Gardner et al., 2002). This great number of 
genes with unknown function could harbour the new Plasmodium falciparum drug or 
vaccine candidate. Utilising the wealth of genomic, transcriptomic, proteomic and 
bioinformatic data available we seek to identify novel Plasmodium antigens involved in 
invasion of host rbcs, a process which is thought to be an ideal target for intervention. 
Novel proteins involved in this process can be uncovered using features such as timing 
of expression from microarray or RNAseq based transcriptome analysis or presence in 
stage-specific proteomes. 
 
3.1.1 P. falciparum transcriptome  
Since the publication of the P. falciparum genome in 2002, a number of global 
transcriptome studies have been published. The first of these as published in 2003 and 
revealed the important relationship between expression timing and gene function. A 
DNA microarray study of the P. falciparum HB3 clone intra-erythrocytic stages (Bozdech 
et al., 2003) revealed that a large number of gene expression profiles exhibit periodicity 
and clear peaks and troughs of maximum and minimum expression within the 48 hour 
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cycle which corresponds to the point in the cycle the gene product is required. For 
example, the gene ama1, known to be involved in the erythrocyte invasion process, 
shows peak transcript expression 40 hours post invasion (p.i.). which coincides with the 
formation of the micronemes of which it is a part.  
An alternative transcriptome by Le Roch et al. (2004) used high density oligonucleotide 
array analysis of RNA from 6 phases from the intra-erythrocytic cycle corresponding to 
the changes in distinct morphological stages of the intracellular parasite - early ring, late 
ring, early trophozoite, late trophozoite, early schizont and late schizont - as well as 
merozoites, sporozoites and gametocytes. Parasites used in the study were obtained 
using two alternative synchronization methods, sorbitol or temperature. Invasion 
related genes such as MSP-1, AMA-1, SUB2 and EBAs were highly expressed in the same 
cluster (cluster 15) suggesting genes expressed at a similar time may also function in 
invasion (Le Roch et al., 2004). 
 
3.1.2 Proteome data 
A number of high-throughput mass spectrometry based proteomic studies have been 
undertaken in the past decade. Florens et al. (2002) identified approximately 2400 
proteins from sporozoites, trophozoites, merozoites and gametocytes using multi-
dimensional protein identification technology (MudPIT)(Florens et al., 2002). The Leiden 
Malaria Group provided a mass spectrometry based merozoite proteome which is 
available on PlasmoDB (http://plasmodb.org). With advances in the field of mass 
spectrometry the data produced are more reliable and able to identify proteins of low 
abundance from every stage of the lifecycle including gametocytogenesis (Silvestrini et 
al., 2010); oocysts, oocyst-derived sporozoites, salivary gland sporozoites (Lasonder et 
al., 2008) and liver stages (Tarun et al., 2008), as well as late/rupturing schizonts (Bowyer 
et al., 2011) and proteomes from clinical samples (Acharya et al., 2009). Additional 
features such as the presence of phosphorylated serine and threonine residues can also 
be detected by mass spectrometry methods and the  first phospho-proteome of blood 
stages has been described (Treeck et al., 2011; Lasonder et al., 2012) . 
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3.1.3 Comparative genomics 
Although the sequencing of the P. falciparum 3D7 genome has provided valuable 
insights into the parasite’s biology, comparison between the genomes of other 
Plasmodium spp. as well as other unicellular eukaryotic pathogens can supply important 
information regarding the evolution and physiology of the parasite. Additionally, it 
enhances our ability to assign function to a predicted protein through identification of 
orthologous proteins in other species. The genomes of several Plasmodium species have 
been published -  P. falciparum IT (Parasite Genomics Group, 2011); P. vivax Sal-1 (Carlton 
et al., 2008); P.knowlesi strain H (Pain et al., 2008); P. berghei strain ANKA (Parasite 
Genomics Group, 2010b);  P.yoelii yoelii str. 17XNL (Carlton et al., 2002);  P. chabaudi 
chabaudi AS (Parasite Genomics Group, 2010a). Genomes of fellow apicomplexa - T. 
gondii, Th. parva, Th. annulata, B. bovis, Cr. parvum, Cr. hominis, Neospora caninum and 
Eimeria tenella are also available as well as a multitude of other organisms such as 
bacteria, yeast, fungi and higher eukaryotes such as plants and vertebrates. Comparison 
with Toxoplasma is particularly relevant as it is currently the best studied Apicomplexa 
due to its superior experimental capacity (Kim and Weiss, 2004).  
 
3.1.4 Protein interaction studies 
The yeast-2-hybrid system is a high-throughput method for identification of protein-
protein interactions and was applied to Plasmodium by LaCount et al.  (2005). The system 
applied to other organisms generated a large number of false positives, as was the case 
for Drosophila (Giot et al., 2003; Formstecher et al., 2005). Also, the use of this system in 
Plasmodium failed to identify a large number of well established interactions such as 
those between MSP-1, -6 and -7, thus the results from this work shall not be included in 
the bioinformatic analysis presented here (LaCount et al., 2005). 
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3.2 Results: the selection process and resulting proteins 
 
The aim of this project was to characterise proteins of the malaria parasite Plasmodium 
falciparum involved in erythrocyte invasion. The published sequence, transcript and 
proteomic data for each gene in any of the sequenced species of the Plasmodium 
genome are housed in the Plasmodium database PlasmoDB (plasmodb.org). To identify 
proteins that fit the criteria (explained in section 1.7) I utilised the database’s refined 
‘search’ tool, taking advantage of published sequencing, transcript, proteomic and 
domain predictions.  
 
Criterion a) Expressed during schizogony and in the merozoite 
Transcription data from Bozdech et al (2003) estimated the peak transcript levels of 
AMA-1 at around 40-42 hours p.i. (data available on PlasmoDB). Therefore the first part 
of my search involved identifying proteins with a maximal expression of 42 ± 4 hours p.i. 
The second, following the same transcription profile, added the additional step of 
including minimum expression of 24 ± 8 hours. This resulted in a list of 566 genes to be 
processed with further stringency.  
 
Criterion b) Presence of a signal peptide or anchor sequence 
Signal sequences are required for entry into the secretory system, the first step for 
transport to apical organelles or the merozoite surface. Signal peptides are characterised 
by a stretch of hydrophobic residues followed by a ‘stop transfer’ motif and the presence 
of a signal peptidase cleavage site, whereas signal anchor sequences lack the cleavage 
site and remain in the ER membrane. The presence of a signal sequence can be 
predicted from the gene product’s translated amino acid sequence using web-based 
algorithms such as SignalP (Nielsen et al., 1997), which was used in this case. After 
searching the 566 genes for those which translated into proteins containing signal 
sequences, 116 qualified for further scrutiny. 
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Criterion c) The proteins should possess one or more transmembrane domain(s) 
From the predicted protein sequences of each gene, regions likely to span the cell 
membrane can be identified. This information is provided on the PlasmoDB database 
and using the TMHMM web-based algorithm (Sonnhammer et al., 1998; Krogh et al., 
2001). Of the 166 genes with late stage transcription and  a gene product with predicted 
secretory signal 64 also had one or more predicted transmembrane spanning regions.  
 
Criterion d) Proteins should be conserved across Plasmodium spp.  
Although the P. falciparum 3D7 was the first genome to be sequenced in 2002, several 
other species of Plasmodium have been sequenced since (P. falciparum IT; P. vivax Sal-1; 
P.knowlesi strain H; P. berghei strain ANKA;  P.yoelii yoelii str. 17XNL;  P. chabaudi 
chabaudi, referenced in 3.1.3 above) and these data were utilised to search for 
orthologous genes. Every one of the 64 predicted proteins possessed homologues in 2 
or more of sequenced species and therefore failed to narrow the list any further. 
 
This list of 64 genes and their putative proteins was filtered further based on available 
data such as transcript expression levels, expression in other life cycle stages, presence 
in schizont/merozoite proteomes, difficulty of study (low expression levels or a large 
number of transmembrane regions) and novelty. The full list of 64 proteins is detailed in 
Appendix A and includes reasons for consideration/dismissal. I selected 4 proteins 
initially for further study: MAL13P1.94, PF11_0443, PF14_0325, and PF02_0040, as well as 
an additional fifth protein of special interest to the lab, PF14_0045. This protein was not 
selected by the initial criteria as the peak transcript expression occurs later than 44 hours 
post invasion however from transcript and proteomic data it appears to be expressed in 
the merozoite.  
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Figure 3.1. The selection process. Five proteins were selected using the following criteria to 
search the database PlasmoDB: a) the protein should be expressed during the blood stage – 
peak expression 42 hours post invasion (p.i.) ± 2 hours and then minimum expression 24 hours 
p.i. ± 8 hours; b) the translated protein should contain a signal peptide/anchor; c) one or more 
transmembrane domains and d) the protein should be conserved between Plasmodium species. 
The last step was unnecessary as all of the 64 proteins selected were conserved within the 
sequenced genomes of Plasmodium species. There were 32 selected proteins which were either 
already defined or under investigation. The list was then filtered further based on available data 
such as transcript expression levels, expression in other life cycle stages, presence in merozoite 
proteome and difficulty of study. * highlight gene chosen due to interest from the lab.  
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3.3 In silico analysis of individual proteins 
 
After selection, the protein sequences were examined using numerous analysis 
programs and web-based algorithms, predicting the presence of some recognisable 
features within the selected proteins.  Transmembrane region predictions were 
confirmed using TMHMM (Sonnhammer et al., 1998; Krogh et al., 2001), TMpred (K. 
Hofmann, 1993) and TopPred (von Heijne, 1992). Signal peptides were detected using 
the latest version of SignalP (SignalP4.0) (Petersen et al., 2011) which predicts signal 
peptidase cleavage sites only, whereas signal anchor regions were suggested using 
SignalP 2.0 which also predicts the presence of transmembrane regions within the signal 
sequence using the Hidden Markov Model (HMM) algorithm (Nielsen and Krogh, 1998).  
Any conserved domains were predicted from the protein sequence by Pfam (Finn et al., 
2008), the conserved domain database (CDD) (Marchler-Bauer et al., 2011). SMART 
(simple modular architecture research tool) was used to confirm the presence of these 
domains as well as transmembrane regions and signal peptides (Schultz et al., 1998). 
Alignments were produced for each protein using the ClustalW algorithm, showing level 
of conservation between their other Plasmodium counterparts and orthologues in other 
species (Larkin et al., 2007). Orthologues were predicted and sequences were obtained 
from the OrthoMCL database (Li et al., 2003; Chen et al., 2006) and confirmed using the 
NCBI BLAST tool. For some proteins, this data mining produced interesting leads into the 
possible function of the protein.  The selected proteins are introduced below and data 
recovered from in silico analysis discussed.  
 
3.3.1 MAL13P1.94 
 
Transcript data 
The transcriptome data produced by Bozdech et al. (2003) shows peak expression of 
MAL13P1.94 mRNA in the HB3 clone at around 38 hours p.i. In accordance with this, the 
Le Roch study showed maximum expression of this protein in late schizonts in both 
sorbitol and temperature synchronised methods (Le Roch et al., 2004). Transcript 
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expression levels are comparable to those of AMA1 and therefore should be in 
reasonable abundance to visualise within the cell (illustrated in figure 3.1 A.).  
 
Proteomic data 
This protein was not present in any proteomic studies available at the time of selection 
of proteins for further study. However this was only based on two studies; Florens et al. 
(2002) and the Leiden Malaria Group merozoite proteome [(Khan, 2008), available on 
PlasmoDB]. Also the protein is relatively small in size and its firm attachment to the 
membrane via four transmembrane passes may have made it difficult to extract and 
solubilise. Since beginning this project 2 peptides from the extreme C-terminus were 
detected in a proteomic study by Treeck et al (2011) (figure 3.1 B.), confirming the 
protein presence in blood stages.  
 
Bioinformatic predictions 
At a predicted molecular weight of 22 kDa, MAL13P1.94 is a relatively small Plasmodium 
protein and yet is predicted to contain 4 transmembrane domains using TMHMM, 
TMpred and TopPred algorithms, their location is detailed in figure 3.1 C. The N-terminal 
transmembrane region overlaps with a signal sequence and is predicted to be a signal 
anchor region using SignalP 2.0. No conserved domains were predicted by either Pfam 
or CDD. 
 
Orthologous proteins in other species 
Orthologues of MAL13P1.94 in other species were identified from PlasmoDB and 
OrthoMCL-DB (Li et al., 2003), from the orthologue group OG5_145102 and confirmed 
using NCBI BLAST tool. The protein is highly conserved in Plasmodium spp. (P. bergei: 
PBANKA_141650; P.chabaudi: PCHAS_141830; P. knowlesi: PKH_141720; P. vivax: 
PVX_122720) with the notable absence of P. yoelii, although this is due to lack of proper 
sequence assembly rather than a notable omission from the genome. Using the tblastn 
algorithm on NCBI BLAST it appears the gene can be found split between contigs 
AABL01001120 and AABL01003528 (amino acids 1-112 and 141-192 respectively). 
MAL13P1.94 has orthologues in other genera, namely Toxoplasma gondii, Neospora 
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canium, Theileria annulata, Babesia bovis and several Cryptosporidium species but not 
outside the phylum of Apicomplexa.  All of these proteins share similar domain 
architecture, with 4 transmembrane domains, the first of which is a signal anchor. The 
protein sequences were aligned using the ClustalW multiple alignment algorithm 
(Thompson et al., 1994) in order to visualise and calculate the sequence similarity 
between species (figure 3.2). P. knowlesi and P. vivax orthologues of MAL13P1.94 are 
highly conserved with identities of 73 and 72% respectively however outside the genus 
this is not the case, with sequence identities of 25% with T. gondii and only 15% for B. 
bovis. Despite this low identity these proteins share a similar predicted size and domain 
architecture, each containing 4 transmembrane regions.  
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Figure 3.2: MAL13P1.94 transcription profiles, proteomic data and predicted domain 
architecture. (A) The transcriptome from Bozdech et al (2003) shows a maximum 
transcript level of mal13p1.94 at 38 h p.i. Two peptides from the C-terminus of the 
protein were recovered from schizont stage parasites in the proteomic study by Treeck 
et al (2011). These peptides have been mapped to the predicted protein sequence and 
highlighted in grey (B). This 22kDA protein is predicted to contain 4 transmembrane 
domains, the first of which a signal anchor region (C).  The domains were mapped onto 
the predicted protein sequence and illustrated in (D).  
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Figure 3.3: Multiple sequence alignment of MAL13P1.94 orthologues. Sequences from 
Plasmodium spp. and orthologues from Apicomplexa of MAL13P1.94 were aligned using 
the ClustalW multiple alignment algorithm. Residues identical in over 50% of the chosen 
sequences are shaded in dark blue and those which are functionally similar are 
highlighted in light blue. Transmembrane domains are shown in yellow based on the 
Plasmodium sequences, regions may be different in other Apicomplexa. 
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3.3.2 PF11_0443 
 
3.3.2.1 Transcript data 
The transcriptome data produced by Bozdech et al. (2003) shows peak expression of 
PF11_0443 mRNA in the HB3 clone at around 33 hours p.i. In accordance with this, the Le 
Roch study showed maximum expression of this protein in early schizonts in 
temperature synchronised cultures however expression is maintained at a high level in 
late schizonts. Using the sorbitol method the transcript levels peak in late schizonts; this 
highlights a discrepancy between the two synchronisation methods and between 
transcriptomes. Expression levels are comparable that of to AMA-1and therefore should 
be in reasonable abundance to ease further experimental analysis (Le Roch et al., 2003). 
These data are depicted in figure 3.3 A. 
 
3.3.2.2 Proteomic data 
This protein was not detected in the proteomic study by Florens et al. (2003) however 
the Leiden Malaria Group merozoite proteome (available on PlasmoDB) identified 3 
peptide matches, confirming the gene PF11_0443 encodes a protein which is expressed 
in the erythrocyte invasive form of the parasite. Since then peptides have been detected 
in several proteomic studies from schizont and merozoite stages, covering the full 
length of the protein with the exception on the extreme N terminus, illustrated in figure 
3.3 B (Bowyer et al., 2011; Siverstrini et al., 2010; Treeck and Saunders et al., 2011). 
 
3.3.2.3 Bioinformatic predictions 
PF11_0443 has a predicted molecular weight of 39kDa with 2 or 3 predicted membrane 
spanning regions depending on the algorithm (illustrated in figure 3.3 C). Although 2 of 
the 3 algorithms used assigned a transmembrane domain to the N-terminus of the 
protein, SignalP 4.0 identified a signal peptide cleavage site after the cysteine at position 
22 with a probability of 0.967 and therefore it is likely this region is not a signal anchor 
region but a classical hydrophobic signal peptide. The fact the N-terminus is absent from 
the previously described proteomes gives weight to this likelihood. The second 
predicted transmembrane was predicted by all 3 algorithms and the third by 2 out of 3, 
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with the third just below the threshold score necessary for transmembrane prediction. 
The reason for this discrepancy may be a proline at position 217 which is traditionally a 
helix-breaker and may disrupt the helical transmembrane domain. Although it is likely 
this is a transmembrane domain, experimental confirmation is required. The most 
distinctive feature of this protein is the presence of a DnaJ domain at the N terminus of 
the protein between residues 36 and 92, making this protein a member of the Hsp40 or J 
protein family.  A study by Botha et al (2007) identified 43 Hsp40s present in P. 
falciparum 3D7 and assigned this protein to a group of type IV J proteins. This means it 
lacks any of the previously recognised features which would allow it to achieve the 
primary function of an Hsp40 which is to bind to Hsp70.  The role of Hsp40s in 
Plasmodium is discussed in chapter 5.1. Botha et al (2007) suggested that PF11_0443 is a 
resident of the apicoplast based on the protein’s charged N-terminal sequence which is 
similar to an apicoplast transit peptide however analysis using the PlasmoAP algorithm 
(Foth et al., 2003) could not confirm this. 
 
3.3.2.4 Orthologous proteins in other species 
Orthologues of PF11_0443 in other species were identified from PlasmoDB and 
OrthoMCL-DB, from the orthologue group OG5_131379 (Li et al., 2003) and confirmed 
using NCBI BLAST tool. The protein is highly conserved in Plasmodium spp. (P. berghei: 
PBANKA_090580; P.chabaudi: PCHAS_070700; P. knowlesi: PKH_094070; P. vivax: 
PVX_092765; P. yoelii: PY01970). Significantly, PF11_0443 has no obvious orthologues in 
other apicomlexa and in fact almost all of the non-Plasmodium orthologous proteins 
appear to be in multi-cellular eukaryotes (listed in table 3.1). The existence of 
orthologous proteins in non-Apicomplexa and non-plant species provides further 
evidence against a role for this protein in the apicoplast. The protein sequences were 
aligned using the ClustalW multiple alignment algorithm (Thompson et al., 1994) in 
order to visualise and calculate the sequence similarity between species (figure 3.4). P. 
falciparum is 59% identical to P. vivax or P. knowlesi and slightly less at 50% and 52% for 
the rodent malarias, P. berghei and P. chabaudi respectively.  This identity drops by up to 
30% when comparing P. falciparum with metazoa for example PF11_0443 shares 20% 
identity with Homo sapiens. The orthologues all share similar a transmembrane domain 
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architecture as well as an N-terminal DnaJ domain. Importantly the non-Plasmodium 
orthologues all share an HPD motif within their J domain, the significance of this will be 
discussed in chapter 5. They also share a higher degree of similarity at the C-terminus 
with 4 conserved tryptophan residues. Tryptophan is a relatively rare amino acid to P. 
falciparum due to its single guanine rich codon suggesting these residues are necessary 
for the protein’s function. These features are illustrated on the PF11_0443 orthologue 
alignment in figure 3.5. 
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Figure 3.4: PF11_0443 transcription profile, proteomic and bioinformatic data summary. (A) The 
transcriptome from Bozdech et al. (2003) shows a maximum transcript level of pf11_0443 at 33 h 
p.i. Several peptides have been recovered from schizont and merozoite stage parasites in a 
number of proteomic studies. These peptides have been mapped to the predicted protein 
sequence highlighted above in (B). This 39kDa protein is predicted to contain either 2 or 3 
transmembrane domains and a signal peptide (C). Domains were mapped onto the predicted 
protein sequence and illustrated in (D). 
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Table 3.1: Species which possess orthologues of PF11_0443. 
Aedes aegypti Dictyostelium discoideum 
AX4 
Ricinus communis 
Anopheles gambiae str. 
PEST 
Drosophila melanogaster Rattus norvegicus 
Arabidopsis thaliana Danio rerio Schistosoma mansoni 
Brugia malayi Gallus gallus Schistosoma mansoni 
Bombyx mori Homo sapiens Trichoplax adhaerens 
Caenorhabditis briggsae 
AF16 
Monosiga brevicollis MX1 Tetraodon nigroviridis 
Caenorhabditis elegans Monodelphis domestica Tetraodon nigroviridis 
Caenorhabditis elegans Mus musculus Thalassiosira pseudonana CCMP1335 
Ciona intestinalis Nematostella vectensis Takifugu rubripes 
Canis lupus familiaris Nematostella vectensis Tetrahymena thermophila SB210
Culex pipiens Ornithorhynchus anatinus Encephalitozoon cuniculi GB-M1 
Culex pipiens Oryza sativa Japonica 
Group 
Ricinus communis 
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Figure 3.5 Multiple sequence alignment of PF11_0443 orthologues. Sequences from 
Plasmodium spp. as well as a varied selection of higher eukaryotic sequences of 
PF11_0443 orthologues were aligned using the ClustalW algorithm. Residues identical in 
over 50% of the chosen sequences are shaded in dark blue and those which are 
functionally similar are highlighted in light blue. The region predicted to contain the 
DnaJ domain is indicated by a purple line, with the conserved HPD motif circled in the 
same colour. Conserved tryptophans are indicated with a yellow star and 
transmembrane domains are shown in yellow.
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3.3.3 PF14_0325 
 
Transcript data 
The transcriptome data produced by Bozdech et al. (2003) shows peak expression of 
PF14_0325 mRNA in the HB3 clone at around 38 hours p.i. (illustrated in figure 3.6 A). In 
accordance with this, the Le Roch study showed maximum expression of this gene in 
late schizonts in both sorbitol and temperature synchronised methods (Le Roch et al., 
2003). Absolute expression levels are comparable to that of AMA-1. Interestingly 
PF14_0325 expression was detected (at equivalent levels to the peak expression in late 
schizonts) in sporozoites, the form of the parasite responsible for invading hepatocyes. 
 
Proteomic data 
This protein has not been detected in any proteomic studies available either at the time 
of selection or present day. The cause for this could be the protein’s relatively small size 
or the protein’s abundance or even that it is not translated at all.   
 
Bioinformatic predictions 
At the time of selection, PF14_0325 possessed 2 different annotations, each of which 
contains a different 5’ end exon assembly. I was able to identify by PCR  from cDNA 
which of the two models was correct (Appendix B) and subsequently the annotation on 
PlasmoDB was also corrected. The gene encodes a protein of approximately 33kDa with 
a signal peptide at the N-terminus, cleaved after residue 22. This signal peptide was not 
predicted using either SignalP2.0 or 4.0 but via SMART, which utilised an undisclosed 
version of SignalP. The P. vivax homologue of this protein possesses a highly predicted 
signal peptide and after sequence comparison it looks as though the negative charge of 
the aspartic acid at position 15 is the reason for the discrepancy. Position 15 is a glycine 
residue in P. vivax and P. knowlesi. It is unlikely this is due to a sequencing error as the 
other sequenced P. falciparum genomes also contain an aspartic acid instead of a 
glycine. This particular residue’s codon is split by an intron and it is possible that the 
location of the intron is incorrect. There is a predicted transmembrane region at the 
extreme C terminus of the protein however there are no positively charged residues 
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after the membrane region (the last residue is an isoleucine) therefore the protein could 
not be anchored in the membrane without the addition of glycosylphosphatidylinositol 
(GPI) membrane-anchor. GPI-anchored proteins are common in all eukaryota including 
Plasmodium, with proteins such as MSP-1 and -2 (Gerold et al., 1996) and CSP (Dame et 
al., 1984) among their number. These proteins require an N-terminal signal peptide for 
entry into the ER lumen and a GPI-anchor signal sequence at the C-terminus which is 
recognised by the transamidase complex (Dailey & Bulleid, 2003). This complex catalyses 
the proteolytic removal of the hydrophobic C-terminal region (often predicted as a 
transmembrane region) between residue ω and ω+1, before the addition of a 
membrane-bound GPI (Eisenhaber et al., 2001). GPI prediction algorithms GPIpred, GPI-
SOM and Big-π (based on protozoa) all failed to predict PF14_0325 to contain the 
suitable signal required for the addition of a GPI-anchor. Fortunately and somewhat 
bizarrely, the Big-π algorithm based on metazoa did predict GPI-anchorage, with 
cleavage predicted to take place after the asparagine residue 265 (ω) with a p-value of 
0.00081. Generally prediction programmes have been designed using metazoa 
sequences and have not been tailored towards protozoa such as P. falciparum. Gilson et 
al. (2006) developed an alternative algorithm, GPI-HMM, based on the hidden Markov 
model and using known GPI-anchored P. falciparum proteins to identify as yet 
unidentified P. falciparum GPI-anchored proteins. Although their algorithm is not 
released for general use, their published list of 30 proteins most likely to be GPI-
anchored featured PF14_0325 at position 29 with a p-value of 0.015. All 16 of the 
characterised proteins on this list contain GPI-anchored and none of the uncharacterised 
proteins have been shown to be without one, validating the model, however 
biochemical classification of the protein is necessary to provide a definitive answer. 
The coiled-coil detection algorithm ‘Coils’ predicts a coiled-coil domain in the centre 
region of the protein (illustrated in figure 3.6). These domains are often involved in 
protein-protein interaction. 
 
Orthologous proteins in other species 
Orthologues of PF14_0325 in other species were identified from PlasmoDB and 
OrthoMCL-DB, from the orthologue group OG5_150579 (Li et al., 2003) and confirmed 
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using NCBI BLAST tool. The protein is highly conserved in Plasmodium spp. (P. bergei: 
PBANKA_101040; P.chabaudi: PCHAS_101130; P. knowlesi: PKH_131490; P. vivax: 
PVX_084815; P. yoelii: PY03139). PF14_0325 has orthologues in other genera, namely 
Neospora canium, Theileria annulata and Babesia bovis but not outside the phylum of 
Apicomplexa.  The so called orthologue of N. caninum appears to be a dramatically 
different protein both in size and in amino acid content however there is one small 
region near the C-terminus which seems to be conserved. Other than this divergent 
orthologous protein from N. caninum, the protein appears only in Apicomplexa of the 
blood, which may give a clue to its function. Protein sequences were aligned using the 
ClustalW multiple alignment algorithm (Thompson et al., 1994) in order to visualise and 
calculate the sequence similarity between species (figure 3.6). The first 119 amino acids 
were removed from the N. caninum sequence as it was not aligned with any other 
protein sequences and this protein is over one hundred amino acids larger than the 
other proteins. All of the sequences contain signal peptides but none are predicted to 
have GPI anchors. Due to the unreliable nature of GPI anchor predictions this does not 
necessarily prove their absence. Although the C-termini of the non-Plasmodium spp. do 
not appear sufficiently hydrophobic, asparagine 265 which is the ω site on P. falciparum 
is completely conserved throughout the orthologous species thus the in silico evidence 
is inconclusive. Sequence identity between the group members is not all that high even 
between Plasmodia since PF14_0325 shares 50% identity with P. vivax and P. knowlesi, 
28% with Th. annulata and 17% with B. bovis. A region of 50-60 residues nearing the C-
terminus is much more conserved with the presence of a number of conserved motifs 
which are perhaps necessary for a function. The asparagine-rich coiled coil region in the 
centre of PF14_0325 is not conserved in the other proteins. 
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Figure 3.6: PF14_0325 transcription profile and domain architecture summary. (A) The 
transcriptome from Bozdech et al (2003) shows a maximum transcript level of pf14_0325 
at 38 h p.i. This 33kDa protein is predicted to contain a signal peptide and a coiled coil 
domain between residues 129 and 159. A transmembrane domain is predicted between 
residues 267 and 284 however this hydrophobic stretch is actually part of the GPI-achor 
signal, as predicted by Big- π. Domains were mapped onto the predicted protein 
sequence and illustrated in (B). 
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Figure 3.7 Multiple sequence alignment of PF14_0325 orthologues. Sequences from Plasmodium 
spp. and orthologues from Apicomplexa of PF14_0325 were aligned using the ClustalW multiple 
alignment algorithm. Residues identical in over 50% of the chosen sequences are shaded in dark 
blue and those which are functionally similar are highlighted in light blue. Transmembrane 
domains are shown in yellow based on the Plasmodium sequences, regions may be different in 
other Apicomplexa. The ω is highlighted with a yellow star. The first 119 amino acids were 
removed from the N. caninum sequence as it was not aligned with any other protein sequences.  
Th. annulata contains 2 orthologous proteins, labelled here as 1 and 2.
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3.3.4 PF14_0045 
 
Transcript data 
With peak expression at 45 hours p.i. (Bozdech et al., 2003) this protein is expressed 
rather later than the previous 3 proteins (figure 3.7 A). In accordance with this, the Le 
Roch study showed maximum expression of this protein in merozoites (Le Roch et al., 
2003). As with the other proteins, absolute expression levels are comparable to that of 
AMA-1 (illustrated in figure 10). This protein is also expressed in sporozoites, suggesting 
a conserved invasion related role. However, transcript levels remain relatively high and 
persistent during early to middle of the ring stage, suggesting a possible function early 
on after invasion of a new host cell. 
 
Proteomic data 
Florens et al. (2003) found one peptide hit for this protein but only in the sporozoite 
form of the parasite. Fortunately the Leiden Malaria Group merozoite proteome 
(available on PlasmoDB) identified 4 peptide matches, confirming the gene PF14_0045 
encodes a protein which is expressed in both human invasive forms of the parasite. No 
other hits were detected in subsequent proteomes. 
 
Bioinformatic predictions 
This 114 kDa protein enters the secretory pathway by way of signal sequence at the N-
terminus from residue 1 to 31, predicted by SignalP 2.0. This is a signal anchor region, 
with a transmembrane region predicted between amino acids 13-34 by TMHMM, 
TMpred and TopPred. The protein contains cysteine-rich patches suggesting these 
regions are particularly folded and also a coiled-coil region, predicted between 391 and 
427 by the Coils algorithm (illustrated in figure 3.7 B). 
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Orthologous proteins in other species 
Orthologues of PF14_0045 in other species were identified from PlasmoDB and 
OrthoMCL-DB, from the orthologue group OG5_205512 (Li et al., 2003) and confirmed 
using NCBI BLAST tool. This protein appears to be unique to Plasmodium with no 
orthologues present in other sequenced species. Moreover, orthologues are only 
present in the human and simian malarias P. knowlesi (PKH_134210) and P. vivax 
(PVX_086195) suggesting a role specific to primate malaria. The protein sequences were 
aligned using the ClustalW multiple alignment algorithm (Thompson et al., 1994) in 
order to visualise and calculate the sequence similarity between species (figure 3.9). 
Sequence identity between PF14_0045 and its P.vivax and P. knowlesi orthologues is 33 
and 34% respectively. Both orthologous proteins possess the coiled coil region as well as 
an additional coiled domain at the C-terminus. Although they do contain a signal 
sequence, it is predicted to be a signal peptide, not anchor, with cleavage predicted to 
take place after residue 26. No other transmembrane regions exist implying the protein 
is soluble in these species. The asparagine rich regions of PF14_0045, which are absent 
from P. knowlesi and P.vivax, are partly responsible for lack of sequence identity. These 
regions are thought to be common in P. falciparum due to the AT bias of the genome 
(codons AAT or AAC). Lysine, coded by AAA or AAG, is also a common amino acid for this 
reason. 
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Figure 3.8: PF14_0045 transcription profile, proteomic data and predicted domain 
architecture. (A) The transcriptome from Bozdech et al (2003) shows a maximum 
transcript level of pf14_0045 at 45 h p.i. Peptides from various regions of the protein 
were recovered from schizont and merozoite stage parasites in several proteomic 
studies. These peptides have been mapped to the predicted protein sequence above 
and highlighted in (B). This 114kDA protein is predicted to contain 1 transmembrane 
domain, a signal anchor and a coiled coil region (C).  The domains were mapped onto 
the predicted protein sequence and illustrated in (D).  
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Figure 3.9: Multiple sequence alignment of PF14_0045 orthologues. Orthologue 
sequences from P. falciparum, P. vivax and P. knowlesi were aligned using the ClustalW 
multiple alignment algorithm. Residues identical in over 50% of the chosen sequences 
are shaded in dark blue and those which are functionally similar are highlighted in light 
blue. Transmembrane domains are shown in yellow based on the P. falciparum 
sequence, regions may be different in other species. The coiled coil region is highlighted 
in red. 
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3.3.5 PF02_0040 
 
Transcript data 
The transcriptome data produced by Bozdech et al. (2003) shows peaks expression of 
PF02_0040 mRNA in the HB3 clone at around 40 hours p.i. In accordance with this, the Le 
Roch study showed maximum expression of this protein in late schizonts in both sorbitol 
and temperature synchronised methods. (Le Roch et al., 2003). As with the other 
proteins selected, absolute expression levels are comparable with AMA-1 (illustrated in 
figure 3.10). It is also expressed in sporozoites and gametocyte stages of the 
intraerythrocytic cycle.  
 
Proteomic data 
This protein was detected in merozoites in the proteome by Florens et al. (2003) and the 
Leiden Malaria Group merozoite proteome (available on PlasmoDB) with substantial 
peptide coverage, confirming the gene PF02_0040 encodes a protein which is expressed 
in the erythrocyte invasive form of the parasite. Since then, peptides have been detected 
in every proteomic study listed on PlasmoDB, covering the full length of the protein with 
the exception on the extreme N terminus. Although the majority of peptides were 
predicted from schizont stages (Gerold et al., 1996; Bowyer et al., 2011; Treeck et al., 
2011), the protein was also detected in trophozoites and gametocytes (Silvestrini et al., 
2010), illustrated in figure 3.9 B. 
 
Bioinformatic predictions 
PF02_0040 encodes a protein with a molecular weight of 33 kDa. Like PF14_0045, the 
protein is predicted to contain 1 signal anchor transmembrane region, as predicted by 
SignalP 2.0 from amino acid 1-18 and TMHMM, TMpred and TopPred between residues 2 
and 21. Classically, transmembrane regions are hydrophobic stretches of around 20 
amino acids and either side of the membrane there are charged, hydrophilic residues 
which strengthen the alpha helical positioning of the domain in the membrane bi-layer. 
There are lysine residues immediately following the membrane spanning region at the 
C-terminal end of the signal anchor however the extreme N-terminus lacks any charge. 
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The positive charge on one side interacting with the negatively charged phospholipid 
head may be sufficient to hold the protein in place or it is also possible that an intra-
membrane interaction anchors the protein. Biochemical validation is required before 
any conclusions can be drawn. 
 
 The Coils algorithm predicts a coiled coil region between amino acids 212-274 
(depicted in figure 3.10 C+D). Pfam predicts the presence of a domain named after the 
yeast secretory pathway mutant SEC66 (aka SEC71) which is part of the pre-protein post-
translational translocase which inserts signal sequence-containing proteins into the ER. 
This domain was predicted from amino-acids 89 to 255 with an e-value of 0.00011 which 
is significant. A search of non-redundant protein sequences using the blastp algorithm 
with the PF02_0040 protein sequence did not identify the yeast protein. However using 
the amino acid sequence of the T. gondii orthologue of PF02_0040 (see below) Sec66 
from Saccharomyces is pulled up in a blastp search. Due to the AT rich nature of the P. 
falciparum genome, amino acids which are coded for by adenosine- or thymidine-rich 
codons will be preferentially utilised. This has a knock-on effect on protein sequence, 
and this could be responsible for the lack of detectable sequence identity between P. 
falciparum and yeast proteins. Further experimental evidence is required to confirm 
PF02_0040 is a functional orthologue of the prototype Sec66 protein. This is discussed 
further in Chapter 6.  
 
Orthologous proteins in other species 
Orthologues of PF02_0040 in other species were identified from PlasmoDB and 
OrthoMCL-DB, from the orthologue group OG5_142839 (Li et al., 2003) and confirmed 
using NCBI BLAST tool. The protein is highly conserved in Plamsodium spp. (P. bergei: 
PBANKA_030200; P.chabaudi: PCHAS_030420; P. knowlesi: PKH_041580; P. vivax: 
PVX_003640; P. yoelii: PY00894). PF02_0040 has orthologues in other genera, namely 
Toxoplasma gondii, Neospora canium, Theileria annulata and several Cryptosporidium 
species from the phylum of Apicomplexa, as well as the eukaryotic marine 
phytoplankton Thalassiosira pseudonana and Phytophora ramorum, the oomycete plant 
pathogen responsible for sudden oak death.  The protein sequences were aligned using 
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the ClustalW multiple alignment algorithm (Thompson et al., 1994) in order to visualise 
and calculate the sequence similarity between species (figure 3.10). PF02_0040 is 70% 
identical to its P. vivax and P. knowlesi orthologues however this level of identity is not 
shared outside the genus. Identity is 22, 21 and 20% with T. gondii, N. caninum and Cr. 
hominus respectively. Despite this diversity, all proteins in the orthologue group are 
predicted to contain a Sec66 domain. All contain predicted signal sequences except Tha. 
pseudomonas however only Plasmodium and Cryptosporidium contain predicted 
transmembrane regions. This is surprising considering the prototype Sec66 of 
Saccharomyces is a transmembrane protein. Although PF02_0040 is predicted to contain 
a transmembrane region, due to a lack of any charged amino acid at the N-terminus of 
the protein it is unclear whether the protein will be able to remain in the membrane 
whilst anchored only at one face, presumably through interaction of lysine at position 22 
with the negatively charged phospholipid head. No orthologues outside Plasmodium 
spp. contain a C terminal coiled coil domain. 
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Figure 3.10: PF02_0040 transcription profile, proteomic and bioinformatic data summary. 
(A) The transcriptome from Bozdech et al (2003) shows a maximum transcript level of 
pf02_0040 at 40 h p.i. Several peptides have been recovered from multiple stages of 
parasites in a number of proteomic studies. These peptides have been mapped to the 
predicted protein sequence and are highlighted above in (B). This 33 kDa protein is 
predicted to contain one transmembrane domain, a signal anchor, as well as a coiled coil 
region and a domain that bears homology to Sec66 (C). Domains were mapped onto the 
predicted protein sequence and illustrated in (D). 
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Figure 3.11 Multiple sequence alignment of PF02_0040 orthologues. Sequences from Plasmodium 
spp. and orthologues from Apicomplexa of PF02_0040 were aligned using the ClustalW multiple 
alignment algorithm. Residues identical in over 50% of the chosen sequences are shaded in dark 
blue and those which are functionally similar are highlighted in light blue. Transmembrane 
domains are shown in yellow, coiled coil domain in red and Sec66 domain in pink. Domains are 
highlighted based on the Plasmodium sequences, regions may be different in other 
Apicomplexa. 
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Chapter 4: Selected proteins, their expression in bacteria and 
production of antibodies 
 
 
4.1 Introduction 
 
Specific antibodies are an essential tool for many of the experiments involved in protein 
characterisation such as western blot, immunofluorescence and immunoprecipitation. It 
was therefore necessary to express fragments of the selected proteins for polyclonal 
antibody production.  
 
Regions within the proteins used for recombinant expression were selected based on 
hydrophilicity predicted from a Kyte-Doolittle hydropathy plot (Kyte and Doolittle, 
1982), hydrophobic patches were avoided. Regions rich in cysteine residues were 
avoided where possible since correct protein folding may require correct disulfide bond 
formation not possible in E.coli. Initially chosen regions were used in a blastp search 
against the whole P. falciparum 3D7 genome to avoid possible cross-reactivity of the 
antibodies raised to other Plasmodium proteins.. Recombinant protein molecular 
weight, isoelectric point (pI) and extinction coefficients were calculated by ProtParam 
(Gasteiger E., 2005). The size and location of chosen regions with respect to the domain 
architecture of each protein are highlighted in figure 4.1 A. 
 
4.2 Strategy 
 
4.2.1 Ligation-independent cloning 
In order to express the regions of each protein depicted in figure 4.1 A, a ligation-
independent cloning (LIC) method was adopted, using the Novagen pET vector system. 
Primers designed to amplify the chosen coding regions contained 5’ or 3’ overhangs 
which after incubation of the PCR product with T4 DNA polymerase, the 3’-5’ 
exonuclease activity allowed annealing to occur within the multiple cloning site of the 
pET vector. In cases where the region for recombinant expression extended between 
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multiple exons, cDNA was used for amplification. Sizes of expected PCR products are 
indicated in Table 4.1. 
 
All LIC inserts created were initially annealed into the pET30-Xa/LIC vector which 
encodes an N-terminal His- and S-tag, allowing identification and affinity purification of 
recombinant protein from E. coli proteins. It also encodes a factor Xa protease cleavage 
site for specific removal of the N-terminal tags from the recombinant protein. In cases 
where recombinant protein was not initially soluble, pET32-Xa/LIC was used as an 
alternative. This vector contains an additional thioredoxin (Txr) tag which aids solubility. 
These vectors were used to chemically transform E. coli Giga Singles competent cells and 
vector DNA was prepared from multiple clones. To screen for inserts of the correct size, 
plasmid DNA was digested using KpnI and XhoI restriction enzymes, which cleave either 
side of the multiple cloning site but do not cleave the amplified gene fragment, 
followed by gel electrophoresis. The DNA sequences of inserts of positive clones were 
confirmed by commercial DNA sequencing before transformation into expression 
competent E. coli. 
 
4.2.2 Protein expression and solubility 
The preparations of cloned plasmid DNA were used to transform E. coli BL21 (DE3) pLysS 
protein expression cells. If solubility was low, a number of different cell types were 
tested. For largely insoluble proteins, BL21 (DE3) Tf2 cells containing an additional 
plasmid which encodes the chaperones GroEL/GroES and trigger factor, were used in 
order to promote protein folding and hopefully solubility. A small volume of culture was 
used for induction of protein expression in the first instance to test the expression levels 
and solubility of the protein. Typically, protein expression was induced using 1mM 
isopropyl β-D-1-thiogalactopyranoside (IPTG) at an optical density reading at 600nm of 
0.6 for 4 hours at 22°C however for less soluble proteins this was amended to 18°C 
overnight. Soluble and insoluble protein fractions were prepared and resolved under 
reducing conditions by SDS-PAGE and visualised by Coomassie blue stain. A large 
number of E.coli proteins are visible by Coomassie so to confirm the suspected protein is 
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in fact the His-tagged protein of interest a western blot was performed on an identical 
SDS-PAGE gel, with an anti-His antibody. Protein expression conditions for each protein 
are summarised in Table 4.1. 
 
4.2.3 Protein purification and quantification 
Protein expression was increased to 100 ml culture in order to test purification methods. 
Taking advantage of the hexa-His tag’s affinity for nickel, the tagged recombinant 
protein was bound to nickel-agarose (Ni-NTA), washed and competitively eluted with 
increasing concentrations of imidazole so that an optimum wash and elution 
concentration could be determined. Once optimised, protein production was increased 
to 2 litres of culture or enough to produce a sufficient quantity for antibody production. 
Purified protein was buffer-exchanged into PBS and concentration was estimated by 
comparison with BSA standards on SDS-PAGE and calculated using the extinction 
coefficient and the absorbance at 280 nm. 
 
4.2.4 Rabbit polyclonal antibody production and affinity purification 
The concentration of the pure recombinant protein in PBS was adjusted to 0.4 mg/ml or 
200μg in 500μl per immunisation, to be diluted 1:1 with adjuvant. Rabbits were 
immunised at Harlan Biosciences following standard protocol. Six immunisations were 
required per protein for one rabbit therefore a minimum of 1.2 mg of protein is required 
for antibody production. Animals to be used were pre-screened prior to inoculation to 
avoid previously existing cross reacting antibodies.  Pre-screening was carried out by 
western blot against whole rbc, schizont and merozoite lysates resolved by SDS-PAGE. 
Selected rabbits were screened after the third and fourth inoculations of recombinant 
protein to ensure the antibody response was sufficient to recognise a protein of the 
predicted size. Terminal bleeds were affinity column purified with recombinant protein 
coupled to CNBr (for methods see section 2.2.7). As a number of future experiments 
require recognition by secondary antibody, the IgG fraction of the affinity purified 
protein was enriched using protein G sepharose (2.2.9). Antibody was dialysed into PBS 
and concentrated to 1mg/ml and stored in 50μl aliquots at 4°C or -20°C until needed. 
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Figure 4.1: Illustration of protein fragments selected for recombinant expression. 
Schematic representation of each selected protein. Signal peptide, transmembrane 
domains and other domains of interest are shown colour-coded above (key in figure). 
Regions selected for recombinant protein expression and antibody production are 
underlined in orange.  
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4.3 Recombinant expression results 
4.3.1 MAL13P1.94 
A 5kDa fragment from the C-terminus of MAL13P1.94 was selected for expression 
(illustrated in figure 4.1). Ideally the fragment would be longer however this was the 
longest stretch of hydrophilic amino acids not predicted to be associated with 
membrane in this 22 kDa 4 TM protein. The region was amplified from P. falciparum 3D7 
genomic DNA, incorporating pET30-Xa/LIC overhangs required for LIC (figure 4.2 A). 
After annealing to the expression vector and transformation into E. coli BL21 (DE3) pLysS 
expression cells,  a 10kDa soluble protein was expressed (including the ~5kDa tag) from 
a 1ml test culture at 22°C for 4 hours (figure 4.2 C+D).  Test purification using increasing 
amounts of imidazole as a Histidine competitor for Ni-NTA revealed a small amount of 
the protein began to elute from the column at 30mM imidazole but more so at 50 and 
100mM (E+F).  Since the protein was bound to the nickel column in 10mM imidazole, 
washing the column with any less than 30mM imidazole would fail to remove non-
specific binding proteins from the column therefore 30mM imidazole was used in the 
column wash buffer and 250mM imidazole in the elution buffer for future purifications. 
Expression culture was scaled-up to 2 litres and after 2 rounds of Ni-NTA purification, 
produced ample protein for antibody production (figure 4.2 G+I). Unfortunately, a 
relatively large amount of an additional 25 kDa protein was also expressed and purified 
alongside the recombinant protein of interest. Curiously this protein also seems to be 
His-tagged as it is recognised by rabbit anti-His antibody (figure 4.2 H). This protein was 
not present in the smaller test cultures. In order to establish the 25 kDa protein’s 
identity, the band was excised from the Coomassie-stained SDS-PAGE gel and prepared 
for MALDI-TOF mass spectrometry analysis. This revealed the protein to be an FKBP-type 
peptidyl-prolyl cis-trans isomerase (rotamase) of bacterial origin that possesses a 
pseudo-His tag within its amino acid sequence.  The binding of E. coli proteins is a 
common occurrence with immobilised metal affinity chromatography (IMAC). This 
particular contaminant, rotamase or SlyD, has been found not to bind to TALON™ which 
is a cobalt resin and can be used to purify His-tagged proteins (Bolanos-Garcia and 
Davies, 2006). Unfortunately MAL13P1.94 also does not bind to cobalt so this cannot be 
used as a method of purification. When preparing the expression culture, E.coli was 
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grown to an O.D. of 0.6 at 600nm at 37°C before induction and incubation at 22°C for 
expression. To investigate whether rotamase was up-regulated due to heat shock in 
large scale cultures, the culture was cooled down slowly, first to 32°C, then 28°C before 
reaching 22°C. This did reduce expression levels of the contaminant however there was 
still a considerable amount of the contaminating protein present in the eluant. Since the 
rotamase contamination only occurred in large scale (4x500ml) culture, I used less resin 
in the hope that the recombinant protein would preferentially bind to the nickel resin 
above rotamase however this was not successful. In the end, the protein cocktail 
containing recombinant MAL13P1.94, rotamase and a small amount of Hsp70 was used 
for antibody production (figure 4.2 I). There are predicted FKBP-type cis-trans isomerases 
in P. falciparum however the protein sequences are divergent and antibodies would not 
be expected to cross-react. Western blot analysis of test bleeds showed rabbit sera was 
reactive with two bands in schizonts, one at ~50kDa and one at ~25kDa, the latter of 
which is likely to be MAL13P1.94. Two bands were again present in merozoites however 
this time a 15kDa band appeared along with the 25kDa band (presumed to be 
MAL13P1.94) but not the 50kDa protein. Terminal bleed serum was affinity and IgG 
purified however the banding pattern persisted (figure 4.7 A). Further investigation into 
this protein is detailed in chapter 7.  
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Figure 4.2. MAL14P1.94 recombinant protein expression. The DNA sequence for the 
chosen C-terminal region of MAL13P1.94 was amplified using specific primers from P. 
falciparum 3D7 genomic DNA, incorporating pET30-Xa/LIC overhangs. The PCR product 
(149bp) was analysed by gel electrophoresis where a band between 0.1 and 0.2 kb was 
visible (A; -, + without and with template DNA).  The gene fragment was annealed into 
the pET30-Xa/LIC expression vector and transformed into E. coli Gigasingles. Plasmid 
DNA was prepared from resulting clones and screened for inserts by digestion with KpnI 
and XhoI before resolving digested fragments by gel electrophoresis (B). DNA size is 
shown in kb. Clones containing inserts with correct sequences were tested for soluble 
recombinant protein expression. A band of around 12 kDa is visibly increased in the 
soluble fractions (S) compared to the un-induced control when resolved by SDS-PAGE, 
molecular weight is shown in kDa (C). No additional bands were visible in the pellet 
fractions (P). Solubility was confirmed by western blot using anti-His antibody (D). 
Protein purification conditions were optimised using a 100 ml culture induced with 
1mM IPTG for 4h at 22°C and elution of recombinant protein from  a nickel-agarose 
column was tested using 30, 50, 100 and 250 mM imidazole. Eluants were resolved by 
SDS-PAGE and stained with Coomassie blue (E) or probed with an anti-His antibody (F.). 
Column flow-through (F) is shown in the left-most lane. A small amount of protein was 
eluted from the column with 30mM imidazole however the majority was eluted at a 
concentration ≥50mM. Protein production was increased, expressing from 2 litres of 
transformed E.coli. The soluble protein fraction was bound to nickel-agarose in 10 mM 
imidazole and washed with 10 and 30 mM imidazole buffer before eluting in 10 ml of 
250 mM imidazole. Samples were taken and resolved by SDS-PAGE (G). The 25 kDa band 
appeared to be His-tagged, shown here on a western blot (H). Purification was repeated 
to increase the purity of the preparation although 3 additional contaminant proteins 
could not be removed (I). MALDI-TOF mass spectrometry analysis revealed the 25kDa 
protein to be rotamase and the identity of the ~70kDa protein as Hsp70. The band just 
below MAL13P1.94 (indicated with a star) is degraded recombinant protein. 
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4.3.2 PF11_0443  
C-terminal protein fragment (PF11_0443CT) 
Initially, a hydrophillc 11kDa fragment from the C-terminus of PF11_0443 was selected 
for expression (figure 4.1). The region was amplified from P. falciparum 3D7 genomic 
DNA, incorporating pET30-Xa/LIC overhangs required for LIC (figure 4.3 A). After 
annealing to the expression vector and transformation into E. coli BL21 (DE3) pLysS 
expression cells,  a 17kDa soluble protein was expressed (including the ~5kDa tag) from 
a 1ml test culture at 22°C for 4 hours (figure 4.3 C+D).  Test purification revealed the 
protein began to elute from the column at 50mM imidazole, thus a lower concentration 
of 30mM imidazole was used to wash the nickel column and 250mM for elution (figure 
4.3 E+F). Expression culture was scaled-up to 2 litres which, after 2 purification steps, 
produced ample protein for antibody production (figure 4.3 G). As with MAL13P1.94, 
rotamase was co-purified with recombinant PF11_0443 using nickel and similar 
attempts to reduce the contaminant were unsuccessful. Western blot analysis of affinity 
and IgG purified antibodies showed rabbit sera was reactive with a single ~37kDa band 
in both schizonts and merozoites but not rbcs (figure 4.7 B).  These antibodies were used 
in further experiments, detailed in chapter 5. 
 
“Middle” region protein fragment (PF11_0443M) 
As the project progressed it became desirable to produce an antibody of a different 
species for immunoprecipitation studies and also from the “other side” of the membrane 
for topology identification. For this purpose the “middle” section of the protein was 
selected, between the 2 membrane-spanning regions from residues 136-202 (figure 4.1).  
Although initially insoluble when expressed from pET30-Xa/LIC in E.coli BL21 (DE3) 
pLysS, when re-transformed into BL21 (DE3) Tf2 cells co-expressing chaperones 
GroEL/ES and trigger factor at 18°C O/N the protein was around 20% soluble and 2 litres 
of culture produced sufficient protein for rat antibody production (figure 4.4). As with 
the C-terminal fragment, antibodies raised recognised a single 37 kDa band in western 
blots of both schizonts and merozoites but failed to recognise any rbc proteins (figure 
4.7 C). 
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Figure 4.3. PF11_0443 C-terminal recombinant protein expression. A DNA fragment 
encoding the chosen C-terminal region was amplified using specific primers from P. 
falciparum 3D7 genomic DNA, incorporating pET30-Xa/LIC overhangs required for LIC. 
The PCR product (284 bp) was analysed by gel electrophoresis where a band between 
0.2 and 0.3 kb was visible (A).  The gene fragment was annealed into the pET30-Xa/LIC 
expression vector and transformed into E. coli Gigasingles. Plasmid DNA was prepared 
from resulting clones and screened for inserts by digestion with KpnI and XhoI before 
resolving digested fragments by gel electrophoresis (B). DNA size is shown in kb. Clones 
containing correct sequence inserts were tested for soluble recombinant protein 
expression. A band of around 17k Da is visibly increased in the soluble fractions (S) 
compared to the un-induced control when resolved by SDS-PAGE, molecular weight is 
shown in kDa (C) No additional bands were visible in the pellet fractions (P). Solubility 
was confirmed by western blot using anti-His antibody (D). Protein purification 
conditions were optimised using a 100 ml expression culture by binding to a nickel-
agarose column and using 30, 50, 100 and 250 mM concentrations of imidazole for 
washing/elution. Eluants were resolved by SDS-PAGE and stained with Coomassie blue 
(E) or probed with an anti-His antibody (F.). Column flow-through (F) is shown in the left-
most lane. Recombinant PF11_0443CT was eluted at a concentration ≥50mM. Protein 
production was increased, expressing from 2 litres of transformed E.coli. The soluble 
protein fraction was bound to nickel-agarose in 10mM imidazole and washed with 10 
and 30mM imidazole buffer before eluting in 10ml of 250mM imidazole. Samples were 
taken and resolved by SDS-PAGE (G). Purification was repeated to increase the purity of 
the preparation although 3 additional contaminant proteins could not be removed. 
MALDI-TOF mass spectrometry analysis revealed the 25kDa protein to be rotamase and 
the identity of the ~70kDa protein as Hsp70. The band just below PF11_0443 (indicated 
with a star) was deemed to be degraded recombinant protein. 
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Figure 4.4: PF11_0443 “middle” section recombinant protein expression. The chosen 
region of PF11_0443 was amplified using specific primers from P. falciparum 3D7 
genomic DNA, incorporating pET30-Xa/LIC overhangs required for LIC. The PCR product 
(233 bp) was analysed by gel electrophoresis where a band between 0.2 and 0.3 kb was 
visible (A.).  The gene fragment was annealed into the pET30-Xa/LIC expression vector 
and transformed into E. coli Gigasingles. Plasmid DNA was prepared from resulting 
clones and screened for inserts by digestion with KpnI and XhoI before resolving 
digested fragments by gel electrophoresis (B.). DNA size is shown in kb. Clones 
containing correctly sequenced inserts were tested for soluble recombinant protein 
expression after transformation into E. coli BL21 DE3 Tf2. A band of around 17 kDa is 
visible by Coomassie blue stain (C.) in the pellet (P) fraction only, however an identical 
gel is probed with anti-His antibody (D.), it is evident there is a proportion of protein 
present in the soluble fraction (S). Molecular weight is shown in kDa.  Soluble protein 
purification conditions were optimised from a 100 ml culture testing elution from a 
nickel-agarose column using 30, 50, 100 and 250 mM concentrations of imidazole. 
Eluants were resolved by SDS-PAGE and stained with Coomassie blue (E) or probed with 
an anti-His antibody (F.). Column flow-through (F) is shown in the left-most lane. A small 
amount of protein was eluted from the column with 30mM imidazole however the 
majority was eluted at concentration ≥50mM. Protein production was increased, 
expressing from 2 litres of transformed E.coli. The soluble protein fraction was bound to 
nickel-agarose in a 10mM imidazole solution and washed with 10 and 30mM imidazole 
buffer before eluting in 10ml of 250mM imidazole. Samples were taken and resolved by 
SDS-PAGE (G). Purification was repeated to increase the purity of the preparation. On 
repetition, the recombinant protein of interest did not re-bind the column and is present 
in the flow-through however the contaminant proteins did bind to the column, thus 
negatively purifying the protein preparation.  
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4.3.3 PF02_0040  
 
Initially a 14kDa fragment from PF02_0040 was selected for expression from the region 
immediately following the signal anchor from residues 29-139 (figure 4.1). The region 
was amplified from P. falciparum 3D7 cDNA from schizont stage parasites 39 h p.i. (figure 
4.5 A). The PCR fragment was annealed into pET30-Xa/LIC after treatment with T4 DNA 
polymerase to generate single strand complementary overhangs. However the resulting 
protein was almost completely insoluble and showed low expression levels.  Protein 
expressed using the pET32-Xa/LIC vector was also largely insoluble irrespective of which 
expression cells and temperature of expression was tested. Attempts to increase protein 
solubility by incorporating an N-terminal glutathione-S-transferase (GST)-tag were also 
unsuccessful, as was changing the region expressed to include the whole protein minus 
the signal anchor (residues 42-276). The low levels of expression may have been due to 
the AT-rich sequence of this protein. To overcome this, an E.coli codon-optimised gene 
was constructed by GeneArt® and new primers designed based on the new sequence to 
incorporate residues 29-139 into pET32-Xa/LIC.  Although this dramatically increased 
expression levels, the protein remained insoluble (figure 4.5 C+D). Due to the nature of 
antibody-antigen recognition, it is desirable to raise antibodies against a soluble, and 
therefore presumed correctly folded, protein however it is possible to raise antibodies 
against insoluble aggregates and often these are more immunogenic. Bearing this in 
mind and owing to the relatively high levels of expression, the recombinant protein 
fragment was expressed from pET32-Xa/LIC at 37°C for 4 hours. Protein was extracted 
from inclusion bodies from 2 litres of cell culture, solubilised in 8M urea and purified 
over a nickel column (figure 4.5 E). The eluted protein was dialysed into PBS where, as 
expected, it precipitated. The concentration of the aggregate was estimated from the 
band size produced by SDS-PAGE compared to a know standard.  Western blot analysis 
of test bleeds revealed that the rabbit sera was reactive with a band just under the 37 
kDa marker in both schizonts and merozoites but not rbcs. Estimated molecular weight 
for Pf02_0040 is  33 kDa,. Unfortunately, this was not the only strong band on the blot. 
The serum also recognised a doublet running close to the 20  kDa marker. Terminal 
bleed serum was affinity purified from protein blotted onto nitrocellulose membrane, a 
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procedure which helped to purify the antibody but did not remove the 20 kDa doublet 
even when used at a dilution of 1:10000  on western blot (figure 4.7). In a further attempt 
to obtain soluble recombinant protein to use in affinity purification of these antibodies, I 
buffer-exchanged of PF02_0040 recombinant protein into room temperature PBS using 
a  a PD-10 de-salting column. This kept the protein in solution. The recombinant protein 
again precipitated when transferred to 4°C thus binding of the protein to CNBr 
sepharose in order to form an affinity column was done at room temperature for 2 
hours. Affinity purified antibodies were further IgG purified to be used in future 
experiments however the 20 kDa bands did persist. PF02_0040 is discussed in chapter 7. 
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Figure 4.5. PF02_0040 recombinant protein expression. The DNA fragment encoding the 
chosen region for protein expression was amplified using primers G and H (Chapter 2, 
Table 2.1) from a plasmid containing a PF02_0040 codom optimised for E. coli 
expression, incorporating pET32-Xa/LIC overhangs required for LIC. The PCR product 
(366 bp) was analysed by gel electrophoresis where a band between 0.3 and 0.4 kb was 
visible (A).  The gene fragment was annealed into the pET32-Xa/LIC expression vector 
and transformed into E. coli Gigasingles. Plasmid DNA was prepared from resulting 
clones and screened for inserts by digestion with KpnI and XhoI before resolving 
digested fragments by gel electrophoresis (B). DNA size is shown in kb. Clones 
containing inserts with correct DNA sequence were tested for protein expression after 
transformation into BL21 DE3 pLysS. A band of around 37 kDa is visible by Coomassie 
blue stain (C) in the pellet (P) fraction only. Although western blot of an equivalent gel 
probed with anti-His antibody (D) shows a thin band in the soluble fractions (S), it is 
most likely the result of over-spill from the abundant pellet fraction. Molecular weight is 
shown in kDa.  Due to its abundance, the insoluble protein fraction was prepared from 1l 
of culture and bound to a nickel-agarose column. The column was washed with 10 mM 
and 50 mM imidazole buffer before eluting with 10 ml of 250 mM imidazole containing 
buffer. Samples were taken and resolved by SDS-PAGE (E).  Most of the protein eluted 
from the column with 50 mM imidazole wash buffer and as this eluant contained a large 
concentration of protein and was free of contaminating proteins, this fraction was used 
after dialysis for antibody production.
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4.3.4 PF14_0045  
A 22 kDa fragment from the centre of PF14_0045 was selected containing the predicted 
coiled coil domain from residues 391-577, avoiding the cysteine-rich areas (figure 4.1). A 
DNA fragment encoding this region was amplified from P. falciparum 3D7 genomic DNA 
(figure 4.6 A). Initially this fragment was annealed into pET30-Xa/LIC and standard 
expression conditions tested. Only approximately 10% of the protein was soluble.  
Changing expression vector to pET32-Xa/LIC also resulted in a largely insoluble protein 
irrespective of which expression cells and temperature of expression was used (figure 
4.5 C+D), although expression levels were higher than when expressed from pET30-
Xa/LIC. Attempted test purification of soluble material from a 100 ml culture resulted in 
very low amounts of purified recombinant protein which eluted with a number of 
contaminant proteins including rotamase (figure 4.5 E+F). This lack of abundance of 
soluble protein made it impractical to produce sufficient quantities for antibody 
production. Attempts to increase protein solubility by incorporating a glutathione-S-
transferase (GST)-tag were also unsuccessful. The recombinant protein was therefore 
purified from inclusion bodies of a 2 liter expression culture of BL21DE3pLysS 
transformed with pET32-Xa-PF14_0045 expression construct induced at 37°C for 4 hours 
with 1mM IPTG. The protein extract was solubilised in 8M urea and purified over a Ni-
NTA column (figure 4.5 G). The eluted protein was dialysed into PBS where, as expected, 
it precipitated. Concentration was estimated comparing intensity of Coomassie stained 
bands separated by SDS-PAGE with that of a marker of known concentration. Western 
blot analysis of test bleeds revealed rabbit sera was reactive with the same 20 kDa 
doublet observed with PF02_0040 antibodies. Only a very weak band was observed at 
approximately 100 kDa, close to the predicted size of PF14_0045 at 110kDa.Terminal 
bleed antibodies were affinity purified by binding to recombinant protein blotted onto 
nitrocellulose membrane. This failed to remove antibody specificities to the cross 
reacting bands (figure 4.7). PF14_0045 recombinant protein was not soluble after buffer-
exchange using a PD-10 desalting column and therefore no further affinity purification 
was attempted. 
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Figure 4.6. PF14_0045 recombinant protein expression. The chosen DNA region was 
amplified using specific primers from P. falciparum 3D7 genomic DNA, incorporating 
pET32-Xa/LIC overhangs required for LIC. The PCR product (593 bp) was analysed by gel 
electrophoresis where a band between 0.5 and 0.6 kb was visible  (A).  The gene 
fragment was annealed into the pET32-Xa/LIC expression vector and transformed into E. 
coli Gigasingles. Plasmid DNA was prepared from resulting clones and screened for 
inserts by digestion with KpnI and XhoI before resolving digested fragments by gel 
electrophoresis (B). DNA size is shown in kb. Clones containing inserts with correct DNA 
sequence were tested for soluble recombinant protein expression. A band of the correct 
size (38kDa) is visible by Coomassie blue stain (C.) in the pellet (P) fraction only, however 
from identical gel probed with anti-His antibody (D.), it is evident there is a proportion of 
protein present in the soluble fraction (S). Molecular weight is shown in kDa.  Soluble 
protein purification conditions were optimised from a 100 ml culture testing elution 
from a nickel-agarose column using 30, 50, 100 and 250 mM concentrations of 
imidazole. Eluants were resolved by SDS-PAGE and stained with Coomassie blue (E) or 
probed with an anti-His antibody (F.). Column flow-through (F) is shown in the left-most 
lane. PF14_0045 did not wash off the column until eluted with 250mM imidazole and 
not all of the protein was eluted. Protein expression is relatively low compared to the 
other recombinant proteins attempted in this thesis. However when production was 
increased to 2 l, no soluble protein was detectable by Coomassie stain. Instead, the 
insoluble protein fraction from a 2 l culture was bound to nickel-agarose and washed 
with 30 mM imidazole buffer before eluting in 10 ml of 250 mM imidazole containing 
buffer. Samples were taken and resolved by SDS-PAGE (G).  The eluted protein sample 
was free of contaminating proteins and of sufficient quantity for antibody production.
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4.3.5 PF14_0325 
A 22kDa fragment from residue 21-210, immediately following the signal peptide of 
PF14_0325 was selected for expression  (figure 4.1). The region was amplified from P. 
falciparum 3D7 cDNA from schizont stage parasites 39 h p.i. Despite annealing to the 
expression vectors pET30- and pET32-Xa/LIC vectors and expression at 37°C, 22°C, 18°C 
for 2, 4, 8 hours and O/N in various E.coli expression cell types, there was very little 
expression only detectable in the pellet fraction by western blot after long (30 minute) 
exposure. Altering the region expressed to a 27 kDa fragment between amino acids 44-
277 had no effect on the expression levels. Due to this lack of success, the 
characterisation of PF14_0325 was not taken any further. 
 
 
Table 4.1 Summary of recombinant protein expression. 
 MAL13P1.94 PF11_0443 CT PF14_0443 M PF14_0045 PF02_0040 
PCR insert size (bp) 149 284 233 593 366 
Expression vector pET30 pET30 pET30 pET32 pET32 
MW of recomb. 
protein (kDa) 
5 11 8 22 14 
MW plus tag (kDa) 10 17 13 38 30 
Expression cells BL21(DE3) 
pLysS 
BL21(DE3) 
pLysS 
Tf2 BL21(DE3) 
 
BL21(DE3) 
Expression 
conditions 
22°C, 4 h 22°C, 4 h 18°C, O/N 18°C, O/N 18°C, O/N 
Soluble? Yes Yes Yes No  No 
Purification 
conditions 
(Imidazole conc.) 
Wash 50mM 
elute 250mM
Wash 50mM 
elute 250mM 
Wash 50mM 
elute 250mM 
Wash 50mM 
elute 250mM 
Wash 50mM 
elute 250mM
Final conc. from 
culture (mg/l) 
5 10 1 N/A N/A 
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Figure 4.7. Western blots on parasite material using purified antibodies against all 4 proteins of 
interest. Antibodies raised against the aforementioned recombinant proteins were affinity 
purified and tested for reactivity against rbc, schizont and merozoite protein preparations 
resolved by SDS-PAGE under reducing conditions by Western blot.  The approximate expected 
molecular weights are highlighted with a star. MAL13P1.94 antibodies recognise a ~27 kDa band 
in both schizonts and merozoites with additional 50 kDa band in schizonts and 15kDa band in 
merozoites. Antibodies raised against the C terminus of PF11_0443 identify a single ~37 kDa 
band in both schizont and merozoite preparations, as do PF11_0443M antibodies. PF02_0040 
antibodies recognise a band of expected size, ~33kDa, in schizonts and merozoites, however 2 
additional bands at ca. 20 kDa are also apparent. PF14_0045 antibodies recognised a faint band 
just above the 75 kDa marker, not the predicted 114kDa, but the more predominant band was of 
around 20 kDa. N.B. Although loading of similar amounts of proteins was attempted the protein 
preparations were not of equal concentrations, hence different intensities between schizont and 
merozoite bands can be detected; the purpose of these westerns was merely to test antibody 
reactivity/specificity not quantification. Detailed, controlled westerns are presented in separate 
protein chapters 5, 6 and 7.
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4.4 Discussion 
 
Protein expression was attempted for all of the 5 selected proteins with varying levels of 
success. Although soluble protein fragments are desirable, in cases where it was not 
possible to produce sufficient quantities of soluble protein, the decision was taken to 
use insoluble protein for antibody production instead. Although not folded, protein 
aggregates can also be immunogenic and immunogenicity cannot be guaranteed, 
irrespective of immunogen solubility.  
 
Antibodies to MAL13P1.94 detected bands of 50, 25 and 17 kDa bands in schizonts and 
merozoite lysates. The 25 kDa band appears to be rbc-specific whereas the 50 and 17 
kDa proteins are parasite-specific. Further work is required to address their identity.  
Antibody cross-reactivity was always a potential problem and this was limited at the 
sequence level utilising blastp to ensure the sequence was not similar to any other 
Plasmodium or human proteins. Polyclonal antibodies however have the potential to 
recognise both linear but also conformational epitopes and therefore cross-reactivity 
cannot be completely prevented by design. 
 
Recombinant protein used to immunise rabbits contained the selected region from the 
protein of interested as well as the tag used in purification. Protease cleavage using 
factor Xa to separate target protein from the affinity-tag was not attempted as His tags 
are not particularly immunogenic and previous antibodies raised against fusion proteins 
using the same vectors resulted in specific antibodies without complications.  The fact 
that PF11_0443 antibodies recognise a single band of approximately 37 kDa which is 
close to its estimated molecular weight of 39 kDa and the absence of other cross-
contaminating bands suggest that the affinity tags do not generate cross reacting 
antibodies by themselves.  Hence it is unlikely that additional bands seen by western 
blot probed with MAL13P1.94 antibodies are caused by histidine reactive antibodies. 
This same argument is valid for the contaminating E. coli protein rotamase which was 
present in both Pf11_0443 and MAL13P1.94 recombinant protein purifications; 
rotamase does not appear to produce antibodies reactive with any P. falciparum protein. 
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Because antibodies raised against both PF02_0040 and PF14_0045 both exhibited 
reactivity to an unspecific 20 kDa, it is likely that this reactivity is caused by antibodies 
generated against the affinity tag. Unlike the previous fusion proteins both of these 
proteins were expressed using the pET32-Xa/LIC vector which contains not only a His-
tag but an additional thioredoxin tag to enhance solubility of the fusion protein. 
Thioredoxins are disulphide oxidoreductases and are present in all kingdoms of life 
including mammals and apicomplexa so it is feasible that this is what the rabbit sera is 
recognise by western blot (Holmgren, 1985). In an attempt to deplete these thioredoxin-
specific antibodies, a pET32-XaLIC vector was obtained in which a stop codon was 
introduced by site directed mutagenesis immediately following the thioredoxin tag 
[kind gift of Dr Judith Green]. This protein was highly soluble and 10 mg were used on 
an affinity column to negatively  deplete the PF02_0040 antisera of thioredoxin-specific 
antibodies. Column depletion was repeated 3 times over fresh columns however this 
was insufficient and the antibodies remained. Despite the presence of the ~20kDa 
bands, PF02_0040 antibodies identify a specific band at 33 kDa and are effective at a 
titre of 1:20000 on Western blot.   
 
After expressing recombinant proteins and generating antisera against 4 of the 5 
selected proteins a decision was made to concentrate on the most promising candidates 
based on resources generated. Therefore the PF14_0325 and PF14_0045 projects were 
terminated. No recombinant protein based on PF14_0325 amino acid sequence could 
be expressed in E. coli and antibodies generated against recombinant PF14_0045 failed 
to recognise a band of the expected size. 
 
On the other hand, good reagents to three of the proteins have been successfully 
generated and therefore we are focussing on a  detailed characterisation of MAL13P1.94, 
PF11_0443 and PF02_0040 and their role in the blood stage life cycle of P. falciparum. 
Each shall be described in detail and results discussed in chapters 5, 6 and 7 respectively. 
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5. Localisation and functional characterisation of the 
Plasmodium type IV Hsp40, PF11_0443 
 
5.1 Introduction 
 
5.1.1 The J protein/Hsp40 family 
J proteins or Hsp40s are a family of co-chaperones which act in conjunction with Hsp70s. 
Multiple J proteins can function with a single Hsp70, either by binding and  targeting 
protein substrates to Hsp70 or targeting Hsp70 activity directly to protein substrates 
within specific cellular locations (Liberek et al., 1991; Laufen et al., 1999). The bacterial 
chaperones DnaJ/ DnaK are the prototypical Hsp40/Hsp70 partnership and members of 
these families exist in every form of life. The pair classically function in binding short, 
unfolded hydrophobic sequences and promote correct protein folding during heat 
shock but family members are also involved in protein complex assembly, disassembly 
or protein translocation across membranes (Walsh et al., 2004).  Binding of an 
Hsp40+substrate complex stabilises Hsp70 in a substrate-bound state via interaction of 
the Hsp40’s J domain with the ATPase domain of the Hsp70, thereby stimulating ATP 
hydrolysis (Greene et al., 1998; Laufen et al., 1999). This highly conserved N-terminal J 
domain contains 4 helices: helix I and IV are shorter and are thought to stabilise the close 
interaction between anti-parallel helices II and III which form a tightly packed ‘finger’ 
that interacts with its Hsp70 binding groove (Pellecchia et al., 1996). The region between 
these two helices contains a protruding tripeptide HPD motif which is essential for 
Hsp70 binding and activation of ATP hydrolysis of Hsp70 (Tsai and Douglas, 1996), and 
mutation of these residues leads to a loss of function in the yeast J protein Sec63 
(Feldheim et al., 1992). The J domain is one of four domains that determine the structure 
and function of the Hsp40. The second is a Glycine/Phenylalanine (GF) rich region which 
regulates substrate binding to Hsp70 (Pellecchia et al., 1996; Mayer et al., 1999). A third 
characteristic domain is a  cysteine rich zinc finger domain which folds upon binding of 2 
zinc ions and is thought to stabilise the structure of Hsp40 or the interaction with 
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substrate (Banecki et al., 1996; Szabo et al., 1996). The C-terminal domain is less 
conserved and is generally involved in substrate specificity (Banecki et al., 1996). Hsp40s 
are classified into 3 subgroups in most organisms depending on the presence/absence 
of certain features (figure 5.1). Type I Hsp40s possess all the features described above; 
type II Hsp40s lack the zinc finger domain and type III proteins lack both zinc finger and 
GF region, containing only the J domain and the divergent C-terminal domain 
(Cheetham and Caplan, 1998). The ability of type III Hsp40s to bind to unfolded protein 
has never been shown and these proteins are thought to posses more diverse roles such 
as recruitment of an Hsp70 to a particular site. This is exemplified by the ER J protein 
Sec63 which recruits BiP to the ER protein translocon (Corsi and Schekman, 1997). A 
review of Hsp40s in P. falciparum by Botha et al (2007), has described a fourth class of J 
protein. These type IV Hsp40s contain an incomplete J domain, with 4 predicted helices 
but lack the HPD motif suggesting a more diverse role [reviewed in (Botha et al., 2007)]. 
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Figure 5.1: Prototypical J protein structure. J proteins are comprised of 4 domains. The conserved 
N-terminal J domain contains 4 helices with a crucial HPD motif between turns II and III. The 
Glycine/Phenylalanine (GF) rich region regulates substrate binding to Hsp70 and the cysteine 
rich zinc finger is capable of binding 2 zinc ions and is thought to stabilise the structure of Hsp40 
or the interaction with substrate. The less conserved C-terminal domain is involved in substrate 
specificity. Hsp40s can be classified into 4 types all of which contain the less conserved C-
terminal domain: type I possess all the features described above; type II lack the zinc finger 
domain; type III lacks both zinc finger and GF region, containing only the J domain; and type IV 
Hsp40s contain the J domain but lack the HPD motif suggesting a more diverse role. 
 
5.1.2 J proteins in P. falciparum 
Compared to the number of Hsp70s (of which there are 6) in P. falciparum, the family of 
Hsp40s is over-represented. According to Botha et al (2007), there are 43 predicted 
within the P. falciparum 3D7 genome, with only 2 classical type I, 9 type II which are 
thought to be capable of stimulating ATP hydrolysis by Hsp70, 20 type III and 12 type IV 
putative J proteins (Botha et al., 2007). Nineteen of these Hsp40s, from types II, III and IV, 
are predicted to contain Plasmodium export element (PEXEL) motifs which enable 
protein export into the erythrocyte cytosol (Marti et al., 2004). Of the 19 PEXEL-
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containing Hsp40s, eleven are classified as type IV leaving only PF11_0443 as the only 
type IV J protein not to contain a PEXEL motif. None of the Hsp70s of P. falciparum 
contain PEXEL motifs therefore the PEXEL-containing Hsp40s are likely to have a 
different role (unless they are able to interact with host derived Hsp70s). Ring-infected 
surface antigen (RESA) is one of the 11 exported type IV J proteins. RESA is found in the 
dense granules and exported into the rbc cytoplasm where it has been shown to bind 
cytoskeletal protein spectrin (Foley et al., 1991), and is implicated in protection against 
thermally induced unfolding of this protein (Da Silva et al., 1994). These data are 
supported by knock-out studies where deletion of RESA resulted in susceptibility to heat 
shock (Silva et al., 2005), thus presenting clear evidence that this divergent class of type 
IV Hsp40s may still function in response to heat shock, despite a lack of exported Hsp70 
co-chaperones.  
 
5.1.3 PF11_0443 orthologues 
PF11_0443 has orthologues in 36 different sequenced species all from higher eukaryotes 
(listed in Chapter 3, Table 3.1), with two exceptions – Dictyostelium discoideum and 
Tetrahymena thermophila. These were identified from PlasmoDB and OrthoMCL-DB, 
from the orthologue group OG5_131379 (Li et al., 2003) and confirmed using NCBI 
BLAST tool – a select alignment is present in Chapter 3, figure 3.5. Curiously, Plasmodium 
is the only Apicomplexan to contain a member of this orthologue group and it is only 
expressed in blood stages. This may imply a role for PF11_0443 in interaction between 
Plasmodium and it’s specific host cell. Fellow Haemosporidia Thieleria and Babesia do not 
appear to possess an orthologue however one major difference between Plasmodium 
and other Haemosporidia is that Plasmodium requires an intact PV to be present 
throughout the lifecycle, Thieleria and Babesia do not. This would suggest a role for the 
protein in PV formation/stabilisation however this speculation requires experimental 
validation. 
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5.1.3.1 Clues from other species 
As mention above, PF11_0443 has many orthologues in other species (Table 3.1, figure 
3.5). One of these is Dmel\CG7872 from the fruit fly Drosophila melanogaster – one the 
most extensively studied multicellular organisms. The online database Flybase 
(flybase.org) was used to obtain information regarding the Drosophila orthologue of 
PF11_0443, Dmel\CG7872. Transcription data reveal that this protein is strongly 
expressed in the larval stage salivary glands at around ten-fold compared to other 
organs (Chintapalli et al., 2007). Salivary glands in the larva stage of fly development are 
responsible for the large scale secretion of a glue-like substance that allows the larva to 
adhere to a single position while developing into an adult fly. This suggests a role for this 
protein in the secretory pathway. Although the salivary glands as a whole are not 
essential in the laboratory environment, it is reasonable to assume that larva lacking 
these organs would be at a selective disadvantage in the field.  
 
Caenorhabditis elegans is another widely studied organism due to its genetic 
amenability. PF11_0443 has two orthologues in this species one encoding a ca.40 kDa 
protein DNJ-2 and the other encodes a truncated form which will not be discussed here. 
Information regarding  dnj-2 (WBGene00001020) was retrieved from wormbase.org. C. 
elegans is used as a model to study the human neuro-degenerative disorder, Parkinson’s 
Disease (PD). In one such study, the targeted knockdown of dnj-2 resulted in 
mislocalisation and aggregation of the transgene alpha-synuclein suggesting DNJ-2 has 
a role in protein targeting and inhibiting protein aggregation (Hamamichi et al., 2008). 
 
The human orthologue of PF11_0443 is classified as DNAJC25, a type III J protein. 
Computational analysis identified high expression levels (determined by relative 
number of expressed sequence tags or ESTs per tissue) of DNAJ25 in the bladder, 
pancreas and salivary glands (Hageman and Kampinga, 2009) all of which are organs 
specialise in secretion.  
 
Data from other species offer a potential insight into the function of PF11_0443, 
however since there are few orthologues of this protein in more closely related 
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organisms, it is likely that Plasmodium has retained or acquired PF11_0443 for a specific 
function which may differ to the function of the protein in metazoa. Thorough 
experimental analysis is required in order to characterise and uncover the function of 
PF11_0443 within Plasmodium. 
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5.2  PF11_0443 is an integral membrane protein in P. falciparum schizonts 
 
PF11_0443 contains multiple predicted transmembrane domains. It is therefore highly 
likely that PF11_0443 is an integral protein, nevertheless experimental confirmation is 
required. P. falciparum 3D7 schizonts were first lysed in high pH 0.1M sodium carbonate 
buffer in order to separate soluble and any peripheral membrane proteins from those 
with membrane anchors. Western blot analysis of the protein extracts revealed that, as 
predicted, PF11_0443 resides within the carbonate pellet fraction, confirming that it is 
indeed an integral membrane protein. SERA-5 is a soluble protein within the PV of 
schizonts and peripherally associated with the cell surface in merozoites. Antibodies to 
SERA-5 and membrane anchored MSP-2 were used to control for loading carbonate 
supernatant and the pellet fractions, respectively. 
 
 
 
Figure 5.2: Western blot analysis of carbonate lysed schizonts. 
P. falciparum 3D7 schizonts were treated with a high pH 
carbonate buffer to separate soluble and peripheral 
membrane proteins from the integral membrane protein 
fraction. Samples from carbonate supernatant and carbonate 
pellet were separate by SDS-PAGE and subject to western 
blot. SERA-5 (peripheral membrane) and MSP-2 (membrane-
anchored) antibodies were used to detect these proteins  as 
loading controls. The blot was probed with PF11_0443CT 
antibodies to reveal this protein as integral to the membrane. 
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5.3 PF11_0443 is expressed from 36 h p.i. in schizonts and merozoites but is 
transferred into ring stages. 
 
Bioinformatic analysis revealed PF11_0443 peak transcript levels occur at around 33h p.i. 
but this is not necessarily indicative of the commencement of protein expression. 
Proteomic data place PF11_0443 in schizonts and merozoites (as discussed in chapter 
3.2.3) however there are no proteomic data available that provide evidence for this 
protein in ring stage parasites. In order to uncover the onset and length of PF11_0443 
protein expression in the P. falciparum blood stage cycle it was necessary to complete a 
time-course experiment, sampling one complete cycle at 4 h intervals, beginning with 
newly invaded rings (time point zero) through to late/rupturing schizonts. Samples were 
subject to western blot analysis, along with a rbc control, probing with specific 
PF11_0443CT rabbit polyclonal antibodies for protein detection (figure 5.2 A) (for 
method please refer to section 2.3.4). Equal loading of rbc lysates in each well was 
visualised by probing with an anti-glycophorin A/B antibody. The blot was also probed 
with an antibody against the ER constituent parasite protein BiP to confirm the presence 
of parasite material in each of the lanes from the time-course (Kumar et al., 1988; Kumar 
et al., 1991). MSP-2, which is expressed in schizonts (Wickham et al., 2003), was used as a 
late stage control. Probing time course samples with PF11_0443CT antibody by western 
blot revealed that protein expression began at 36 h p.i. in early schizogony and 
increased during the following 4 hours. Protein levels were then maintained until egress 
however PF11_0443 was not visible in ring stage parasites by western blot suggesting 
either the C-terminus was lost perhaps by shedding upon entry into the host cell or 
rapidly degraded within the parasite (figure 5.2 A).  
 
Based on the western blot results, PF11_0443CT antibodies were used in indirect 
immunofluorescence (IFA) experiments using parasite slides from each time point 
beginning at 36h p.i. (figure 5.2 B). At the beginning of protein expression, which from 
the western blot is around 36h and around the start of schizogony, PF11_0443 appears 
peripheral to the nucleus which would imply that perhaps it is to be found within the ER 
however distinct foci are clearly visible. As this protein contains predicted 
 148
transmembrane domains these foci might be ER-derived transport vesicles or ER 
subdomains. This punctate staining was also detected at 40h p.i. schizonts although the 
staining moves from peri-nuclear to what appears to be foci throughout the schizont 
cytoplasm. Interestingly, as the schizont matures and undergoes cell division (44h p.i.) , 
PF11_0443 appears to associate with the individual merozoites located anterior to the 
nucleus. This pattern is similar to that exhibited by residents of the apical organelles. Co-
localisation IFA studies with known organelle markers was attempted to pinpoint the 
intracellular location of PF11_0443. 
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Figure 5.3:  Expression of PF11_0443 throughout the lifecycle.  
 
A) Protein samples of synchronous parasite culture taken every 4 hours for one complete 
synchronised blood-stage cycle were hypotonically lysed and the pellet fraction was 
solubilised in Laemmli SDS reducing sample buffer and separated by SDS-PAGE. 2x106 
rbcs were loaded per well. As a control an equal number of uninfected rbcs prepared 
identically were loaded per well.. Expression of PF11_0443 was analysed by western blot 
using the previously generated PF11_0443CT rabbit polyclonal antibody. A glycophorin 
A/B antibody was used as a loading control (rbc). Antibodies against the parasite ER 
resident protein BiP were used to confirm the presence of parasite material in each lane, 
and against MSP-2 were used as a schizont marker. Giemsa stained parasites from each 
time point are presented as an example to demonstrate parasite morphology for each 
stage. 
 
 B) Thin smears of parasite culture from each time point were fixed in paraformaldehyde 
and permeabilised with Triton X-100, and used in IFAs to detect the presence of 
PF11_0443 in the parasite using specific antibodies. PF11_0443 is detected by a 
fluorescent secondary antibody (shown in green) and the nucleus is stained with DAPI 
(blue).A single merozoite is shown for the 48-h time point. Scale bar on the brightfield 
image represents 5μm. 
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5.4 PF11_0443 co-localises with apical organelles in late schizonts and 
merozoites. 
 
A clear change was observed in the localisation of  PF11_0443  from numerous small foci 
close to the nucleus in early schizonts to larger foci located apical in late schizonts. To 
determine which apical organelle PF11_0443 was located in, it was necessary to co-
localise with antibodies to protein markers of known sub-cellular location. In order to do 
this, thin smears of P. falciparum 3D7 were fixed and permeabilised and subjected to 
indirect immunofluorescence using PF11_0443CT polyclonal rabbit antibodies. 
Although PF11_0443middle antibodies strongly recognised a band of the correct size in 
western blot based assays, they produced a weak fluorescence pattern in IFAs and were 
not used to identify protein location. 
 
The fluorescence pattern was compared to that produced by antibodies against proteins 
of already determined location, encompassing a number of locations within the cell. 
PF11_0443 is present in early schizogony where it appears to reside within the ER as 
shown by colocalisation with BiP (Kumar et al., 1991) (figure 5.4). As schizogony 
progresses and daughter cells begin to segregate, the location of PF11_0443 appears to 
change from the periphery of the nucleus to a more punctuate pattern common among 
proteins of the apical organelles. Focussing on late schizonts, the protein appears to co-
localise best with AMA-1 (Healer et al., 2002; Bannister et al., 2003) and EBA-175 (Sim et 
al., 1992), both micronemal proteins and not MSP-1 (Holder and Freeman, 1984a) (figure 
5.4). There is some overlap of fluorescence between PF11_0443 and RhopH2 of the 
rhoptry bulb (Holder et al., 1985) in schizonts  and with the rhoptry neck protein RON-4 
(Alexander et al., 2006) in merozoites. Due to their close proximity within the merozoite 
and the fact that the diameter of fluorescence is around 200-300nm, it is often difficult 
to distinguish between micronemal and rhoptry locations. There also appears to be a 
small amount of residual PF11_0443 associated with the periphery of the nucleus, 
presumably the ER. In free merozoites there is at least partial colocalisation with both 
AMA-1 and EBA-175 (figure 6.3). Interestingly AMA-1 and EBA-175 do not co-localise 
with each other and are therefore thought to reside in different subsets of micronemes – 
 152
AMA-1 is released onto and diffuses across the plasma membrane upon release whereas 
EBA-175 only ever appears at the apex of merozoites. EBA-175 is generally seen as a 
single point of fluorescence in merozoites however PF11_0443 is clearly visible in 
multiple points of fluorescence at the apex of the cell (in comparison with the nucleus at 
the posterior). As there are multiple micronemes within the cell, this pattern could 
indicate PF11_0443 is present in each of them.  
 
Micronemes and rhoptries are not the only organelles present at the apex of merozoites. 
The protein SUB-1 is present in a subset of the micronemes – the exonemes – which are 
released into the PV of schizont stage parasites before merozoite release. PF11_0443 
does not co-localise with this subset (data not shown), and is still present in released 
merozoites. The dense granules are apical organelles of spherical nature which are 140 – 
120 nm and therefore smaller than the two rhoptries but larger than micronemes. 
PF11_0443 does not co-localise with the dense granule constituent protein RESA (figure 
5.5). Ruling out colocalisation with markers of these other organelles, the micronemes or 
rhoptries remain the most likely destination for PF11_0443. 
 
Micronemal proteins such as AMA-1 and EBA-175 are released onto the merozoite 
surface and shed upon invasion (Harris et al., 2005; O'Donnell et al., 2006) and 
consequently these proteins can be detected in culture supernatants by western blot. 
PF11_0443 was not detected in culture supernatants by western blot (data not shown). 
To address where PF11_0443 is after egress and reinvasion we analysed ring stage 
parasites by western blot and IFA. Although PF11_0443 was not detected in rings by 
western blot (figure 5.3), use of the PF11_0443CT antibody in an IFA revealed this 
protein can be detected in early rings by this method (figure 5.5). It is important to note 
that antibodies used here were used at a more concentrated level in ring stage IFAs than 
in  schizont or merozoite IFAs and the camera exposure times were doubled when 
capturing the images implying PF11_0443 is present at a lower level. This apparent 
reduction could explain why this protein was not visible by western blot using ring stage 
lysates. Presumably the protein is degraded within the newly invaded  rbc when no 
longer needed. 
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Indirect immunofluorescence has identified PF11_0443 as a possible micronemal 
protein however carry-over of a small amount of this protein into early rings calls this 
localisation into question as other micronemal proteins are shed during invasion. The 
expression from 36 h onwards when apical organelles are formed and the presence 
within the ER in early schizonts together with the putative divergent Hsp40 function 
suggests a possible role for this protein in protein sorting or trafficking. Further 
investigation is required to determine the protein’s function within the P. falciparum 
intra-erythrocytic cycle.  
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Figure 5.4: Indirect immunofluorescence assay of early and late schizonts.  
 
Thin smears of early and late schizonts were fixed and permeabilised as described in 
2.2.13.1 and used in IFAs to detect the presence of PF11_0443 in the parasite using C-
terminal specific rabbit polyclonal antibodies. The primary anti-PF11_0443CT antibody 
was detected by a fluorescent secondary antibody (AlexaFluor 488 – green) and the 
nucleus is stained with DAPI (blue). Compartments were identified using previously 
characterised antibodies to proteins of known location followed by secondary 
antibodies labelled with AlexaFluor 594 (red) and images were merged to determine 
comparative location (BiP: ER; AMA-1 and EBA-175: microneme; RhopH2: Rhoptry bulb; 
MSP-1: parasite surface). Antibodies and dilutions are described in chapter 2, table 2.4. 
Areas of co-localisation appear yellow. Scale bar on the bright-field image represents 
5μm. 
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Figure 5.5: Indirect immunofluorescence assay of merozoites and ring stages.  
 
Thin smears of late schizonts and merozoites as well as early rings were fixed and 
permeabilised as described in 2.2.13.1 and used in IFAs to detect the presence of 
PF11_0443 in the parasite using C-terminal specific rabbit polyclonal antibodies. Primary 
anti PF11_0344CT antibody was detected by a fluorescent secondary antibody 
(AlexaFluor 488 – green) and the nucleus is stained with DAPI (blue). Compartments 
were identified using previously characterised antibodies to proteins of known location 
followed by secondary antibodies labelled with AlexaFluor 594 (red) and images were 
merged to determine comparative location (AMA-1 and EBA-175: microneme; RON4: 
rhoptry neck; RhopH2: Rhoptry bulb; MSP-1: surface; RESA: dense granules). Antibodies 
and dilutions are described in table 2.4. Areas of co-localisation appear yellow. Scale bar 
on the bright-field image represents 5μm in ring-infected rbc and 1μm in merozoite 
images.  
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5.5 PF11_0443 is not released onto the surface of the merozoite prior to 
invasion. 
 
Contents of the micronemes contain proteins such as AMA1 and EBA175 which are 
necessary for merozoite entry into rbcs. It is therefore necessary that the contents are 
released onto the surface of the merozoite prior to invasion to allow for contact with 
host cell proteins. If PF11_0443 resides in the micronemes, a part of the protein must 
end up on the surface of the merozoite. The protein sequence of PF11_0443 was used in 
several topology algorithms in an attempt to predict which sections of the protein 
would end up on the surface however, of the 4 algorithms, 2 predicted the C-terminus 
and J-domain as external and 2 predicted these domains to be cytoplasmic with the 
middle section of the protein on the outside of the cell. An experimental approach was 
therefore required.  
 
Antibodies against both the C-terminal and the middle region of PF11_0443 were used 
in a live or un-fixed immunofluorescence assay of newly ruptured schizonts in the 
absence of fresh rbcs in order to visualise free merozoites (methods described in 
2.2.13.2). Cells were incubated with primary antibodies to PF11_0443CT, 
PF11_0443middle, MSP-2 which served as a positive control for surface staining and 
MTIP – a marker of the IMC (Baum et al., 2006; Green et al., 2006b), to ensure the cells 
were not permeable to antibody. As visible from figure 5.6, although positive control 
MSP-2 showed clear surface fluorescence in the absence of any staining from MTIP 
labelled parasites, antibodies to both the middle and C-terminal sections of PF11_0443 
failed to be detected on the parasite surface. 
 
There are several possible explanations of this negative result. The first is that PF11_0443 
is not a micronemal protein and therefore would not be expected to be released onto 
the surface prior to invasion, despite a convincing co-localisation by IFA. However other 
micronemal proteins such as EBA 175 are not observed on the surface of free merozoites 
in the absence of rbcs whereas AMA 1 is readily observed on the surface of merozoites 
(E. Knuepfer, unpublished data). This  provides further evidence for a sub-division of the 
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micronemes both in content and in discharge conditions. Also, as mentioned in the 
previous section, PF11_0443middle antibody has lower affinity than the C-terminal-
specific rabbit polyclonal antibody. To compensate it was used at a higher concentration 
but perhaps this weaker affinity was responsible for the lack of detection on the 
merozoite surface.  A final possibility is that both the C-terminus and the middle section 
are on the same side of the membrane and that the second transmembrane domain of 
slightly weaker prediction is actually not a transmembrane spanning region after all. 
Looking at the sequence of this region (Chapter 3, figures 3.4 and 3.5), there are a couple 
of hydrophilic and charged lysine residues as well as the helix-breaker proline in the 
middle of the region which would interrupt a transmembrane helix. Further 
investigation into the validity of the TM prediction is required to rule this out as the 
reason for the negative result. 
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Figure 5.6: Unfixed IFA with PF11_0443 middle and C-terminal antibodies. A) Synchronised 
P. falciparum 3D7 schizonts were allowed to release free merozoites in the absence of 
rbcs and incubated with PF11_0443CT, PF11_0443middle, MSP-2 or MTIP antibodies 
followed by the fluorescent secondary antibody (AlexaFluor 488 – green) (methods 
described in 2.2.13.2). B) Schematic illustrates the predicated domain architecture for 
PF11_0443 and highlights regions to which antibodies were raised. This negative IFA 
result calls into question the validity of the second transmembrane prediction.
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5.6 Immunoprecipitation experiments using protein-specific 
polyclonal rabbit antibody pulls down PF11_0443 as well as potential 
interaction partners  
 
In the quest to determine the function of PF11_0443, the identification of interaction 
partners was attempted by immunoprecipitation followed by LcMS/MS analysis.  
Initially, PF11_0443-specific antibody was used to immuno-precipitate protein from 35S-
labelled schizonts (methods described in chapter 2.2.15). Resolution of this radio-
labelled protein sample by SDS-PAGE and subsequent exposure to film revealed a band 
of ca 37 kDa which is consistent with the predicted and observed size of PF11_0443 by 
western blot. Other precipitated bands in the antibody IP and absent from the pre-
immune IgG control IP were visible at ca 39kDa band and at ca 250kDa (figure 5.7 A). In 
order to separate and visualise larger bands, labelled protein samples were resolved on a 
lower percentage, 4-12% Tris-acetate gel (figure 5.7 B). A band of 37kDa, presumably 
representing PF11_0443, was visible, as well as 2 unique bands greater than 250kDa and 
one at approximately 130kDa. Parasites were labelled at approximately 42h p.i. for 2 h 
therefore only proteins being expressed at this time will incorporate 35S, anything 
expressed later or that has completed expression for this cycle would not have been 
labelled therefore it is possible that additional binding partners exist. Proteins require a 
number of cysteine or methionine residues in order to incorporate detectable 35S label, 
any proteins lacking in these amino acids would also not be detected here.  
 
In order to identify possible binding partners, a protein preparation from 3ml pelleted 
schizonts was passed over a column of PF11_0443 specific IgG bound to activated CNBr 
(method described in 2.2.26). Unbound proteins were washed off with 300mM NaCl 
before eluting bound proteins in low pH buffer containing 100mM glycine. The elution 
was concentrated to 50 μl, of which 30μl was loaded onto a gel and eluted proteins were 
separated by SDS-PAGE. Initially the gel was stained with Instant Blue® (figure 5.7 C) 
however only faint bands were visible so an addition gel was prepared using the 
remaining 20μl of sample and silver-stained using a mass spectrometry-compatible 
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method (Blum, 1987) (figure 5.7 D). Visible bands were excised and analysed by Lc 
MS/MS analysis (PNAC, University of Cambridge). Results from mass spectrometry 
analysis are summarised in appendix A. Only proteins regarded as significant had a 
MOWSE (Molecular Weight SEarch) score of around 200 and over. The MOWSE score is 
based on the probability that the observed match is a random event: the lower the 
probability that the match is due to chance, the higher the score.  
 
The experiment successfully precipitated PF11_0443 which, in-keeping with its apparent 
molecular weight observed in previous western blots, was primarily found in band 1 
(figure 5.7 C), although peptides were recovered from other bands. PF11_0443 was not 
recovered from rings stages and here the only significant hit was the ER Hsp70 BiP (band 
6, figure 5.7 D). Unfortunately, due to the role of Hsp70s in binding unfolded proteins, 
they are common contaminants in immunoprecipitation experiments. This is particularly 
problematic considering the function of type IV Hsp40 may well involve binding this 
family of proteins. Abundant proteins are also common contaminants and it is likely this 
is the reason for the presence of MSP-1 and SERA-5. Rhoptry proteins have also been 
found to non-specifically bind to the matrix however four rhoptry proteins have been 
identified here – RhopH2, RhopH3, RAP1 and RAP3 and this could be significant. In T. 
gondii, dynamin-related protein B (DrpB) has been implicated in rhoptry targeting 
(Breinich et al., 2009) and this experiment co-precipitated a dynamin-like protein which 
could perhaps function in a similar way although this has never been verified in 
Plasmodium. 
 
Interestingly micronemal proteins AMA-1 and EBA-181 also were co-precipitated. These 
proteins are not common non-specific binders and could be the result of specific 
interaction.  Other proteins of interest include Hsp60, Hsp101, the DnaJ containing 
proteins, IMC resident GAP50, protein phosphatases and conserved proteins of 
unknown function.  The presence of a FKBP-type isomerase in the IP eluant is likely to be 
due to the presence of antibodies on the column that recognise the bacterial FKBP-type 
isomerase rotamase, which was present in the recombinant protein fraction  used to 
immunise the rabbit that produced the PF11_0443CT antibodies.  Interestingly two 
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protein disulphide isomerases (PDIs) were co-precipitated. These proteins have long 
been established to form and preserve disulphide bridges in the ER but they are also 
present in the P. berghei ookinete microneme proteome (Lal et al., 2009), where the 
authors suggest it may be required for the conservation of protein structure. In P. 
falciparum, PDI exhibits punctate staining in schizonts staining which could correspond 
to micronemes (Mouray et al., 2007) and PDIs are also present in micronemes of N. 
caninum (Naguleswaran et al., 2005) and on the surface of T. gondii (Meek et al., 2002), 
however it has not been determined whether it is secreted through the micronemes in 
this particular organism. As ookinetes do not possess rhoptries, it is not clear whether 
this protein is present in this organelle also. The ookinete microneme proteome also 
uncovered a large number of chaperones, eight of which were DnaJ domain-containing 
proteins. Although PF11_0443 is not among them as it is not expressed at this stage and  
it is not clear how many of these are contaminants; this microneme proteome suggests 
potential role for the J protein family in these organelles.  
 
Equivalent bands eluted from the pre-immune column were not initially analysed as it 
was thought necessary to first determine whether or not the experiment was successful. 
Although PF11_0443 was clearly identified, a vast array of other proteins appeared to 
co-precipitate, calling in to question the quality/strength of this method for identifying 
binding partners. Immunoprecipitation of an epitope tagged protein may lead to more 
specific results therefore the relevance of pre-immune analysis was postponed until 
other avenues of binding partner identification were explored.  
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Figure 5.7: Immunoprecipitation studies using PF11_0443 antibodies.  
 
(A+B) PF02_0040 antibodies were used to immuno-precipitate interacting proteins from 
50μl of pelleted 35S labelled schizonts (methods described in chapter 2.2.15). Co-
precipitating proteins were separated by SDS-PAGE under reducing conditions with 12% 
Bis-Tris (A) and a 4-8% Tris-Acetate (B) gels and exposed to film. A band of the predicted 
size of PF11_0443, approximately 37kDa, was observed and highlighted with * and 
unique precipitated bands were indicated with an arrow.   
 
(C+D) Purified schizonts were lysed and passed over a column of 10mg of pre-immune 
rabbit IgG followed by that containing affinity purified anti-PF11_0443 rabbit polyclonal 
antibodies conjugated to activated CNBr (methods described in chapter 2.2.16). Co-
precipitating proteins were resolved under reducing conditions by SDS-PAGE on 4-8% 
Tris Acetate (C) and 12% Bis-Tris (D) gels and visualised by Instant Blue (C) and silver 
stain (D) respectively. Unique bands compared to the control were excised (labelled 1-7) 
and the protein complement of each was identified by LC-MS/MS.  
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5.8 Epitope tagging of the PF11_0443 locus by targeted homologous 
recombination 
 
Incorporation of a sequence coding for an epitope tag into the genomic locus of a gene 
is a useful tool for characterisation of the resulting protein. Often there are commercial 
monoclonal and polyclonal antibodies available which have been tried and tested for 
reactivity and specificity for the tag antigen.  Due to the problems with 
immunoprecipitation seen using the polyclonal antibodies generated here, 
incorporating an epitope tag into the PF11_0443 locus would provide a useful tool for 
further characterisation of the protein. 
 
One of the most common epitope tags is green fluorescent protein (GFP). Fluorescent 
tags such as this allow direct visualisation of the endogenous protein using a fluorescent 
microscope, without the need for antibodies. This can be used in video-microscopy to 
track the life history of the protein, from translation to degradation or shedding, with 
trafficking to cellular location in between.   
 
One potential problem with the fluorescent proteins is that they are relatively large 
compared to other tags. GFP is 26kDa and may not be suitable to add-on to the C-
terminus as the protein is only predicted to be 39 kDa and this would effectively double 
its molecular weight. For this reason, smaller tags were initially selected to incorporate 
into the C-terminus of PF11_0443. Since the N-terminus contains a signal peptide which 
is cleaved upon translocation into the ER, tagging the N-terminus is not possible. One of 
the chosen tags is the 3xFLAG tag. FLAG™ (Sigma-Aldrich) is an 8 aa, aspartic acid-rich 
tag with an enterokinase cleavage site incorporated between the C-terminus of the 
endogenous protein and the tag sequence. Sigma-Aldrich produces a multitude of 
products useful in protein characterisation such as mono- and polyclonal antibodies; 
antibodies directly conjugated to HRP for western blots or to fluorophores for direct 
immunofluorescence; and immunoprecipitation kits which include monoclonal 
antibody M2 conjugated to an agarose resin and 3xFLAG peptide for specific elution. 
The 3xFLAG tag is 21aa long and was chosen over a single copy of FLAG due to the 
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increased sensitivity it gives in terms of recognition by the αFLAG monoclonal M2 
antibody which will detect the presence of 3xFLAG peptide at femtomolar 
concentrations. The second eptiope tag chosen was the TY-1 tag, a 10aa tag first 
described in Trypanosomas brucei (Bastin et al., 1996), used commonly in Toxoplasma 
gondii and also used previously in P.falciparum (Treeck et al., 2009).  
 
In order to introduce these tags onto the C-terminus of the protein, a region of 
homology of 540 bp from the 3’ end of the PF11_0443 locus (minus the stop-codon) was 
amplified by PCR using primer combinations R/S and R/T (see chapter 2, table 2.1). Ty1 
and FLAG epitope tag sequences (including a stop codon at the 3’ end) were included in 
reverse primers S and T respectively and used to amplify the region of homology, 
thereby incorporating the tag sequences. This region of homology plus tag sequence 
was cloned into the multiple cloning site of the pHH3 vector via the EcoRI/SacII 
restriction sites generating pHH3_PF11_0443_Ty1 and pHH3_PF11_0443_3xFLAG. An 
AvrII site was included between the gene and tag sequences to allow the use of these 
vectors to epitope tag other genes. This strategy is summarised in figure 5.8 A. The pHH3 
transfection vector which includes the Blasticidin resistance cassette as a selectable 
marker is depicted in appendix D. The same region of homology of PF11_0443 was in 
addition cloned into the pHH3 vector via EcoRI/SacII without the presence of an epitope 
tag to serve as a 3’ replacement vector. 
 
Inserts were initially sub-cloned into the pGEM T-easy vector and transformed into E. coli 
TOP10 cells. Colonies were selected and sequenced before excising the correct inserts 
using EcoRI and SacII. Inserts were gel-purified and ligated into the pHH3 vector and 
transformed into E. coli TOP10. Colonies were re-sequenced and one construct with 
correct DNA sequence was propagated and plasmid DNA purified for transfection. For 
analysis purposes the construct was subject to digestion with EcoRI and SacII to confirm 
the presence of the correct sized (540 bp) insert prior to transfection (figure 5.8 B) 
 
Complete and purified plasmids pHH3_PF11_0443_3xFLAG, pHH3_PF11_0443_Ty1 and 
pHH3_PF11_0443_3’ were transfected into ring-stage parasites and selected for 
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presence of episome by 2.5μg/ml of Blasticidin applied to cultures . Stock samples of 
these cultures were cryopreserved and genomic DNA was prepared. Transfection 
cultures were taken off drug for 3 weeks before re-application of drug which is required 
for enrichment of the parasite population that contains integrated versus episomal 
copies of the transfection vector. This was repeated for up to 3 cycles.  
 
A diagnostic PCR on genomic DNA prepared from drug cycle 2 was designed to test for 
integration events using a forward primer (a) from the PF11_0443 5’UTR region (primer 
N, table 2.1) and reverse primers from either (b) the PF11_0443 3’UTR region (primer Q, 
table 2.1) to identify the wild type locus of 1293 bp or (c) from the HRP2 3’UTR contained 
within pHH3_PF11_0443_Ty1 construct (primer NN, table 2.1) to detect integrated 
plasmid of 1345 bp(figure 5.8 A). The upper bands on the diagnostic PCR gel represent 
correct integration of the constructs pHH3_PF11_0443_3xFLAG, pHH3_PF11_0443_Ty1 
and pHH3_PF11_0443_3’ into the PF11_0443 locus by drug cycle 2, the lower band is 
most likely a result of mispriming (figure 5.8 C).  
 
To test whether these integrated tags after drug cycle 2 are expressed in parasites, 
protein samples were prepared from 3D7 WT and tagged lines and subject to western 
blot analysis with either tag-specific or PF11_0443M antibodies (figure 5.8 D+E). 
PF11_0443M recognised a single band in WT 3D7 parasites however a clear doublet was 
visible in both of the tagged lines illustrating 2 distinct parasites populations with the 
lower band representative of WT parasites and the higher band representing epitope 
tagged parasites, with the tag responsible for the small increase in molecular weight 
(3xFLAG – 39 kDa; Ty1 - 41 kDa). When both WT 3D7 and tagged proteins were probed 
with Ty-1 or FLAG antibodies no band was visible in the WT line and only a single band 
appeared in the tagged lines.  Parasites containing a Ty-1 or FLAG-tagged copy of 
PF11_0443 were used in IFA (figure 5.9). Antibodies to either tag revealed the epitope-
tagged PF11_0443 exhibited a similar cellular location to the wild type protein, with 
what appears to be ER staining pattern in early schizonts and a more punctuate and 
apical location in late, segmented schizonts and merozoites, however colocalisation 
with known markers is required to confirm this. 
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These initial tests of FLAG and TY-1 specific antibodies by western blot and IFA revealed 
the αFLAG M2 monoclonal antibody to be the better reagent in terms of sensitivity and 
commercial availability, therefore all further experiments were performed with the 
3xFLAG-tagged line. The mixed population culture was cloned by limiting dilution and 
clones screened by PCR using primer combination R/S and R/T (mentioned above) to 
ensure there was no wild type PF11_0443 present. Although WT and integrated DNA was 
present in the uncloned drug cycle 3 parasite line, clones a and c contained only 
integrated DNA (figure 5.10 A). A Southern blot was designed to confirm integration into 
the correct locus (figure 5.10 B). Genomic DNA taken each drug cycle was digested by 
PacI and BglII before separating resulting fragments by gel electrophoresis and blotting 
onto nitrocellulose membrane. The membrane was hybridised with a radiolabelled DNA 
probe encompassing the region of homology used in the construct design. The resulting 
banding pattern from exposure to film revealed the presence of wild type DNA with a 
band of 2560 bp (WT) in cycle 0 as well as the presence of both integrated (2789 bp) and 
episomal construct DNA (E) (5985 bp) in cycle 3. In the 3 cloned lines tested (clones a, c 
and e), this episomal band is lost and only the integration band at 2789 remains. There is 
a fourth band present which does not correspond to WT, episome or integration into the 
PF11_0443locus in both C3 and clone E which may correspond to integration of the 
construct into another region of the genome. Random integration of the blasticidin 
cassette has been observed by other lab members using this construct to epitope tag 
other genes. 
 
Colocalisation of PF11_0443-FLAG with known markers of sub-cellular compartments 
confirmed that this protein is present in early schizonts where it co-localises with the 
rhoptry bulb marker RhopH2. The pattern is indicative of presence in the ER, however an 
ER marker antibody of the correct species was not available. In late schizonts, FLAG 
antibodies co-localise with RhopH2 suggesting PF11_0443-FLAG is present in rhoptries. 
Whereas previously in section 5.4 it was shown that WT PF11_0443 colocalised best with 
micronemal markers, only partial colocalisation was observed with AMA1 in merozoites. 
Again using the FLAG-tagged PF11_0443 no colocalisation was observed with MSP1 but 
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colocalisation with the rhoptry neck protein RON4 could not be tested as both 
antibodies are mouse derived. Colocalising PF11_0443 CT antibodies with anti FLAG 
antibodies shows only modest overlap. 
 
The difference in fluorescence pattern could be due to experimental difficulties, since 
the resolution of light microscopy may not be sensitive enough to distinguish between 
the different locations. It is currently unclear whether PF11_0443 in 3D7 parasites resides 
within rhoptries or micronemes since IFAs using WT parasites did not uncover a 
definitive location for this protein. It is therefore unknown whether the localisation of 
the FLAG-tagged PF11_0443 in rhoptries is depicting the same localisation as the wild 
type protein or whether C-terminal tagging resulted in the mislocalisation of this 
protein. Introduction of a tag to the C-terminus of PF11_0443 may have caused a change 
in the proteins sub-cellular location, perhaps by interfering with trafficking signals. If the 
latter proves to be true, perhaps the protein is not essential, as a change in location 
suggests the protein’s function in its original location is unnecessary. It is also possible 
that the increased sensitivity of the anti-FLAG antibodies has led to the discovery of 
PF11_0443’s location within the cell.  
 
Definitive localisation studies using epifluorescense is difficult when trying to detect 
proteins located in closely assembled organelles. Only electronmicroscopy studies with 
newly produced polyclonal antibodies will clarify the discrepancies definitively. 
 
The PF11_0443 locus has proven to be an accessible locus, with all 3 vectors integrating 
into the locus by drug cycle 2. These tags could be detected using Ty-1 and FLAG 
specific antibodies by western blot and IFA of tagged parasite lines. Due to the superior 
sensitivity of the FLAG antibody, this line was cloned and clone C was chosen to be used 
as a tool for further characterisation of PF11_0443. Incorporation of FLAG onto the C-
terminus of this protein did not result in any observable invasion phenotype, with 
invasion rates comparable to the WT 3D7 line (data not shown).  
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Figure 5.8: Introduction of 3’ epitope tags to the gene PF11_0443. A 540 bp region of 
homology of PF11_0443 was amplified using primers R/S and R/T (chapter 2, table 2.1) 
and introduced into the pHH3 transfection vector along with TY-1 and 3xFLAG epitope 
tag via EcoRI and SacII restriction sites (A)The pHH3 vector contains the Blasticidin 
resistance cassette and a copy of the P. falciparum hrp2 gene 3’ untranslated region 
(UTR). Restriction digest of the complete construct (5985bp) using EcoRI and SacII shows 
the 540bp insert and 5445bp vector backbone (B). The plasmid was transfected into P. 
falciparum 3D7 and drug cycled to promote loss of episomal copies of the construct. A 
diagnostic PCR was designed to test for integration events using a forward primer from 
the PF11_0443 5’UTR region (a: primer N, table 2.1) and reverse primers from either the 
PF11_0443 3’UTR region (b: primer Q, table 2.1) to identify the wild type (WT) locus or the 
HRP2 3’UTR  region from the pHH3_PF11_0443_Ty1 or 3xFLAG constructs (c: primer NN, 
table 2.1) to detect integrated plasmid. PCR revealed the presence of integrated Ty-1, 
3xFLAG and 3’ replacement constructs into the PF11_0443 locus (C). Protein samples 
from tagged lines as well as WT parasites were resolved by SDS-PAGE and subject to 
western blot analysis. Blots were probed with PF11_0443M rat polyclonal antibodies and 
either Ty1 (D) or FLAG antibodies (E). Both Ty-1 and FLAG antibodies recognise a band of  
the predicted 39 and 41 kDa respectively in the tagged line but not WT line. 
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Figure 5.9:  IFAs using anti-Ty1 and FLAG antibodies. Thin smears of synchronised parasite 
culture containing either early or late schizonts were fixed in paraformaldehyde and 
permeabilised with Triton X-100 (as described in 2. 2.13.) and used in IFAs to detect the 
presence of Ty-1 or FLAG tagged PF11_0443 in the parasite using specific antibodies. 
Tags were detected by a fluorescent secondary antibody (Ty-1: AlexaFluor 488 shown in 
green; FLAG: AlexaFluor 594 shown in red) and the nucleus is stained with DAPI (blue). 
Scale bar on the brightfield image represents 5μm. 
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Figure 5.10: Cloning and Southern blot of 3xFLAG-tagged PF11_0443.  
 
A) The integrated PF11_0443-3xFLAG line was cloned by limiting dilution (for methods 
see section 2.3.5.6). DNA was prepared from two of the clones and screened by PCR for 
presence of integrated 3xFLAG (using primers N [a]+NN [c], table 2.1) and for the 
absence of WT PF11_0443 (using primers N [a]+Q [b]).  
 
B) +C) A Southern blot was designed to test for integration of the 
pHH3_PF11_0443_3xFLAG construct in to the PF11_0443 locus (B). Genomic DNA taken 
each drug cycle was digested by PacI and BglII before separating resulting fragments by 
gel electrophoresis and blotting onto nitrocellulose membrane. The membrane was 
hybridised with a radiolabelled DNA probe identical to the region of homology used in 
the construct. The resulting banding pattern from exposure to film revealed the 
presence of wild type DNA with a band of 2560 bp (WT) in cycle 0 as well as the presence 
of both integrated (2789 bp) and episomal construct (E) (5985 bp) in cycle 3. In the 3 
cloned lines tested (clones a, c and e), this episomal band is lost and only the integration 
band at 2789 remains. There is a fourth band (X) present which does not correspond to 
WT, episome or integration into the PF11_0443locus in both C3 and clone E which may 
correspond to integration of the construct into another region of the genome.  
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Figure 5.11: FLAG tag PF11_0443 colocalises with RhopH2 in early, late schizonts and 
merozoites. Thin smears of synchronised parasite culture containing schizonts and 
merozoites were fixed in paraformaldehyde and permeabilised with Triton X-100 
(methods described in section 2. 2.13.) and used in IFAs to detect PF11_0443-FLAG in 
the parasite using the anti-FLAG M2 monoclonal antibody, labelled by a fluorescent 
secondary antibody AlexaFluor 594 (shown in red). Compartments were identified using 
previously characterised antibodies to proteins of known location followed by 
secondary antibodies labelled with AlexaFluor 488 (green) and images were merged to 
determine comparative location (AMA-1: microneme; RhopH2: Rhoptry bulb; MSP-1: 
surface).  The PF11_0443CT antibody was used in combination with anti FLAG  
antibodies to show colocalisation. Antibodies and dilutions are described in chapter 2, 
table 2.4. The nucleus is stained with DAPI (blue). Scale bar on the brightfield image 
represents 5μm. 
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5.9 Immunoprecipitation with anti-FLAG antibodies uncovers potential 
binding partners of PF11_0443. 
 
Immunoprecipitation experiments using rabbit polyclonal antibodies identified a 
number of potential binding partners of PF11_0443. With an integrated 3xFLAG tag line 
now established, FLAG antibodies could be used to pull down PF11_0443-FLAG and any 
binding partners and therefore confirm the previously found partners. Protein samples 
were prepared from 3 ml of pelleted schizonts and passed over a column of FLAG M2 
monoclonal antibody coupled to agarose beads (Sigma-Aldrich) (method described in 
2.2.26). Unbound proteins were washed off with TBS before eluting bound proteins in a 
solution of 3xFLAG peptide at a final concentration of 150 nM in TBS (TBS or PBS?). The 
same experiment was performed using 3ml of WT 3D7 purified schizont pellet to control 
for unspecific binding to and elution from the FLAG affinity column. The elutions were 
concentrated to 30 μl and loaded onto a gel, separating eluted proteins by SDS-PAGE. 
The gel was stained with the fluorescent protein stain, Sypro Ruby (Invitrogen) (figure 
5.12 A). This fluorescent stain was used in place of silver stain and is at least as sensitive 
but is also easier to remove from the protein during band preparation for mass 
spectrometry. Due to its increased sensitivity a large number of proteins were visible, 
however unique bands were identified and excised along with their equivalent control 
IP spot and analysed by Lc MS/MS in house by Dr. Steve Howell (Division of Molecular 
Structure). Results from mass spectrometry analysis are detailed in Appendix B. The table 
lists detected proteins’ accession number, gene description, number of peptide 
matches, percentage peptide coverage and the band in which they were discovered. 
The table is ordered by descending MOWSE score. Proteins with lower scores but 
discovered in the PF11_0443_FLAG IP and absent from the control  were also included 
as the lower score may be swayed by abundance, with proteins that are expressed at 
relatively low levels resulting in lower score and less percentage coverage. PF11_0443 is 
highlighted in blue, the next highest scoring protein in pink, other DnaJ domain-
containing proteins are shown in purple and rhoptry proteins in yellow. 
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Looking at the results table, the strongest band with a high score of 2116.20 and 
coverage of 44.24%, labelled as number 9 (figure 5.12 A), was the protein of interest – 
PF11_0443-FLAG, confirming successful expression of the C-terminal epitope tag. The 
next highest scoring band comes from Hsp60 (PF10_0153) present in band 5. With a 
score of 1188.61 and coverage of 48.97%, this protein is far higher scoring than any of 
the other eluted proteins and no peptides were detected from it in the control lane. The 
same protein was present in the previous IP using antigen specific polyclonal antibodies, 
albeit at a lower level and with a score of 167 and 16% peptide coverage. Interestingly 
this protein was shown by IEM to reside within the mitochondrion in Plasmodium blood 
stages (Das et al., 1997), and is located exclusively within this organelle (Sato et al., 2003). 
The possibility of PF11_0443 residing within the mitochondria has not been investigated 
by IFA however the mitochondrion does not colocalise with apical organelles and 
PF11_0443 lacks any mitochondrial targeting sequence, as predicted by the PlasMit 
algorithm (Bender, 2002). For these reasons it is unlikely that the Hsp60 PF10_0153 is a 
binding partner of PF11_0443. Equally unlikely to bind PF11_0443 is the third highest 
scoring protein on the list, regulator of chromosome condensation MAL7P1.38. This 
protein is found in the nucleus [reviewed in (Frankel and Knoll, 2009)] and from IFAs 
using both specific polyclonal and FLAG monoclonal antibodies it is clear that 
PF11_0443 is not. Three conserved proteins of unknown function were identified as 
potential binding partners however since their function is unknown it does not aid the 
discovery of function of PF11_0443. Instead they should be kept in mind for future 
analysis. A Plasmodium –specific guanine nucleotide exchange factor (GEF) was co-
precipitated and although these protein display a range of functions, including 
involvement in vesicular transport, the specific role of this protein is not known. 
Erythrocyte membrane protein (PfEMP)-3 is exported out into rbc cytsol in ring and 
trophozoite stages where it resides in Maurer’s clefts (Pasloske et al., 1993; Knuepfer et 
al., 2005). This expression does not coincide with PF11_0443 and therefore these 
proteins are unlikely to function together. Rhoptry neck protein 4 (RON4) was also co-
precipitated with PF11_0443-FLAG. Unlike the other co-precipitants, this protein is 
expressed in schizonts and merozoites and transferred into rings at the tight junction. 
It’s also present at the apex, and although the best observed colocalisation of 
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PF11_0443 was with micronemal protein, the rhoptry neck is in close enough proximity 
for overlap to be observed with this sub-cellular compartment also. Another rhoptry 
protein observed is RhopH3, a protein of the rhoptry bulb. This protein was also co-
precipitated with PF11_0443CT antibodies. There was a notable absence of any 
micronemal proteins, such as those observed in the previous pull down, AMA-1 and 
EBA-181. If PF11_0443 was to reside in the micronemes one might expect it to bind 
proteins present in these organelles.  
 
In order to improve upon this IP it is important to reduce the background non-specific 
binding to the FLAG resin. In the previous experiment 500μl of FLAG-agarose was used 
in each precipitation. A western blot of the parasite lysates used before and after 
binding to the FLAG affinity column showed the complete removal of PF11_0443-FLAG 
from the column flow through (data not shown) so in an attempt to reduce background 
binding, less FLAG agarose could be used. This experiment was then repeated but using 
100μl of FLAG agarose and washing with 300mM NaCl in place of TBS in the hope that 
this will decrease background binding. In the previous IP, the column was washed with 
TBS which contains a physiological concentration of NaCl since it was presumed that 
FLAG antibody binding and eluting with 3xFLAG peptide would only select specific 
interactors. Also washing with increased salt can disrupt protein complexes meaning 
results only represent salt-resistant complexes and not necessarily those that exist 
within the parasite. Due to the reduced volume of beads, binding and washing was 
performed in batch. The eluted protein was resolved by SDS-PAGE under reducing 
conditions however the protein gel was only allowed to run for 1.5 cm before staining 
with Instant Blue®  and each lane was dissected into 6 equal bands 2.5 x 2.5 mm in 
preparation for analysis by LcMS/MS (as before, performed in house by Dr. Steve 
Howell). This difference in band preparation allows the analysis of the full protein 
complement instead of the subjective process of selecting and excising particular bands 
which can result in over-looked binding partners. Results of the mass spectrometry 
analysis are summarised in table 5.3, below and in detail in Appendix C. As before, the 
table lists detected proteins’ accession number, gene description, number of peptide 
matches, percentage peptide coverage and the band in which they were discovered. 
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The table is ordered by descending MOWSE score. Proteins with lower scores but 
discovered in the PF11_0443_FLAG IP and absent from the control  were also included 
as were proteins with high scores in the FLAG specific pull down but  also present in the 
WT control IP, albeit at a reduced level. PF11_0443 is highlighted in blue, the next 
highest scoring protein in pink, other DnaJ domain-containing proteins are shown in 
purple and rhoptry proteins are in yellow. PF11_0443 was detected with a MOWSE score 
of 440.92, 5 fold less than with the previous IP. Only 2 other proteins obtained a higher 
score, however these were none specific binders, determined by presence in the WT 
control IP at an equivalent level to the FLAG IP.  PF11_0443 co-precipitated a peptidyl-
propyl cis-trans isomerase (PPIase) or cycophilin named CYP24 or CYP25 based on its 
predicted molecular weight of 24.9 kDa.  This protein was present in band 9 (figure 5.12 
B), and with a score of 421.56 and coverage of 33%, it is a strong binding partner 
candidate. These proteins display PPIase activity that is crucial in folding of proteins that 
require switching of peptidyl-propyl bonds from a trans to cis conformation during 
assembly and transport (Fischer and Aumuller, 2003). Cyclophilins are also known as  
immunophilins as they are targets of the immunosuppressive drug, cyclosporin A (CsA), 
the binding of which leads to the inhibition of protein phosphatase calcineurin in T-
lymphocytes, a component of the calcium signalling pathway (Matsuda and Koyasu, 
2000). CsA is also a potent anti-malarial (Bell et al., 1994). Reddy (1995) showed CYP25 is 
capable of PPIase activity and is sensitive to CsA (Reddy, 1995) however this finding 
could not be replicated in a more recent study where CYP25 was instead shown to 
exhibit chaperone activity, in particular the prevention of protein aggregation (Marin-
Menendez et al., 2012). CYP25 is expressed throughout the lifecycle but it is possible that 
it could be recruited by PF11_0443 in late stages for a specific chaperoning role. 
Interestingly the initial IP using PF11_0443CT polyclonal antibodies pulled down the 
FKBP PPIase which is also an immunophilin, so what was originally attributed to the 
potential presence of anti-rotamase antibodies due to an unclean protein preparation 
may be a specific interaction with PF11_0443. Another cycophilin, CYP19A, is present in 
the ookinete microneme protein (Lal et al., 2009), providing further evidence for a role 
for these proteins in the apical organelles. 
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Both 40S and 60S ribosomal subunits featured heavily in this experiment. The 
nucleoproteins are common contaminants of pull down experiments however from 
experience with other immunoprecipitation experiments, including the two PF11_0443 
related IPs preceeding this one, these proteins are always also seen in the control. 
Although PF11_0443 is predominantly observed in the ER in early schizonts, it is 
certainly apical in late schizonts – ribosomes are not. It therefore seems unlikely that this 
interaction is specific, particularly since the majority of ribosomal proteins were also 
observed in the control IP with WT parasites.  
 
One of the highest scoring co-precipitating proteins in this experiment was actin 
depolymerising factor (ADF)-1. This protein has been shown to exclusively bind 
monomeric actin and its function is essential to Plasmodium blood stages (Schuler et al., 
2005).  ADF1 is cytosolic and recruited to the plasma membrane via its capacity to bind 
phosphatidyl inositol derivatives so it is hard to see what purpose the binding of 
PF11_0443 would serve. 
 
In this second attempt, the rhoptry neck protein RON2 was co-precipitated but not its 
binding partner RON4, the reverse of what was observed in FLAG IP attempt 1. 
Moreover, rhoptry neck proteins, RON3 and RON5 were also co-precipitated. Although 
RON3 was present in the wild type control, the peptide coverage was less than half that 
observed in the FLAG specific IP and the score for per band was considerably less in the 
control IP. RON5 was only present in the FLAG specific IP however the score per band 
peaked at 79. This would normally be considered low however, since the score for the 
PF11_0443 were also lower, at 440.92, therefore it would be expected that all interactors 
will achieve even lower scores in comparison. Rhoptry bulb protein CLAG9 was also co-
precipitated at similar levels to RON5. 
 
PF11_0443-FLAG co-precipitated 2 other DnaJ domain containing proteins in this 
experiment. There is a precedent for J protein interactions in yeast where the 
mitochondrial pre-sequence-associated motor complex component J protein PAM18 
has been shown to bind to J-like proteins (that lack an HPD) via their respective J 
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domains. PAM16 functions here in tethering PAM18 to the translocon and regulates the 
ability of PAM18 to stimulate ATP hydrolysis of the Hsp70 Ssc1(Frazier et al., 2004; Li et 
al., 2004b; D'Silva et al., 2005). The first of the co-precipitated J proteins is an 
uncharacterised type III J protein, PF08_0032, from which no functional clues can be 
derived. Like PF11_0443, it is also membrane bound however it appears to be expressed 
at a different stage of the intraerythrocytic cycle, with peak expression occurring in late 
rings and trophzoites and rapidly declining in schizonts (Bozdech et al., 2003), therefore 
it is improbable that they interact. The second is a soluble type II J protein, Pfj4, which 
has been shown to reside within the nucleus and cytoplasm and binds PfHsp70-1 (Pesce 
et al., 2008), and therefore unlikely to bind PF11_0443 due to spatial incompatibility.  
 
Importantly this second attempt at the FLAG IP showed the presence of Hsp60 
PF10_0153 in both wild type and FLAG specific pull downs, suggesting that it might be 
unspecific interactions that retained the protein on the matrix.  This experiment also 
revealed that aldolase interacts nonspecifically with the column as it is present in both 
wild type and PF11_0443-FLAG IPs despite being present at high levels in the IP using 
PF11_0443CT polyclonal antibody. 
 
Despite providing a more specific method of immunoprecipitation than use of 
polyclonal antibodies coupled to CNBr, there are many problems with the system. 
Surprisingly there was a large amount of unspecific binding to the FLAG agarose. Many 
eluted proteins were present in both WT 3D7 and PF11_0443-FLAG line extracts despite 
eluting with 3xFLAG peptide at physiological pH. Also, on the second FLAG IP attempt, a 
large proportion of PF11_0443-FLAG remained on the column after elution with 3xFLAG, 
as determined by boiling the FLAG-agarose beads in reducing sample buffer after 
3XFLAG peptide elution and resolving the proteins by SDS-PAGE. This is perhaps due to 
a strong affinity of the FLAG M2 antibody to 3xFLAG and the 150nM concentration of 
3xFLAG peptide solution used for elution was not high enough. 
 
Immunoprecipitation studies using both anti PF11_0443 CT and the anti-FLAG M2 
monoclonal antibody affinity gel has revealed a multitude of potential binding partners 
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some of which were also found eluted from the control columns. CYP25 is one of these 
potential interaction partners of PF11_0443. The presence of rhoptry proteins in the 
PF11_0443-FLAG elute suggests this protein may reside within this compartment.  
However unless PF11_0443 can be detected in a reverse IP no definitive conclusions can 
be drawn. If PF11_0443 is working in a chaperone secretory role one would expect it to 
interact with a substantial number of proteins. To try and attempt clarification of 
PF11_0443’s function, analysis of phenotype from transgenic knockout or truncation 
lines is required. 
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Figure 5.12: Immunoprecipitation with anti-FLAG antibodies to uncover potential binding partners 
of PF11_0443. Purified late schizonts from the PF11_0443-FLAG line were lysed in buffer 
containing 1% Triton X-100. The cleared lysate was bound in batch to anti-FLAG M2 affinity gel 
(methods described in chapter 2.2.26). Co-precipitating proteins were eluted using 150 nM 
3xFLAG peptide in TBS and resolved under reducing conditions by SDS-PAGE. During the first 
attempt (A), proteins were allowed to run the full length of the gel and were visualised by Instant 
Blue. Unique bands compared to the control were excised (labelled 1-16) and the protein 
complement of each was identified by LC-MSMS. This experiment was repeated (B), however the 
gel was run 1.5 cm and both the control and PF11_0443-FLAG lanes were divided in to 6 
approximately equal sized bands (WT control: 1-6; PF11_0443-FLAG: 7-12)before analysis by 
LcMS/MS. 
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5.10 Unsuccessful attempts to knock out PF11_0443 suggest an essential 
role for this gene within blood stages. 
 
Although there is a lack of functional data regarding the many othologues of 
PF11_0443, there is evidence from Drosophila melanogaster (flybase.org) and C. elegans 
(wormbase.org/species/c_elegans) that the corresponding genes in these species can 
produce viable knock-outs in a laboratory environment. To ascertain whether this is also 
the case for the P. falciparum version of the gene, the production of a PF11_0443 knock-
out line was attempted. A double homologous recombination strategy was employed 
utilising the pHTK vector (figure 5.13 A), which contains 2 multiple cloning sites that 
flank the human dihydrofolate reductase cassette, conferring resistance to WR99210 
upon integration. The construct also contains the thymidine kinase cassette which 
confers susceptibility to ganciclovir.  A region of 480 bp from the 5’ UTR and ORF of 
PF11_0443 was amplified by PCR using primers N and O (sequences listed in chapter 2, 
table 2.1) and introduced to the construct via the first flank multiple cloning site (F1) 
using the restriction sites of SacII and BglII. A second region of homology from the 3’ end 
and UTR of PF11_0443 was amplified by PCR using primers P and Q (chapter 2, table 2.1) 
and introduced into the second multiple cloning site (F2) utilising EcoRI and AvrII sites to 
produce the integration transfection vector pHTK_PF11_0443_KO.  
 
Inserts were initially sub-cloned into the pGEM T-easy vector and transformed into E. coli 
TOP10 cells. Colonies were selected and sequenced before excising the correct 
sequence inserts using SacII and BglII (F1) or EcoRI and AvrII (F2). Inserts were gel-purified 
and ligated into the pHH3 vector and transformed into E. coli TOP10. Colony plasmid 
DNA was screened by restriction digest using SacII and BglII (F1) or EcoRI and AvrII (F2) 
(figure 5.13 B) and re-sequenced before selecting one correctly sequenced vector to 
propagate and purify for transfection. 
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Figure 5.13: PF11_0443 KO strategy and vector construction. A double homologous 
recombination strategy was employed for the KO of PF11_0443 which would result in the 
complete removal of the gene. The transfection vector pHTK was manipulated to include 480 bp 
from the 5’ UTR and ORF of PF11_0443, amplified by PCR using primers N and O (sequence listed 
in chapter 2, table 2.1) and introduced to the construct’s flank 1 (F1) multiple cloning site using 
the enzymes SacII and BglII. A 540 bp fragment was amplified using primers P and Q (table 2.1) 
and introduced into flank 2 using EcoRI and AvrII. Digestion with these enzymes from the 
completed plasmid excised resulted in the correct size bands from flanks 1 and 2 (B).  
 
 
As with the epitope tag constructs, the complete and purified pHTK_PF11_0443_KO was 
transfected into ring-stage parasites. Selection for presence of episome was achieved by 
the addition of 5 nM of WR to transfection cultures until parasitaemia recovered to 
around 10%. Stock samples of these cultures were taken and stored in liquid nitrogen 
and genomic DNA was prepared in order to test for presence of integrants. Transfection 
cultures were taken off drug for 3 weeks before its re-application,  which was repeated 
initially 3 cycles or in the absence of integration, 5 cycles. A Southern blot was designed 
to analyse potential integration events (figure 5.14 A). Genomic DNA taken each drug 
cycle was digested by PacII and BglII before separating resulting fragments by gel 
electrophoresis and blotting onto nitrocellulose membrane. The membrane was probed 
with a radiolabelled oligomer of the region of homology.  The first knock-out attempt 
resulted in no integration throughout 5 cycles; this was repeated with an additional 2 
transfections, both of which resulted in 3’ integration. On these occasions (one of which 
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is presented in figure 5.14 B below), the resulting banding pattern of Southern blot on 
exposure to film revealed the presence of wild type DNA with a band of 2560 bp (figure 
5.14) in the control lane containing 3D7 DNA, as well as at drug cycles 1 and 2 before 
disappearing completely. As the WT band disappears, a band of between 6 and 8 kb 
appears (labelled ‘int’), corresponding to the 7218 bp fragment produced upon digest in 
the presence of integration of flank 2 into the 3’ end of the locus. A band corresponding 
to the episome (labelled ‘E’) is present throughout the drug cycling until cycle 5 on 
WR99210 and ganciclovir when only the band corresponding to 3’ integration is 
observed.  
 
Integration of only the second flank may not result in a knock out since a full copy of the 
gene will be present only minus the 3’ UTR. The absence of 3’ UTR could mean 
termination of translation is suspended or RNA stability affected due to lack of poly A 
tail. In order to test whether PF11_0443 is still expressed in the flank 2 integrated line 
and at the same level as the wild type protein, both lines were synchronised to 
approximately 1.5 h and protein samples were prepared from late schizonts. Samples 
were separated by SDS-PAGE under reducing conditions and subject to western blot 
analysis. Bands produced by exposure to film from wild type and flank 2 integrated lines 
were compared using ImageJ software. Blots were also probed with a BiP antibody to 
ensure equal loading and with an MSP2 antibody to ensure the protein samples were of 
late schizonts.  From figure 5.15 A it appears that PF11_0443 is expressed in the flank 2 
integrated line and to a similar level as the wild type. Using ImageJ software (Collins, 
2007) to quantify band intensity, it was clear that a greater number of KO parasites were 
loaded compared to wild type at a ratio of 1.1 as calculated by comparison with BiP 
expression in each line. MSP2 levels were used as a stage-specific control and it appears 
parasites loaded in the KO lane were more mature than the wild type parasites at a ratio 
of 1.3. There was 1.2 times more PF11_0443 in the KO lane compared to the wildtype. 
Therefore the expression of PF11_0443 in the KO construct integrated line was 91.5% 
that of the wildtype. An IFA of flank 2 integrated parasites using the specific rabbit 
polyclonal PF11_0443CT antibody revealed that the protein is expressed in every 
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parasite in that particular field and this was representative of the entire slide (figure 5.15 
B). 
 
Three unsuccessful knock-out attempts of PF11_0443, despite a clearly accessible locus, 
suggest an essential role for this gene within the parasite. Although flank 2 was seen to 
integrate in 2 of these attempts, only a small reduction in PF11_0443 expression ocurred, 
which is well within the error of the quantification method used and not considered as a 
genuine phenotype. However the region of homology of flank 1 of 480 bp is relatively 
short and contains a component of AT rich 5’UTR sequence therefore the possibility that 
the lack of integration is due to this technical hurdle in homologous recombination 
cannot be ruled out.  
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Figure 5.14: Attempted KO of PF11_0443 by double homologous recombination results in 
integration of flank 2 only. A Southern blot was designed to confirm this result (A). 
Genomic DNA taken each drug cycle was digested by PacI and BglII before separating 
resulting fragments by gel electrophoresis and blotting onto nitrocellulose membrane. 
The membrane was probed with a radiolabelled oligomer of the region of homology (B).  
The wild type DNA band of 2560 bp is present in the control lane containing 3D7 DNA, 
as well as in drug cycles 1 and 2 before disappearing completely. As the WT band 
disappears, a band of between 6 and 8 kb appears (labelled ‘int’), corresponding to the 
7218 bp fragment produced upon digest in the presence of integration of flank 2 into 
the 3’ end of the locus. A band corresponding to the episome (labelled ‘E’) is present 
through out the drug cycles until cycle 5 on WR99210 and ganciclovir when only the 
band corresponding to 3’ integration is present. 
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Figure 5.15: PF11_0443 KO construct flank 2 integration had a small effect on PF11_0443 
expression. 
 
A) Protein samples of purified late schizonts from wild type and flank 2 integrant (knock-
out attempt 2, drug cycle 5 on WR99210 and ganciclovir) parasite lines, synchronised to 
approximately 1.5 hrs, were resuspended in reducing SDS sample buffer and separated 
by SDS-PAGE with approximately 2x106 parasites loaded per well. Expression of 
PF11_0443 was analysed by western blot using the specific rabbit polyclonal antibody 
PF11_0443CT. Antibodies recognising the parasite ER resident protein BiP were used to 
analyse equality of loading between lanes and a monoclonal antibody against MSP-2 
was used as stage-specific marker, ensuring the schizonts loaded into control and 
integrant lanes were the same level of maturity. Molecular weight markers for each 
western blot are shown in kDa on the left hand side of the figure. The intensity of each 
band was analysed by ImageJ software (Collins, 2007) and the ratio of KO to wild type 
was calculated. This revealed that expression in the flank 2 integrated line was 91.45% 
that of the WT.  
 
B) Thin smears of flank 2 integrated parasite culture from synchronised late schizonts 
and merozoites were fixed and permeabilised and used in IFAs to detect the presence of 
PF11_0443 in the parasite using specific rabbit polyclonal antibodies PF11_0443CT. 
PF11_0443 localisation is depicted in green (achieved by secondary antibody 
AlexaFluor488) and the nucleus is stained with DAPI, shown in blue. The length of 
representative scale bars are stated on individual images. PF11_0443 can be detected in 
every parasite and the images taken were representative of all observed fields.  
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5.11 Discussion 
 
The data presented here show that PF11_0443 is an integral membrane protein 
expressed from early schizogony from 36 h post invasion and maintained until early ring 
stages.  In early schizonts this protein appears within the ER, as shown by IFA where it 
co-localises with ER resident Hsp70 BiP. The early expression and presence within the ER 
in schizonts suggests a role for PF11_0443 in protein sorting and trafficking, particularly 
given the change in location upon daughter cell segmentation. In these late schizonts 
PF11_0443 moves to the apical end of the merozoite where it appears to co-localise with 
micronemal proteins AMA-1 and EBA-175. As there are multiple micronemes within the 
merozoite and AMA-1 and EBA-175 do not co-localise with each other this pattern could 
indicate PF11_0443 is present in each of them. This is consistent with the fact there are 
multiple foci of fluorescence observed by IFA with PF11_0443CT antibodies.  
 
One potential problem with this finding is that PF11_0443 was not detectable on the 
surface of the free merozoite where micronemal proteins are secreted immediately prior 
to invasion. Also, micronemal protein such as AMA-1 and EBA-175 are shed upon 
invasion (Harris et al., 2005; O'Donnell et al., 2006), however this protein was not 
detectable in culture supernatants by western blot. Although PF11_0443 was not 
detected in rings by western blot, the protein was detected by IFA at this stage 
immediately following erythrocyte invasion. Antibodies were used here in more 
concentrated form for ring stage IFAs than the schizont or merozoite IFAs and camera 
exposure times were doubled when taking the images, implying PF11_0443 is present at 
a lower level. This apparent reduction could explain why this protein was not visible by 
western blot using ring stage lysates (figure 5.3).  
 
The fact that PF11_0443 is carried through into rings suggests PF11_0443 resides within 
a different apical organelle such as the dense granules or rhoptry neck/bulb. Due to their 
close proximity within the merozoite and the fact the limit of the resolution of light 
microscopy, it is often difficult to distinguish between the rhoptry neck and 
micronemes. Although an IFA using a RESA antibody did not show colocalisation with 
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PF11_0443, the antibody was not sensitive and gave rise to an unexpected pattern – 
only one point of fluorescence, despite its presence in multiple dense granules, as seen 
by immuno-electron microscopy (IEM) (Culvenor et al., 1991). IEM would have provided 
stronger evidence to determine the sub-cellular location of PF11_0443 however 
attempts at this method using PF11_0443CT rabbit polyclonal antibodies were 
unsuccessful.  
 
Without IEM, the ambiguous apical location cannot be pin-pointed to a particular 
organelle and the sub-cellular location of PF11_0443 must be verified by another means. 
For this reason the introduction of a C-terminal epitope tag into the genomic locus of 
the protein was undertaken, so that the antibodies against the tag could be used to 
determine protein location. The aspartic acid rich FLAG epitope tag was chosen due to 
its small size and commercially available tools such as monoclonal antibodies and 
affinity resin. Antibodies to this tag have also been used in IEM  in the past (Wada and 
Kanwar, 1998). Both 3xFLAG and Ty1 epitope tags were successfully integrated into the 
PF11_0443 locus by cycle 2, highlighting its accessibility to genetic manipulation. Both 
tags were visible by western blot using tag specific antibodies however due to the 
superior sensitivity of the FLAG antibody, this tagged line was chosen for use in future 
experiments and was subsequently cloned. PF11_0443-FLAG confirmed what was 
already seen by IFA using PF11_0443CT antibodies – that this protein is present in the ER 
in early schizonts but this location changes upon daughter cell segregation, as in late 
schizonts PF11_0443-FLAG is seen in an apical location. Colocalisation with organelle 
markers show PF11_0443 co-localises with RhopH2 in schizonts and merozoites, but not 
with micronemal marker AMA1, as had previously been seen by IFA using wild type 
parasites. Since the IFAs using wild type parasites were inconclusive due to 
colocalisation with markers of multiple organelles, it is possible that the superior 
sensitivity of the anti-FLAG M2 monoclonal antibody has produced the actual 
localisation of both tagged and wild type PF11_443. Although the colocalisation of WT 
PF11_0443 with micronemal proteins was strong, PF11_0443 was not released onto the 
surface or shed into culture supernatants, as seen with other characterised micronemal 
proteins; instead it is transferred into the newly invaded rbc, a fact which supports a 
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rhoptry location. To address the question of subcellular location IEM should be 
undertaken in the future using the anti-FLAG M2 monoclonal antibody on the 
PF11_0443-FLAG parasite. 
 
The multi-foci, punctate staining observed by immunofluorescence using anti-
PF11_0443 or FLAG antibodies is reminiscent of the small vesicle-like structures or ‘J-
dots’ which are exported into the rbc cytoplasm and contain the type II J proteins 
PFA0660w and PFE0055c. These highly motile vesicles are thought to be involved in the 
transport of parasite proteins through the rbc cytoplasm. Similar structures are observed 
using antibodies to the human orthologue of PF11_0443, DNAJC25. Appendix F shows a 
fluorescent image of DNAJC25 from the skin derived cell line A-431 from antibodies 
produced by the Human Protein Atlas [www.proteinatlas.org (Uhlen et al., 2010)]. These 
vesicles appear in both the nucleus (excluding nucleolus) and the cytoplasm. Although 
the function of both human and parasite proteins are unknown, the presence of J 
proteins in small vesicular structures appears to be common throughout eukaryotes and 
supports a common role in vesicular transport. 
 
Although clearly membrane bound, it is not clear which orientation PF11_0443 exists. 
Chaperone activity may be required inside apical vesicles in order to prevent protein 
aggregation or may facilitate formation of protein complexes therefore one might 
expect the J domain to be present inside these vesicles. Equally PF11_0443 may interact 
with molecules involved in vesicular transport and therefore the J domain and C-
terminus would be present on the cytoplasmic side of the membrane. The topology of 
PF11_0443 will be addressed in the future by proteinase K digestion, as previously 
described (Feldheim et al., 1992; Cabrera et al., 2012). 
 
If PF11_0443 is to reside within the rhoptries then a rhoptry targeting motif should be 
present. Although dileucine and tyrosine based motifs have been described in 
Toxoplasma for the rhoptry-targeting of membrane proteins (Hoppe et al., 2000; Ngo et 
al., 2003), evidence for these particular motifs is lacking in Plasmodium. Looking at the 
PF11_0443 protein sequence (Chapter 3, figure 3.4), there is a potential tyrosine based 
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motif at the C-terminus. Additionally, a dileucine motif exists immediately following the 
predicted signal peptididase cleavage site. This dileucine motif has to be cytoplasmic in 
order to facilitate targeting to the rhoptries (Hoppe et al., 2000; Ngo et al., 2003), 
therefore if this is a targeting motif then the N-terminus and J domain would be present 
of the cytoplasmic face of the ER and rhoptries. Experimental manipulation of these 
potential targeting motifs would establish whether they are required for targeting 
PF11_0443 to the rhoptries. 
 
Ghoneim et al (2007) identified the first 24 aa of PfRhopH2 as sufficient to target this 
protein to the rhoptries however the first 20 of these amino acids are predicted to 
contain a signal peptide and will be cleaved upon translocation into the ER. The authors 
suggest a role for chaperones in identifying rhoptry targeting sequences however 
experimental evidence is lacking. Since signal peptides are hydrophobic and chaperones 
such as Hsp40 and Hsp70 recognise unfolded hydrophobic stretches, perhaps 
PF11_0443 has a role here.  
 
Although identifying the protein’s location is important, determining the function of 
PF11_0443, in the absence of any data from orthologous proteins this is difficult. 
Uncovering binding partners in order to establish a function is one approach and initial 
immunoprecipitation experiments using PF11_0443CT rabbit polyclonal antibodies 
coupled to CNBr did reveal a number of candidates.  However verification was lacking. 
Immunoprecipitation studies using the anti-FLAG M2 monoclonal antibody affinity gel 
has revealed, amonst others, the cycophilin CYP25 as a potential interaction partner. 
This protein has been shown to possess chaperone activity in the form of prevention of 
protein aggregation in vitro (Marin-Menendez et al., 2012), which is consistent with data 
from the C. elegans orthologue, dnj-2; the RNAi knockdown of this protein results in a 
protein aggregation mutant (Hamamichi et al., 2008). CYP25 is also present in C. elegans, 
and all other species where PF11_043 orthologues were detected as well as other 
Apicomplexa in which PF11_0443 was not. CYP25 does not contain a signal peptide 
which implies it is cytosolic and therefore could not function to prevent protein 
aggregation inside any of the apical organelles. Since PF11_0443 is membrane bound, it 
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may function to recruit CYP25 to a specific membrane where required. A member of the 
cyclophilin family, CYP19A, is present in the microneme proteome, indicating a role for 
these chaperones in the apical organelles (Lal et al., 2009). The result presented here 
needs to be replicated and confirmed by IP followed by western blot and using anti 
CYP25 as well as anti-FLAG antibodies before coming to definite conclusions.  
 
The P. berghei microneme proteome identified 23 members of the vesicular trafficking 
network and an additional 23 chaperones, one, as discussed above was CYP19A, and a 
further 8 belonged to the J protein family (Lal et al., 2009). Although there is no available 
rhoptry proteome (ookinetes don’t have rhoptries), this data suggests there is a role for 
chaperones in the apical organelles. 
 
PF11_0443-FLAG also co-precipitated a number of rhoptry proteins, in particular rhoptry 
neck proteins; providing further evidence that PF11_0443 may be a resident of the 
rhoptries. To confirm this finding, immunoprecipitation experiments should be 
performed using RON2 or RON4 antibodies to ascertain whether the interaction is 
reciprocal. The FLAG IP did not pull down protein disulphide isomerase (PDI) which is a 
putative ookinete micronemal protein (Lal et al., 2009), and was co-precipitated in the IP 
using PF11_0443CT antibodies. Unfortunately this protein is a common contaminant in 
IP experiments in the lab and therefore reciprocal IP experiments are required to confirm 
this protein as a binding partner for PF11_0443. 
 
The introduction of this C-terminal tag did not appear to confer a phenotype on the 
parasite since there was no difference in parasite invasion rates (data not shown). It is 
therefore presumed that the tag does not prevent protein-protein interactions, 
validating the use of the tagged line in IP experiments. However perhaps the protein is 
not essential and the phenotype was too subtle to be observed. Evidence from 
PF11_0443 orthologues suggest a non-essential role since the corresponding genes  of 
Drosophila melanogaster (flybase.org) and C. elegans (wormbase.org/species/c_elegans) 
produce viable knock-outs in a laboratory environment. To ascertain whether this is true 
for PF11_0443, production of a knock-out line was attempted by double homologous 
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recombination. The first KO attempt resulted in no integration of either flank after 5 drug 
cycles. The transfection was repeated in triplicate and attempts 2 and 3 resulted in 
integration of flank 2 at the 3’ end of the gene. Because integration of only this flank 
would result in the presence of a full copy of the gene but without the full 3’UTR, 
PF11_0443 could still be expressed and this was in fact the case, with only a small 
reduction in expression level compared to wild type, lying within the margin of error of 
the experiment. Although the locus is clearly accessible, there was never any specific 
control for integration of N-terminal region of PF11_0443. Also the region of homology 
of flank 1 is shorter than that of flank 2  (480 bp) and contains a component of AT rich 
5’UTR sequence therefore the possibility that the lack of integration is due to this 
technical difficulty in homologous recombination cannot be ruled out.  
 
A conditional KO would be beneficial here to establish a possible phenotype derived 
from the removal of the protein, however the capacity to generate a conditional KO is 
not fully established in P. falciparum and RNAi knock down, so commonly used in other 
organisms, is not available for the study of Plasmodium as it lacks the protein machinery 
necessary for RNAi based gene regulation (Baum et al., 2009b). 
 
The fact that Plasmodium has retained this gene at all suggests it has a function 
important to the parasite, but it is not necessary in other Apicomplexa. So what could be 
the function? Host cell choice seems to be the most obvious answer. The only reason a 
parasite as well adapted to its environment as Plasmodium would hold on to this protein 
is if it had a specific need for it that it couldn’t get from its host. Although this protein is 
not likely to be expressed in rbcs it is also unlikely that the other apicomplexa recruit and 
internalise a specific host chaperone. Also, there are two other erythrocyte-dwelling 
apicomplexa – Theileria and Babesia and they also do not appear to harbour a copy of 
this gene. There are in fact several major differences between Plasmodium and its fellow 
Haemosporidia, in both the mode of invasion and nature of habitation within 
erythrocytes. Theileria merozoites are not polarised and lack micronemes; preferring 
instead to invade at any orientation following irreversible attachment of their surface 
proteins (Shaw, 2003). Babesia, possess merozoites that are more similar to that of 
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Plasmodium and invasion mechanisms appear conserved due to the presence of 
rhoptries and micronemes (Potgieter and Els, 1977). Interestingly, both Babesia and 
Theileria form a PV that rapidly disintegrates upon the completion of rbc invasion, unlike 
the PV of Toxoplasma and Plasmodium which require an intact PV throughout the 
asexual cycle (Sam-Yellowe, 1996). If one speculates that PF11_0443 were to have a 
unique and necessary function, it could be linked in some way to the parasitophorous 
vacuole. Since PF11_0443 levels diminish in ring stages, perhaps their role is linked to 
the rhoptries since proteins from both the bulb and the neck are to be found there post 
invasion. Although theoretical, this hypothesis, along with the experimental evidence 
presented here, suggests that PF11_0443 is to be found in the rhoptries of late schizonts 
and merozoites.  
 
This study has identified a schizont-stage with possible chaperone function, present in 
the ER in early schizonts until segregation of daughter merozoites brings about a 
change in localisation resulting in translocation of the protein to the apex, where it 
appears to be present in the rhoptries. The signal dictating this change in location 
remains to be determined. A recent phosphoproteomic study detected the 
phosphorylation of serine 316, 5 residues from the C-terminus of PF11_0443 (Treeck et 
al., 2011) and it is possible that this signal is responsible for the change in location. Initial 
work has begun to substitute this serine with alanine and this integration has been 
successful, implying phosphorylation of this residue is not essential for parasite growth, 
but further study of this phosphorylation is required.  
 
The initial aim of this study was to identify and characterise a protein involved in the 
invasion of erythrocytes by Plasmodium falciparum merozoites. PF11_0443 is a 
(putatively) essential protein present at the apex of merozoites and although the precise 
location has not been elucidated, the protein has met the project criteria. Further work is 
required to identify definitive binding partners and uncover the function of this protein 
within the parasite. 
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Chapter 6. Localisation and functional characterisation 
of PF02_0040 
6.1 Introduction 
6.1.1 ER targeting and translocation 
Proteins destined for an extracellular existence or residence in a membrane-enclosed 
compartment must enter the ordered labyrinth of the endoplasmic reticulum. In order 
to enter the ER, newly synthesised proteins require a signal sequence at the N-terminus. 
This sequence is recognised by components of the protein translocation machinery 
which grant the signal containing protein access to the ER lumen (if soluble) or permit 
insertion into the ER membrane. There are two mechanisms of entry into the ER: co-and 
post-translation translocation.  Each translocation pathway is illustrated in figure 6.1. The 
co-translational translocation of proteins into the ER (figure 6.1 a) involves recognition 
and interaction of the signal sequence and signal recognition particle (SRP) at the exit 
site of a ribosome during translation, causing a temporary arrest in elongation (Meyer 
and Dobberstein, 1980a, b; Walter and Blobel, 1981b). The complex of SRP, polypeptide 
and ribosome docks with the membrane associated SRP-receptor (SRPR) in the ER 
membrane (Walter and Blobel, 1981a), and can now be translocated into the ER 
lumen/membrane through the Sec61 complex comprised of α, β and γ subunits that 
form a pore (Stirling et al., 1992; Wirth et al., 2003).  Completion of translocation involves 
the recruitment of the ER luminal Hsp70 immunoglobulin heavy-chain-binding protein 
(commonly known as BiP) by its Hsp40 partner, membrane bound Sec63 (Feldheim et al., 
1992; Corsi and Schekman, 1997). BiP gates the Sec61 channel (Alder et al., 2005) and 
serves as a molecular ratchet (Tyedmers et al., 2003). The signal peptide is removed by 
signal peptidase unless the peptide is a transmembrane region (signal anchor), in which 
case no cleavage will take place. Translocation is also possible without the SRP and SRPR. 
The post-translational translocation pathway (figure 6.1 b) is SRP-independent and 
instead recognition of signal sequence is thought to be performed by a heterotrimeric 
complex of membrane bound Sec62, Sec63 and Sec71, and soluble Sec72 before 
 202
translocation through the Sec61 complex (Deshaies et al., 1991; Feldheim et al., 1993; 
Fang and Green, 1994; Wittke et al., 2000; Harada et al., 2011). Signal sequences 
recognised by the Sec71/Sec72 complex of the post-translational translocon are often 
less hydrophobic than those bound by SRP (Ng et al., 1996).  
 
Note: Sec71 was characterised independently by two different laboratories investigating 
two different mutations in Saccharomyces cerevisiae – SEC66 (Feldheim et al., 1993) and 
SEC71 (Fang and Green, 1994). Although Sec66 was published first, the authors suggest 
the protein should be termed Sec71 in the event that the genes were shown to be 
identical which was achieved by Fang & Green (1994). For this reason the protein shall 
hence-forth be termed Sec71.  The protein domain name according to the Pfam 
database (pfam.sanger.ac.uk) remains Sec66. 
 
6.1.2 Translocation across the kingdoms 
Much of our knowledge of eukaryotic cell biology comes from work performed in yeast, 
and the secretory pathway is no different. However with the increasing prevalence of 
whole genome sequencing, more information is becoming available from other 
organisms. Saccharomyces possess the machinery for and utilises both the SRP-
dependant and independent pathways at an apparent equal frequency, but this is not 
the situation in other organisms. Homo sapiens appear not to utilise the SRP-
independent pathway as they do not possess Sec71 or Sec72 orthologues (Zimmermann 
and Blatch, 2009). Interestingly, much of our recent knowledge of the ER protein 
translocon comes from work done by Goldschmidt et al (2008) from their work on the 
protozoan parasite Trypanosoma brucei, the cause of African sleeping sickness. Although 
this organism does not possess Sec72, it does contain an orthologue of Sec71 and this 
was shown to be essential by RNA interference. Furthermore, SEC71 silenced parasites 
showed a significant reduction of GPI-anchored proteins that was not observed in SRP68 
silenced cells. Like Plasmodium, the T. brucei cell surface is predominated by a GPI-
anchored protein – variant surface glycoprotein (VSG) – and the parasite could not 
tolerate a reduction in its production (Goldshmidt et al., 2008). 
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Very little is known regarding the secretory pathway of P. falciparum. The only member 
of the translocation machinery characterised is PfSec61 (Couffin et al., 1998). A study by 
Tuteja in 2007 bioinformatically identified the components of the translocon complex in 
P. falciparum and although they uncovered orthologues of the co-translational 
translocation pathway, putative Sec71 or Sec72 proteins were absent suggesting 
Plasmodium does not utilise the post-translational translocation pathway (Tuteja, 2007). 
Due to the A/T rich nature of the P. falciparum genome, there is often little sequence 
identity between proteins, despite sharing a homologous function.  
 
The protein selection criteria in this study uncovered a potential orthologue of Sec71 in 
P. falciparum. 
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Figure 6.1: Co- and post-translational translocation into the endoplasmic reticulum. a) The signal 
sequence of a protein is recognised by the signal recognition particle (SRP) during translation at 
the exit site of a ribosome. The complex docks with SRP-receptor (SRPR) and is translocated into 
the ER lumen/membrane through the Sec61 complex. BiP is recruited to the complex by Sec63 
and gates the Sec61 channel (Alder et al, 2005) and serves as a molecular ratchet (Tyedmers, et 
al, 2003). The signal peptide is removed by signal peptidase unless the peptide is a 
transmembrane region (signal anchor), in which case no cleavage will take place. b) Recognition 
of signal sequence in the post-translational translocation pathway is performed by a complex of 
Sec71 and Sec72 [adapted from (Zimmermann and Blatch, 2009)].  
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6.2 Cellular fractionation reveals PF02_0040 is an integral membrane 
protein 
 
PF02_0040 contains a predicted signal anchor region at the N-terminus however the 
protein lacks any charge in front of the hydrophobic membrane-spanning region 
therefore it is not obvious how this protein is retained within the membrane. To test 
whether PF02_0040 is a soluble protein or whether it is a peripheral or integral 
membrane protein, P. falciparum 3D7 schizonts were treated with a high pH carbonate 
buffer to separate any soluble and peripheral membrane proteins from those with 
membrane anchors. Western blot analysis of the protein extracts revealed PF02_0040 
resides within the carbonate pellet fraction and therefore must be an integral 
membrane protein, despite the lack of charge preceding the signal anchor region at the 
N-terminus. SERA-5 is a soluble protein, peripherally associated with the merozoite cell 
surface and antibodies to this protein were used to control for loading of carbonate 
supernatant samples. Antibodies recognising membrane anchored MSP-2 control for 
the carbonate pellet. 
 
 
Figure 6.2: Western blot analysis of carbonate lysed 
schizonts. P. falciparum 3D7 schizonts were treated with a 
high pH carbonate buffer to separate soluble and 
peripheral membrane proteins from the integral 
membrane protein fraction. Samples from carbonate 
supernatant and carbonate pellet were separate by SDS-
PAGE and subject to western blot. SERA-5 (peripheral 
membrane) and MSP-2 (membrane-anchored) 
antibodies were used as loading controls. The blot was 
probed with PF02_0040 antibodies to reveal this protein 
as an integral to the membrane (highlighted with *). The 
antibodies cross-react with a protein between 20 and 25 
kDa.  
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6.3 PF02_0040 is present throughout the P. falciparum erythrocytic cycle 
 
In the previous chapter it was shown that peak transcript levels of PF11_0443 occurred 
around the same time that protein expression was initiated however this may not be the 
case for PF02_0040. Peak transcript levels for this gene are detected at 42h p.i. however 
the protein has been detected in trophozoites stages (Silvestrini et al., 2010), which are 
typically observed between 24 and 32h p.i. In order to better understand the protein 
expression profile of PF02_0040 in the P. falciparum blood stage cycle, PF02_0040 
polyclonal antibodies were used to probe a western blot of parasite material separated 
by SDS-PAGE from a highly synchronous culture, sampled every 4 hour from invasion to 
egress (figure 6.3) (for method please refer to section 2.3.4). Rbcs were also included in 
the western blot to ensure antibodies were parasite specific and an anti-glycophorin A/B 
antibody was used to ensure equal loading of cells in each well. The blot was also 
probed with an antibody against the ER constituent parasite protein BiP to confirm the 
presence of parasite material in each of the lanes containing time-course samples 
(Kumar et al., 1988; Kumar et al., 1991). MSP-2, which is expressed in schizonts (Wickham 
et al., 2003), was used as late stage control. Probing the time-course with the PF02_0040 
antibody revealed the protein to be present throughout the lifecycle in a similar pattern 
to that seen with the ER protein BiP and not just in late stages, as the publish transcript 
data would suggest, but throughout the erythrocytic cycle. This is in agreement with the 
prediction of the presence of a Sec66 domain within the protein and the possibility that 
PF02_0040 is a functional homologue of the yeast prototype from this family. 
 
PF02_0040 antibodies were also used in indirect immunofluorescence assays of each 
time point and a selection of images covering the complete intra-erythrocytic cycle is 
displayed in figure 6.3 B. Indirect immunofluorescence reveals a peripheral location in 
early ring stage parasites, 4h pi which looks to be close to the parasite surface. A similar 
pattern is observed in trophozoites (28h pi) although the ring-like staining is more 
diffuse. In late schizonts, staining appears to be more tightly associated with the 
nucleus, a pattern which is often associated with the ER. Co-localisation studies are 
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required to rule out other possible localisations surrounding the nucleus such as the IMC 
or the parasite cell surface. 
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Figure 6.3:  Expression of PF02_0040 throughout the lifecycle.  
 
A) Protein samples taken every 4 hours for one complete synchronised blood-stage 
cycle were hypotonically lysed and separated by SDS-PAGE with 2x106 parasites loaded 
per well. Hypotonically lysed rbcs were included in the western blot to control for 
parasite versus rbc specific band recognition. Expression of PF02_0040 was analysed by 
western blot using the specific polyclonal antibody. A glycophorin A/B antibody was 
used as a loading control. Antibodies against the parasite ER resident protein BiP were 
used to confirm the presence of parasites in each lane and a monoclonal antibody 
against MSP-2 was used as schizont marker. Images of Giemsa-stained parasites from 
each time point are shown to demonstrate parasite morphology at each stage. 
Molecular weight markers for each western blot are shown in kDa on the right hand side 
of the figure. 
 
B) Thin smears of parasite culture from each time point were fixed and permeabilised 
and used in IFAs to detect the presence of PF02_0040 in the parasite using specific 
rabbit polyclonal antibodies. PF02_0040 localisation is depicted in green  and the 
nucleus is stained with DAPI and shown in blue. Scale bar on the bright-field image 
represents 5μm. 
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6.4 PF02_0040 co-localises with ER resident protein BiP  
 
PF02_0040 contains a predicted Sec66 domain which would indicate that the protein is 
present within the ER membrane however experimental conformation is required.  
Localisation was determined by indirect immunofluorescence using polyclonal 
PF02_0040 rabbit antibodies in comparison to proteins of known organellar location. In 
ring stage parasites the protein is present around the periphery and is located between 
the nucleus and  the PVM marker RhopH2 (Hiller et al., 2003) (figure 6.4). PF02_0040 
partially co-localises with both the 19kDa fragment of parasite surface protein MSP-1 
(Holder and Freeman, 1984a) and the ER marker BiP in these newly invaded parasites 
(Kumar et al., 1988; Kumar et al., 1991) (figure 6.4).  It is surprising that the ER should be 
found around the periphery of the cell; this is perhaps due to the spatial limitation 
imposed by the concave morphology of the rbc. As the parasite develops within its host 
MSP-1.19 is translocated from the surface of the plasmalemma to the food vacuole 
(Dluzewski et al., 2008) whereas the ER appears to remain associated with the nucleus. 
From figure 6.4, MSP-1.19 is clearly visible in the food vacuole (around the haemozoin) in 
the earliest stages of schizogony whereas PF02_0040 is associated with the newly 
divided nuclei. The IMC, visualised using the resident protein GAP45, forms around the 
periphery of early schizonts (Yeoman et al., 2011; Ridzuan et al., 2012) however 
PF02_0040 is already associated with individual nuclei and appears to co-localise well 
with BiP suggesting this protein is to be found within the ER. In late schizonts where 
cytokinesis occurs and individual merozoite are approaching full maturity, PF02_0040 is 
seen to reside inside of the plasmalemma, depicted by merozoite surface protein MSP-1 
and also inside of the IMC protein GAP45. It does not appear to co-localise with 
cytoplasmic protein calmodulin but at least partially colocalises with BiP (figure 6.5). This 
pattern can also be observed in individual merozoites.  
 
These colocalisation experiments reveal a single location for PF11_0443 however the 
same antibodies used here recognised additional bands between 20 and 25 kDa by 
western blot, as seen in figure 6.2. It is important that the identity of these bands are 
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uncovered to ensure the sub-cellular location observed by IFA is that of PF02_0040 and 
not the other protein/proteins recognised by the polyclonal antibodies. 
 
Indirect immunofluorescence has identified PF02_0040 as an ER resident protein. The 
nature of this ER retention is not clear since there is no obvious ER retention sequence 
present at the C-terminus. ER association is in-keeping with the possibility that the 
protein is an orthologue of yeast Sec71 however further investigation is required to 
determine the protein’s function within the P. falciparum intra-erythrocytic cycle.  
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Figure 6.4: Indirect immunofluorescence assay of ring and early schizont stage P. 
falciparum parasites.  
 
Thin smears of parasite culture 4h post invasion (ring stage)  and 32h p.i. (early schizont 
stage parasites) were fixed and permeabilised as described in 2.2.13.1 and used in IFAs 
to detect the presence of PF02_0040 in the parasite using specific rabbit polyclonal 
antibodies. Primary antibodies were detected by a fluorescently labelled secondary 
antibody (AlexaFluor 488 – green) and the nucleus is stained with DAPI (in blue). 
Intracellular compartments were identified using previously characterised antibodies to 
proteins of known location followed by secondary antibodies labelled with AlexaFluor 
594 (red) and images were merged to determine comparative locations (MSP-1: cell 
surface; RhopH2: PV; Bip: ER; GAP45: IMC).  Specific antibody targets and dilutions used 
are listed in table 2.4. Areas of co-localisation appear yellow. Antibodies and dilutions 
are listed in chapter 2, table 2.4. Scale bar on the bright-field image represents 5μm. 
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Figure 6.5: Indirect immunofluorescence assay of late schizonts and merozoites. 
 
 Thin smears of late schizonts and merozoites were fixed and permeabilised as described 
in 2. 2.13.1 and used in IFAs to detect the presence of PF02_0040 in the parasite using 
specific rabbit polyclonal antibodies. Primary antibodies were detected by a fluorescent 
secondary antibody (AlexaFluor 488 – green) and the nucleus is stained with DAPI (in 
blue). Compartments were identified using previously characterised antibodies to 
proteins of known location followed by secondary antibodies labelled with AlexaFluor 
594 (red) and images were merged to determine comparative locations (MSP-1: surface; 
GAP45: IMC; Calmodulin: cytoplasm; BiP: ER). Areas of co-localisation appear yellow.  
Antibodies and dilutions are described in chapter 2, table 2.4. Scale bar on the bright-
field image represents 5μm in schizont or 1μm in merozoite images.  
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6.5 Immunoprecipitation experiments using protein-specific polyclonal 
rabbit antibody pull down PF02_0040 and thioredoxin but no obvious 
interaction partners  
 
In the quest to determine the function of PF02_0040, it is necessary to find out what 
other molecules the protein interacts with. If this protein is a true orthologue of Sec71 
then it might be expected to bind components of the ER protein translocon such as 
Sec61/62/63.  Initially, PF02_0040-specific antibody was used to immunoprecipitate 
protein from 35S-labelled schizonts (methods described in chapter 2.2.15). Resolution of 
this radio-labelled protein sample by SDS-PAGE and subsequent exposure to film 
revealed these antibodies pulled down a band of around 33kDa which corresponds to 
the predicted size of PF02_0040 however no other bands were obvious when compared 
to the pre-immune IgG control IP. The ~20kDa bands observed by western were not 
visible but this may be due to the time point at which the parasites were labelled - if no 
new protein was being expressed at around 42h p.i. then the proteins would not be 
labelled. Also, the proteins would require a number of cysteine or methionine residues 
in order to incorporate the 35S labelled amino acids. 
 
In order to confirm the identity of the 33kDa band, the ~20kDa bands and possible 
binding partners, a protein preparation from 3ml pelleted schizonts was passed over a 
column of PF02_0040 specific IgG bound to activated CNBr sepharose (methods 
described in section 2.2.16). Unbound proteins were washed off using a 10 mM Tris 
pH8.0  containing 300mM NaCl before eluting bound proteins in low pH buffer 
containing 100mM glycine. The elution was concentrated to 50 μl using protein spin 
concentrators with 10 kDa MW cutoff , of which 30μl was loaded onto a Bis-Tris gel and 
eluted proteins were separated by SDS-PAGE. Initially the gel was stained with Instant 
Blue™ however this failed to show up any bands so the gel was stained with silver nitrate 
using a mass spectrometry-compatible method (Blum, 1987) (figure 6.6 B). The same 
experiment was performed with early ring stage parasites ~4 h p.i. (figure 6.6 C) Band of 
approximately 1x4mm were excised and analysed by Lc MS/MS analysis (PNAC, 
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University of Cambridge). Results from mass spectrometry analysis are summarised in 
table 6.1, below.  
 
Bands D from the schizont IP and H from ring IP were predominated by the protein of 
interest, PF02_0040, confirming the specificity of the antibodies. As suspected, 
thioredoxin (bands a and f) and thioredoxin-related protein (bands b, c, d, e) featured 
heavily in the eluate, verifying that the ~20kDa contaminating bands are a consequence 
of antibodies raised against the pET32-Xa/LIC recombinant protein tag. Bands b and d 
also contained elongation factor 1 alpha which are involved in conveying tRNAs to 
ribosomes however this protein is a common contaminant in IP experiments in the lab. 
The ribosome 60S subunit was also precipitated but this is also a common contaminant 
in IP experiments with P. falciparum. Although it may make sense for components of the 
co-translational translocation pathway to bind translation machinery, it doesn’t seem 
logical that the post-translational pathway components would do the same since their 
function takes place after the translation has been terminated. Merozoite surface 
proteins MSP-1 and MSP-9 were also co-precipitated however these proteins are 
abundant and therefore also abundantly found in pull down experiments involving P. 
falciparum blood stages.  
 
 Equivalent bands from the pre-immune column were not initially analysed as it was 
thought necessary to first determine whether or not the experiment was successful. 
Although PF02_0040 was detected and contaminant bands seen by western were 
identified, no other relevant proteins, in particular components of the ER protein 
translocon, were identified therefore the relevance of preimmune analysis was not 
justifiable. Unfortunately this experiment failed to identify any binding partners of 
PF02_0040. 
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Band Protein identified from significant peptide hits 
a Thioredoxin 1 (356) 
b EF-1-α (364), thioredoxin related protein (TxrRP) (310), PF02_0040 (278), SERA 
5 (221) 
c TxrRP (302), MSP-9 (220) 
d PF02_0040 (876), MSP-1 (548), EF-1-α (471), TxrRP (376), enolase (350), 
aspartic proteinase (247), PF14_0567 (227), SERA5 (211) 
e TxrRP (346), aldolase (227) 
f Thioredoxin 1 (202) 
g 60S ribosomal protein L12 (329) 
h PF02_0040 (383) 
i No significant hits 
 
Table 6.1: Summary of schizont and ring IP results. Bands related to those highlighted on 
the silver-stained gel picture in figure 6.6 B and C. Significant peptide hits are defined as 
those with a MOWSE score over 200 and with 2 or more peptide hits per protein per 
band. The individual scores are shown in brackets in blue of each protein. 
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Figure 6.6: Immunoprecipitation studies using PF02_0040 antibodies. A) PF02_0040 
antibodies were used to immuno-precipitate interacting proteins from 50 μl of pelleted 
35S labelled schizonts (methods described in chapter 2.2.15). Co-precipitating proteins 
were separated by SDS-PAGE and exposed to film. A band of the predicted size of 
PF02_0040, approximately 33kDa, was observed and highlighted with *.  Purified 
schizonts (B) and synchronised early rings of ~10% parasitaemia (C) were lysed and 
passed over a column of 10mg of pre-immune rabbit IgG follwed by that containing 
affinity purified anti-PF02_0040 rabbit polyclonal antibodies conjugated to activated 
CNBr sepharose (methods described in chapter 2.2.16). Co-precipitating proteins were 
resolved by SDS-PAGE and visualised by silver stain. Unique bands compared to the 
control were excised (labelled a-f) and the protein complement of each was identified by 
Lc-MS/MS.  
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6.6 Epitope tagging of the PF11_0443 locus by targeted homologous 
recombination 
 
As discussed in chapter 5.7, incorporating an epitope tag into the genomic locus of a 
gene is a useful tool for characterisation of the resulting protein. Due to the limitations 
of immunoprecipitation seen with polyclonal antibodies, incorporating an epitope tag 
into the PF02_0040 locus may increase the experimental capacity of the protein. As with 
PF11_0443, the smaller epitope tags 3xFLAG and TY-1 tags were selected to incorporate 
into the PF02_0040 locus.  Again, these tags are to be introduced into the C-terminus 
since the protein contains a signal sequence.  
 
PF02_0040 is comprised of 5 exons and 4 introns concentrated around the 3’ end of the 
gene. Since these introns contain A/T rich, repetitive sequences, including them in the 
region of homology could allow integration into any number of A/T rich, repetitive 
sequences in the genome. For this reason, the decision was taken to omit these 
sequences from the region of homology and amplify a region of 881 bp from cDNA 
which included the entire gene, minus the stop codon and with the addition of a region 
of the 5’ UTR so that the largest consecutive region of homology was 436 bp.  The 
sequence was amplified by PCR using primer combinations W/X and W/Y (sequence 
detailed in chapter 2, table 2.1). Ty1 and FLAG epitope tag sequences (including a stop 
codon at the 3’ end) were included in reverse primers X and Y respectively, thereby 
incorporating the tags at the 3’ end of the PF02_0040 exon sequence. This region of 
homology plus tag sequence was cloned into the multiple cloning site of the pHH3 
vector via the EcoRI/SacII restriction sites generating pHH3_PF02_0040_Ty1 and 
pHH3_PF02_0040_3xFLAG. An AvrII site was included between the gene and tag 
sequences to allow the use of these vectors to epitope tag other genes. The pHH3 
transfection vector which includes the Blasticidin resistance cassette as a selectable 
marker is depicted in appendix D. The same region of homology of PF02_0040 was in 
addition cloned into the pHH3 vector via EcoRI/SacII without the presence of an epitope 
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tag to serve as a 3’ replacement vector which upon successful integration would swap 
the endogenous 3’UTR with hrp2 3’UTR.  
 
Inserts were initially sub-cloned into the pGEM T-easy vector and transformed into E. coli 
TOP10 cells. Colonies were selected and sequenced before excising the inserts of correct 
sequence using EcoRI and SacII. Inserts were gel-purified and ligated into the pHH3 
vector and transformed into E. coli TOP10. Colonies were re-sequenced and one correct 
DNA sequence was propagated and plasmid DNA purified for transfection. For analysis 
purposes the construct was subject to digestion with EcoRI and SacII to confirm the 
presence of the correct sized (881 bp) insert prior to transfection (figure 7.6 B) 
 
Unfortunately due to complications in preparation and time constraints, the 
pHH3_PF02_0040_3’ construct were never completed or transfected. Complete and 
purified plasmids pHH3_PF02_0040_3xFLAG, and pHH3_PF02_0040TY were transfected 
into ring-stage parasites and selected for presence of episome by 2.5μg/ml of Blasticidin 
applied to cultures. Stock sample of these cultures were cryo-preserved and genomic 
DNA was prepared. Transfection cultures were taken off drug for 3 weeks before re-
application of drug which is required for enrichment of the parasite population that 
contains integrated versus episomal copies of the transfection vector. This was repeated 
for 5 cycles. A diagnostic PCR was designed to test for integration events using a forward 
primer from the PF02_0040 5’UTR region (primer DD, table 2.1) and reverse primers from 
either the PF02_0040 3’UTR region (primer EE, table 2.1) to identify the wild type locus or 
from the HRP2 3’UTR contained within the pHH3 constructs (primer NN, table 2.1) to 
detect integrated plasmid (figure 6.7 A).  As shown in Figure 6.7 C, this diagnostic PCR 
revealed no integration of Ty1 or 3xFLAG epitope tag after 5 cycles however  western 
blot of Ty1-tagged versus WT PF02_0040 containing parasites revealed Ty1 antibodies 
detected a band of the correct size of 37kDa in Ty1-tagged but not the WT 3D7 line 
(figure 6.7 D). This discrepancy is perhaps due to an incompatibility of the locus and 
episome derived primers DD and NN (table 2.1). Further analysis by Southern blot 
analysis showed no integration into the PF02_0040 locus (figure 6.8). This would imply 
that integration did not occur and PF02_0040 should not contain a Ty1 tag at its C-
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terminus. If this is true, the specific 37kDa band observed by western blot would have 
been brought about by integration into another locus, which expresses a protein of 
similar molecular weight. The chance of this happening seems very small indeed. 
Alternatively, there is a small possibility the protein plus tag is being expressed from the 
episome, however since there is no 3’ UTR contained within the construct this is unlikely, 
but not impossible. It would be impossible if there was no promoter region however in 
order to increase the number of base pairs in the region of homology, 56 bp of the 
promoter region immediately upstream of the ATG start codon was included in the 
region of homology. It is therefore possible (although unlikely) that expression is 
episomal. The fact that PF02_0040_3xFLAG shows no detectable expression by western 
blot (figure 6.7 E) despite detection with a very sensitive antibody (Chapter 5) makes the 
argument of episomal expression even more unlikely.   
 
The FLAG M2 monoclonal antibody did not detect 3xFLAG protein by western blot 
(figure 6.7 E) which is in agreement with the diagnostic PCR (figure 6.7 C) and Southern 
blot (data not shown).  
 
Integration of Ty1 into PF02_0040 would demonstrate that the locus is amenable to 
genetic manipulation however conflicting evidence from DNA and protein analysis 
leaves the question of ability to integrate unanswered.  
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Figure 6.7: Epitope tagging of the PF02_0040 locus. A 881 bp region of homology of 
PF02_0040 was amplified using primers W/X and W/Y respectively (chapter 2, table 2.1) 
introduced into the pHH3 transfection vector along with TY-1 and 3xFLAG epitope tag 
via EcoRI and SacII restriction sites (A). The pHH3 vector contains the Blasticidin 
resistance cassette and a copy of the P. falciparum hrp2 gene 3’ untranslated region 
(UTR). Restriction digest of the complete construct (6287bp) using EcoRI and SacII shows 
the 881bp insert and 5406bp vector backbone (B). The plasmid was transfected into P. 
falciparum 3D7 and drug cycled to promote loss of episomal copies of the construct. A 
diagnostic PCR was designed to test for integration events using a forward primer from 
the PF02_0040 5’UTR region (a: primer DD, table 2.1) and reverse primers from either the 
PF02_0040 3’UTR region (b: primer EE, table 2.1) to identify the wild type (WT) locus or 
from the HRP2 3’UTR from the pHH3_PF02_0040_Ty1 or 3xFLAG constructs (c: primer 
NN, table 2.1) to detect integrated plasmid. PCR revealed the presence of WT DNA only 
and a faint band of correct size (bp) for Ty1 crossover into the PF02_0040 locus (C). 
Protein samples from tagged lines as well as WT parasites were resolved by SDS-PAGE 
and subject to western blot analysis. Blots were probed with PF02_0040 rabbit 
polyclonal antibodies and either Ty1 (D) or FLAG antibodies (E). Ty1 antibodies recognise 
a band of 33 kDa in the tagged line but not WT. FLAG antibodies failed to detect the 
expression of 3xFLAG in the line containing pHH3_PF02_0040_3xFLAG. 
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Figure 6.8: Southern blot of attempted 3’ epitope tagging of PF02_0040 with Ty1. 
A Southern blot was designed to test for integration of the pHH3_PF02_0040_Ty1 
construct in to the PF02_0040 locus (A). Genomic DNA taken each drug cycle was 
digested by AflIII before separating resulting fragments by gel electrophoresis and 
blotting onto nitrocellulose membrane. The membrane was probed with a radiolabelled 
oligomer of either (B) the region of homology (probe 1) or (C) the blasticidin ORF of the 
pHH3_PF02_0040_Ty1 construct (probe 2). The resulting banding pattern from 
exposure to film revealed the presence of wild type with a band of 2678 bp (WT) and a 
band just above the 6 kb markers corresponding to the 6287 bp episome (E). These 
bands persist throughout the 5 drug cycles and suggest no integration into the 
PF02_0040 has taken place.  
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6.7 Unsuccessful attempts to knock out PF02_0040 by truncation suggest an 
essential role for this gene within blood stages 
 
Sec66 is not essential in yeast growing at 22°C but is when growth temperature is 
increased to 37°C (Feldheim et al., 1993; Fang and Green, 1994). Based on this one might 
expect to be able to knock-out PF02_0040. However the transfer from insect to 
mammalian host already imposes such a temperature change. Indeed the protein has 
not been detected in the mosquito stages of the Plasmodium lifecycle (Lasonder et al., 
2008). Alternatively a knock out may be viable ay 37°C but not when growth 
temperature is increased as would be experienced during febrile episodes in malaria 
patients.  
 
To test these hypotheses, a construct was designed to integrate into the 5’ end of the 
PF02_0040 which, if successful, would express a truncated version of the protein with 
149 of the 276 amino acids removed from the C-terminus. A complete or partial 
reduction of expression can be expected due to the lack of a 3’ UTR and terminator 
sequence that would be imposed upon integration of the plasmid (see figure 6.9 for KO 
strategy). Unfortunately, due to the AT rich nature of the 5’ and 3’ UTRs and the presence 
of 4 introns in the 3’ end of the gene, a full knock out of PF02_0040 by double 
homologous recombination was not possible. It was hoped however that successful 
integration would disrupt function and either exhibit a phenotype, or in the case that 
PF02_0040 is an essential gene, result in non-viable parasites and therefore integration 
would not be possible. 
 
The integration transfection vector pHH3_PF02_0040_KO was manipulated to include 
486 bp from the 5’ UTR and ORF of PF02_0040, amplified by PCR using primers U and V 
(sequences listed in chapter 2, table 2.1) and introduced to the construct’s multiple 
cloning site using the enzymes EcoRI and BamHI. The construct contains the blasticidin 
resistance cassette to be used as a selectable marker, conferring blasticidin resistance to 
successfully transfected parasites. Inserts were initially sub-cloned into the pGEM T-easy 
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vector and transformed into E. coli TOP10 cells. Colonies were selected and sequenced 
before excising the correct sequence inserts using EcoRI and BamHI. Inserts were gel-
purified and ligated into the pHH3 vector and transformed into E. coli TOP10. Colony 
plasmid DNA was screened by restriction digest using EcoRI and BamHI (figure 6.9 B) and 
re-sequenced before selecting one correctly sequenced vector to propagate and purify 
for transfection. 
 
As with the epitope tag constructs, complete and purified pHH3_Pf02_0040_KO was 
transfected into ring-stage parasites. Selection for presence of episome was achieved by 
the addition of 2.5μg/ml of Blasticidin to transfection cultures until parasitaemia was 
recovered to around 10%. Stock sample of these cultures were taken and stored in liquid 
nitrogen and genomic DNA was prepared in order to test for presence of integrants. 
Transfection cultures were taken off drug for 3 weeks before its re-application which was 
repeated until integration occurred or for 5 cycles in the absence of any detectable 
integration. A diagnostic PCR was designed to test for integration events using a forward 
primer from the PF02_0040 5’UTR region (a: primer DD, table 2.1) and reverse primers 
from either the PF02_0040 3’UTR region (b: primer EE, table 2.1) to identify the wild type 
locus or from the hsp86 promoter sequence of the pHH3_PF02_0040_KO vector back-
bone (c: primer OO) to detect integrated plasmid (figure 6.9 A). No integration was 
detected by this method within 5 drug cycles (figure 6.9 C). A Southern blot was 
designed to confirm this negative result. The genomic DNA prepared after each cycle 
was subject to digest by restriction enzyme AflIII before separating the resulting 
fragments by gel electrophoresis and blotting onto a nitrocellulose membrane. In order 
to ascertain whether integration had occurred, the membrane was probed with a 
radiolabelled oligomer of either the region of homology (probe 1) or the blasticidin ORF 
of the pHH3_PF02_0040_KO construct (probe 2). The resulting banding pattern from 
exposure to film revealed the presence of wild type with a band of 2678 bp (figure 6.9 E) 
and a band between the 5 and 6 kb markers corresponding to the 5283 bp episome 
(figure 6.9 E+F) throughout the 5 cycles. In accordance with the diagnostic PCR (figure 
6.9 C), no bands of 3995 or 3597 bp corresponding to an integration event were 
detected. Instead, the 5.2kDa episome band disappears in cycles 4 and 5 when probed 
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with probe 1 and is replaced by 2 bands of approximately 2.9 and 6.5 kDa, seen using 
probe 2 suggesting the episome has integrated elsewhere in the genome. This 
attempted KO by truncation was repeated in triplicate however none of the attempts 
resulted in integration into the PF02_0040 genomic locus (data not shown).  
 
The data presented here suggests that PF02_0040 cannot be knocked-out and by 
implication, is an essential gene. Caution must be taken in drawing this conclusion. The 
region of homology of 486 bp is relatively short and contains a component of AT rich 
5’UTR sequence therefore the possibility that the lack of integration is due to this 
technical difficulty in homologous recombination cannot be ruled out.  
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Figure 6.9: Attempted KO of PF02_0040 by truncation. A) A single cross-over strategy was 
employed for the KO of PF02_0040 which would result in a truncated version of the gene 
with no 3’UTR. Primers a, b and c (listed in table 2.1 as primers DD, EE and OO) were 
designed to detect the integrated and wild type (WT) locus. The transfection vector 
pHH3 was manipulated to include 486 bp from the 5’ UTR and ORF of PF02_0040, 
amplified by PCR using primers U and V (sequence listed in chapter 2, table 2.1) and 
introduced to the construct’s multiple cloning site using the enzymes EcoRI and BamHI. 
Digesion with these enzymes from the completed plasmid excised a band of 881 bp (B). 
After transfection of P. falciparum 3D7, the positive parasites were cycled on/off 
blasticidin for 5 cycles, and the diagnostic PCR was used to test for integration events 
using primer combinations a and b (detection of WT) or a and c (to detect integration of 
plasmid). These PCRs from WT and transfected 3D7 gDNA revealed the presence of the 
WT locus but not of any integration events (C). A Southern blot was designed to confirm 
this result (D). Genomic DNA taken each drug cycle was digested by AflIII before 
separating resulting fragments by gel electrophoresis and blotting onto nitrocellulose 
membrane. The membrane was probed with a radiolabelled oligomer of either (E) the 
region of homology (probe 1) or (F) the blasticidin ORF of the pHH3_PF02_0040_KO 
construct (probe 2). The resulting banding pattern from exposure to film revealed the 
presence of wild type with a band of 2678 bp (WT) throughout the 5 cycles and a band 
between 5 and 6 kb markers corresponding to the 5283 bp episome (E) in the first three 
drug cycles. The two bands labelled X seen when probing the digested DNA with the 
blasticidin probe illustrate an integration event but do not correspond to the expected 
size of integration into the PF02_0040 locus.  
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6.8 Discussion 
 
PF02_0040 is a putative orthologue of the ER protein translocon component Sec71, an 
integral membrane protein of the ER in yeast (Feldheim et al., 1993; Fang and Green, 
1994), and it appears that the P. falciparum protein is no different owing to its presence 
in the pellet of parasites lysed in a high pH carbonate buffer (figure 6.2).  PF02_0040 
contains a predicted signal anchor region at the N-terminus however the protein lacks 
any charge in front of the hydrophobic membrane-spanning region therefore it was not 
clear if this region alone is sufficient to sustain membrane integration. Since treatment 
with a high pH carbonate buffer should remove any peripheral membrane proteins, this 
result confirms that PF02_0040 is an integral membrane protein. TheSec71 proteins of 
Saccharomyces and Trypanosoma also contain a signal anchor domain but this is 
approximately 30 aa downstream of the N-terminus with clear charged residues either 
side of the membrane spanning region (Goldshmidt et al., 2008). Although one might 
assume that to fulfil the same role as the prototype Sec71, the Plasmodium orthologue 
should also reside within the membrane however the putative Toxoplasma orthologue 
of Sec66 does not contain a predicted membrane spanning region which could indicate 
a diverse role of the protein between genera. Not all organisms appear to require Sec71 
to function and indeed Homo sapiens do not possess the SEC71 gene.  
 
The ER is a fundamental part of the eukaryotic cell architecture and is certainly present 
throughout the blood stage of the lifecycle of Plasmodium. However from earlier 
transcription data, PF02_0040 appeared to be upregulated in late blood stages (Bozdech 
et al., 2003). If this protein is an ER resident then one might expect its presence 
throughout the lifecycle. Western blot analysis of parasite protein samples taken at 
regular intervals throughout the lifecycle revealed that PF02_0040 is in fact present 
throughout the blood stages, with a similar pattern of expression to the ER protein BiP 
(figure 6.3 A). This finding is now backed up by recent proteomic data, with peptide hits 
from ring (Oehring & Woodcroft et al., unpublished – available on plasmodb.org), 
trophozoite and even stage V gametocytes (Silvestrini et al., 2010), as well as schizonts 
and merozoites (Florens et al., 2002; Silvestrini et al., 2010; Bowyer et al., 2011; Treeck et 
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al., 2011). The protein could also be detected by IFA at ring, trophozoite and schizont 
stages as shown in this thesis (figure 6.3 B). PF02_0040 must be expressed de novo in 
late stages since metabolic labelling in schizonts at 42 h p.i. resulted in a band of the 
protein’s size (33 kDa). This may simply be due to the need for ER expansion ready for 
segregation of developing daughter cells but also may be due to the requirement for 
specific recognition of certain proteins to facilitate their export via different route.  
 
To identify the protein’s subcellular location, rabbit polyclonal antibodies were used to 
colocalise PF02_0040 with known protein markers of parasite organelles by IFA. Like 
Sec71, PF02_0040 was to be found in the ER throughout the lifecycle, as determined by 
colocalisation with ER resident Hsp70, BiP. The partial colocalisation between GAP45 and 
PF02_0040 in merozoites is likely to be a product of the close proximity of all 
compartments in a cell that is approx. 1μm in diameter at its longest point (from anterior 
to posterior). PF02_0040 also co-localises with MSP-1.19 in rings however it is known 
that MSP-1 is internalised at some point during ring development (Dluzewski et al., 
2008), so this may represent the beginning of its transit. Also, the cellular architecture of 
ring stage parasites is a little unclear. One model (“the Big Gulp”), based on EM data, 
predicts that the parasite takes on a cup formation upon entry into the erythrocyte 
before sealing at the open end to enclose a vacuole that will be later filled with the bi-
product of haeme degradation (Elliott et al., 2008). This explains why a ‘ring’ is observed 
in early trophozoites before intensive feeding and DNA replication brings about the 
morphological change indicative of the late trophozoite, however why the ER then 
moves from a peri-nuclear location to one that extends to the ring periphery is unclear.  
 
Comparison to BiP by IFA did suggest that PF02_0040 is an ER resident however the 
antibodies used to come to this conclusion clearly recognise 2 bands between 20 and 25 
kDa, one of which is membrane associated, as shown in figure 6.2.  From LcMS/MS 
analysis these bands were identified as thioredoxin 1, a soluble protein found in the 
cytoplasm (Kanzok et al., 2000) and thioredoxin related protein (PF13_0272), a putative 2 
transmembrane containing protein of unknown sub-cellular location (plasmodb.org). No 
colocalisation was seen with cytoplasmic protein calmodulin ruling out any cross-
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reactivity with thioredoxin 1 however thioredoxin related protein is predicted to reside 
within a membrane bound compartment which may be the ER. Even if this is the case, 
the antibodies used in IFA appear to only label the ER, indicating both proteins are 
present in this organelle. It is also possible that these proteins are only recognised under 
reducing conditions when linear epitopes are exposed, in which case what we see by IFA 
is the location of PF02_0040 only. 
 
PF02_0040 appears to reside within the ER however, upon analysis of the primary amino 
acid sequence the nature of this ER retention is unclear. The secretory pathway is 
continuous between the ER, Golgi and secretory vesicles, transporting cargo to 
organelles and the cell’s exterior; therefore proteins of the ER membrane will be lost in 
transit if not for a signal that directs these proteins back to the ER from the Golgi 
complex.  Soluble ER proteins are brought back to the ER via recognition of a C-terminal 
KDEL motif in mammals (Munro and Pelham, 1987) or HDEL motif in yeast (Pelham et al., 
1988) by the protein ERD2 (Lewis et al., 1990). Plasmodium contains an orthologue of 
this retrieval protein (Elmendorf and Haldar, 1993), although it appears  only the ‘DEL’ is 
important for recognition (Kumar et al., 1991; Kumar and Zheng, 1992) . A C-terminal di-
lysine motif, KKXX and KXKXX, has been shown to be involved in ER retrieval of type-I 
integral membrane proteins (Nilsson et al., 1989; Jackson et al., 1993; Gaynor et al., 1994) 
and that this retrieval is mediated by the coatomer complex (Cosson and Letourneur, 
1994; Letourneur et al., 1994). PF02_0040 contains a version of this retrieval sequence 
(KKSK) however the P. vivax and P. knowlesi homologues have no such motif. 
Surprisingly, neither does the yeast or trypanosome Sec71 despite evidence suggesting 
Sec71 to continuously cycled between the ER and Golgi and that this process is 
dependant on the coatamer complex (Sato et al., 1997). The Saccharomyces protein 
instead contains a δ-COP1-binding retrieval sequence (δL) from residues 147-166, 43 
amino acids from the C-terminus for the protein which is characterised by the presence 
of acidic residues followed by an essential aromatic residue (Cosson et al., 1998). This 
region appears relatively conserved in orthologues in T. brucei and N. crassa  (Goldshmidt 
et al., 2008). PF02_0040 contains a potential sequence of this nature 
(EEFLEEFNFILHEANCLSDKW) however experimental evidence is lacking and out-with the 
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scope of this study. The transmembrane domain of ER proteins has also been implicated 
in retrieval from the Golgi, as is the case for ER resident Sec21 (Sato et al., 1996) and 
cytochrome b5, which requires a transmembrane domain of less than 22 aa for retrieval 
from the Golgi as well an as yet undefined luminal motif for retention within the ER 
(Honsho et al., 1998).  
 
So it seems there are a number of ER retrieval/retention sequences and to uncover 
which is the functional one in the case of PF02_0040 is no trivial undertaking. In order to 
investigate whether the signal anchor region of PF02_0040 is responsible for ER 
retention, this region was amplified and incorporated into the 
pHH3_MSP3prom_GFPstop episomal expression construct which would allow the 
expression of the PF02_0040 signal anchor fused to soluble GFP. This would serve a dual 
purpose in establishing if the region is sufficient for membrane anchorage and in 
determining if this region sufficient for ER retention or if and additional/alternative 
retention sequence is required. Although this vector was produced and transfected, data 
is currently unavailable. 
 
If the Ty1 tag had successfully integrated and was expressed then it is possible to rule 
out a retrieval signal which requires localisation directly at the C-terminus of the protein. 
Unfortunately, genetic evidence suggests integration did not take place therefore one 
might suggest that the Ty-1 C-terminal tag was not a stable parasites line, although 
further investigation is required.  
 
Although location was identified with reasonable certainty by IFA, PF02_0040’s binding 
partners were not successfully identified using specific rabbit polyclonal antibodies. A 
lack of sensitivity of the antibodies combined with a potentially weak interaction with 
other members of the translocon components and a weak and temporal interaction with 
proteins to be imported post-translationally resulted in only abundant proteins such as 
MSPs and SERA5, or ‘sticky’ proteins (common contaminants) such as EF-1-α and 
ribosomal subunits to be identified by affinity chromatography followed by LcMS/MS 
analysis. Apart from one peptide and an insignificant hit from Sec61 beta subunit (which 
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Sec71 has not been documented to bind), none of the translocon components were co-
precipitated with PF02_0040. There is a possibility that Triton X-100 is not a strong 
enough detergent to remove this complex from its tight membrane association 
therefore the rest of the complex (other than PF02_0040) is not being solubilised. 
Moreover, if the detergent is strong enough to remove the translocon complex from the 
membrane, it may also be strong enough to disrupt the interaction between individual 
translocon components. Unfortunately, all yeast IP experiments involving the translocon 
complex use this detergent in their lysis buffer. The translocon complex in yeast was 
precipitated from purified ER microsomes, a difficult technique that has not been 
achieved in Plasmodium. In an additional attempt to precipitate the complex from P. 
falciparum, purified schizonts were treated with the cross-linker Dithiobis[succinimidyl 
propionate] (DSP) before lysis and subject to immunoprecipitation (methods described 
in chapter 2.2.17). This IP was unsuccessful and no protein bands were observed after 
sample separation by SDS-PAGE and subsequent staining with Coomassie or silver-
nitrate (data not shown). It is unfortunate that the 3xFLAG tag was not introduced into 
the locus, since from the previous chapter it appears to be a promising tool for the 
purpose of immunoprecipitation in particular. Ty1 antibodies are not as sensitive as the 
anti-FLAG M2 monoclonal antibody (Sigma-Aldrich) and perhaps not suitable for 
immunoprecipitation.  
 
The data presented in section 6.7 suggests that PF02_0040 cannot be knocked-out and 
by implication, is an essential gene. Caution should however be used here as it is 
possible that other factors influenced the ability of the construct to integrate. One such 
factor is accessibility of the locus to the construct – the gene may be subject to 
modification that obstructs integration. To rule this out the 3’ replacement control 
would be required to demonstrate locus accessibility and should be attempted in the 
future. 
 
In T. brucei, Goldschmidt et al., (2008) used RNAi to knock-down SEC71 and show a 
significant reduction of GPI-anchored proteins present in these parasites. Like 
Plasmodium, GPI-anchored proteins cover the parasite cell surface and one in particular 
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– the variant surface glycoprotein VSG. This protein is essential for parasite survival and 
the parasites could not tolerate a reduction in its presence on the surface and it is this 
that is thought to cause the lethal consequence of silencing Sec71. Consequently, Sec71 
of T. brucei is now a major potential drug target and compounds are being developed to 
inhibit its function. The fact that it has no human homologue makes it particularly 
attractive. If PfSec71 has a similar function then it too could serve as a target for novel 
anti-malarial drugs.  
 
Alternatively, PF02_0040 and the post-translational secretory pathway may function in 
an Apicomplexan or Plasmodium specific manner. As described in the previous chapter, 
the targeting of RhopH2 appears to involve specific recognition of its signal peptide for 
correct targeting to the rhoptries (Ghoneim et al., 2007), and given the role of Sec71 in 
other species, a role in recognition of this alternative and specific set of signal peptides is 
possible but requires experimental validation. Since rhoptry proteins are important 
invasion organelles, a role in rhoptry targeting would also present PF02_0040 as an 
attractive drug target. 
 
This study has shown that PF02_0040 is a membrane protein of the ER. Deciphering 
whether it is a functional homologue of Sec71 requires further characterisation, and co-
precipitating other components of the translocon complex would increase the validity 
of this hypothesis, as would the study of a conditional knock-out. Unfortunately this is 
not achievable at present but hopefully in the future the technology will allow this 
analysis and the characterisation of what could be an important and much-needed new 
drug target.  
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7. MAL13P1.94 expression timing, localisation and 
functional characterisation 
 
7.1 Introduction 
 
MAL13P1.94 is predicted to encode a 22 kDa protein with 4 transmembrane domains 
which, unlike the other two genes under investigation in this thesis (PF11_0443 and 
PF02_0443) appears to be exclusive to apicomplexa. Considering that the invasion 
process is relatively conserved throughout apicomplexa and apical organelles are 
pivotal in this process MAL13P1.94 is an attractive protein to study.  
Although much of what we know of Plasmodium host cell invasion was derived from 
findings in T. gondii, there is little information regarding this protein in the literature or 
on the Toxoplasma database ToxoDB (toxodb.org). Interestingly and in accordance with 
MAL13P1.94, the only proteomic data confirming the presence of this protein in 
Toxoplasma was from the proteomic study of Treeck et al. (2011), finding one peptide 
from the C-terminus.  Due to this lack of information from orthologous proteins in other 
species, characterisation of MAL13P1.94 will hopefully provide  further insights into 
Plasmodium host cell invasion and further our knowledge of this process in other 
apicomplexa. 
 
7.2 MAL13P1.94 is an integral membrane protein in P. falciparum schizonts 
 
MAL13P1.94 contains 4 predicted transmembrane domains therefore it is highly likely 
this protein is an integral membrane protein, nevertheless experimental confirmation is 
required. P. falciparum 3D7 schizonts were first hypotonically lysed in a high pH 0.1M 
sodium carbonate buffer to separate soluble and peripheral membrane proteins from 
those with membrane anchors. Western blot analysis of the protein extracts revealed 
MAL13P1.94, with an apparent molecular weight of 17 kDa, resides within the carbonate 
pellet fraction, confirming that it is indeed an integral membrane protein. Other bands 
seen by immunoblot of approximately 30 and 50 kDa are equivalent to rbc proteins and 
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crossreact with the antibodies produced against MAL13P1.94 (see chapter 4, figure 4.7 
A). SERA-5 is a soluble protein, peripherally associated with the merozoite cell surface 
and antibodies to this protein were used to control for correct solubilisation of 
peripheral membrane proteins by carbonate buffer extraction, while anti-MSP2 
antibodies were used to detect the GPI-anchored merozoite surface protein in the 
carbonate pellet fraction. 
 
 
 
 
 
Figure 7.1: Western blot analysis of carbonate lysed schizonts. P. 
falciparum 3D7 schizonts were lysed in 0.1 M sodium carbonate 
buffer, pH11.0 to separate soluble and peripheral membrane 
proteins from the integral ones. Samples from carbonate 
supernatant and carbonate pellet were separated by SDS-PAGE 
and subject to western blot. SERA-5 (peripheral membrane) 
and MSP-2 (membrane-anchored) antibodies served as 
controls. The blot was probed with MAL13P1.94 antibodies and 
revealed this protein to be integral to the membrane. 
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7.3 MAL13P1.94 is expressed from 40h p.i. in schizonts and merozoites. 
 
Bioinformatic analysis revealed MAL13P1.94 peak transcript levels occur around 38h p.i. 
but this is not necessarily indicative of the commencement of protein expression. 
Proteomic data places MAL13P1.94 in schizonts however, due to the lack of a ring stage 
proteome, it is unclear if it is carried through into ring stages. In order to discover at 
what point and for how long the protein MAL13P1.94 is present in the P. falciparum 
blood stage cycle it was necessary to complete a time-course experiment, sampling one 
complete cycle at 4 h intervals for protein detection (for method please refer to chapter 
2.3.4). Samples were taken every 4 h starting with newly invaded rings (time point zero) 
through to late/rupturing schizonts and subjected to western blot analysis, including a 
rbc control (figure 7.3 A). Equal loading of rbcs in each well was confirmed by probing 
with an anti-glycophorin A/B antibody. The blot was also probed with an antibody 
against the parasite ER constituent protein BiP to confirm the presence of parasite 
material in each of the lanes containing material from the time-course (Kumar et al., 
1988; Kumar et al., 1991). MSP-2, which is expressed in schizonts (Wickham et al., 2003), 
was used as a late stage control. Probing the time course with MAL13P1.94 antibody 
revealed protein expression began approximately 40 h p.i. during schizogony and 
increased during the following 4 hours. Protein levels were maintained until egress 
however the protein is not visible in ring stage parasites suggesting either the C-
terminus was lost perhaps by shedding upon entry into the host cell or the protein is 
rapidly degraded within the parasite (figure 7.2 A).  
 
In addition to western blot analysis, MAL13P1.94 antibodies were used in indirect 
immunofluorescence experiments carried out on each time point at which the protein 
was seen to be expressed by western blot (figure 7.2 B). Probing with a fluorescent 
secondary antibody revealed the presence of distinct foci associated with individual 
merozoites which reside in an anterior position in comparison to the nucleus. As 
MAL13P1.94 is an integral membrane protein, it must be associated with the membrane 
of an organelle or vesicle and this pattern is similar to that exhibited by residents of the 
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apical organelles. Although the protein is detectable from 40h p.i. by western blot, 
sufficient levels of fluorescence were not detectable by immunofluorescence until late in 
schizogony (figure 7.2 B). Co-localisation IFA studies with known organelle markers 
would give a clearer indication of the intracellular location MAL13P1.94 and this is 
addressed in the next section. 
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Figure 7.2:  Expression of MAL13P1.94 throughout the lifecycle.  
 
A) Samples of parasitized and uninfected rbcs were taken every 4 hours for one 
complete synchronised blood-stage cycle and hypotonically lysed , the pellet fraction 
solubilised in Laemmli SDS sample buffer and separated by SDS-PAGE  (2x106 parasites  
loaded per well). Pellets of hypotonically lysed rbcs were included in the western blot to 
control for parasite versus rbc band recognition. Expression of MAL13P1.94 was 
analysed by western blot using the previously generated rabbit polyclonal anti 
MAL13P1.94. A specific antibody was used to detect glycophorin A/B antibody as a 
loading control. Antibodies against the parasite ER resident protein BiP were used to 
confirm the presence of parasites in each lane and anti MSP-2 was used as a late stage 
marker. Giemsa stained parasites from each time point are shown to demonstrate 
parasite morphology at each stage.  
 
B) Thin smears of parasite culture from each time point were fixed in paraformaldehyde, 
permeabilised with Triton X-100 and used in IFAs to detect the presence of MAL13P1.94 
in the parasite using specific antibodies. MAL13P1.94 is detected by a fluorescent 
secondary antibody (shown in green) and the nucleus is stained with DAPI (blue). Scale 
bar on the bright field image represents 5μm. 
. 
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7.4 MAL13P1.94 is to be found in the rhoptry neck of late schizonts and 
merozoites from where it is transferred to the PVM in early rings. 
 
From the western blot analysis of the time-course protein samples it appears that 
MAL13P1.94 is expressed late in schizogony but it is not clear where it resides within the 
cell.  In order to uncover the cellular location of this protein, thin smears of P. falciparum 
3D7 were fixed and permeabilised and subject to indirect immunofluorescence assay 
using specific rabbit polyclonal antibodies. Fluorescence was compared to that 
produced by antibodies against proteins of already determined location, encompassing 
a number of locations within the cell. Focussing on later stages, MAL13P1.94 is clearly 
visible in multiple points of fluorescence at the apex of the cell (in comparison with the 
nucleus at the posterior) and appears to co-localise with rhoptry neck protein RON-4 
(Alexander et al., 2006) in both schizonts (figure 7.4 A) and merozoites (figure 7.4 B), 
suggesting a rhoptry neck localisation. There is a similarity between the pattern of this 
protein and the micronemal protein AMA-1 (Healer et al., 2002; Bannister et al., 2003) in 
schizonts however the resulting fluorescence pictures from the assay does not overlap. 
Looking at micronemes in merozoites, there is some overlap between MAL13P1.94 and 
microneme resident protein EBA-175 (Sim et al., 1992). Due to their close proximity, size 
and the resolution limit of light microscopy, it is often difficult to distinguish between 
the rhoptry neck and micronemes. Although MAL13P1.94 does not co-localise with 
rhoptry bulb protein RhopH2 (Holder et al., 1985) in schizonts and in merozoites this 
protein appears at a single point at the apical tip, overlapping to some extent with 
RhopH2. However the rhoptry bulb protein covers a larger area and the parasite appears 
to be orientated at an angle, therefore MAL13P1.94 could well be closer to the anterior. 
Some overlapping fluorescence is seen between MAL13P1.94 and surface protein MSP-1 
(Holder and Freeman, 1984a), however  only in a small section which is more an 
indication of the organelles proximity to the cell membrane than evidence of the 
protein’s presence on the surface.  
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From the time-course data presented in figure 7.3, MAL13P1.94 was not detected in ring 
stage parasites by western blot however rhoptry neck and bulb proteins such as RON4 
and RhopH2 are transferred into rings upon invasion. To test whether this is true of 
MAL13P1.94, thin smears of early ring stage parasites were probed with specific 
antibodies and compared with RhopH2 which is transferred to the outer face of the PVM 
upon invasion (Hiller et al., 2003). Figure 7.4 C demonstrates that MAL13P1.94 is indeed 
present in rings and although the pattern of fluorescence differs slightly from RhopH2, 
they appear to be on the same plane suggesting MAL13P1.94 is transferred to the PVM 
(Ling et al., 2003) or the plasma membrane of the ring stage parasite. It is important to 
note that antibodies were used at a higher concentration in ring stage IFAs than in the 
schizont or merozoite IFAs and the camera exposure time was doubled when taking the 
images implying MAL13P1.94 is present at a lower level  or more diffuse. This apparent 
reduction of MAL13P1.94 in ring stages could explain why this protein was not visible by 
western blot in the lysates ofring stage parasites. 
 
In summary, indirect immunofluorescence has identified MAL13P1.94 as a possible 
rhoptry neck protein. Further investigation is required to determine the protein’s 
function within the P. falciparum intra-erythrocytic cycle.  
 
 
 
 
 
 
 246
 
 
 
 
Figure 7.3: Indirect immunofluorescence of late schizonts and merozoites.  
 
Thin smears of late schizonts (A), merozoites (B) and ring stage parasites (C) were fixed 
and permeabilised as described in section 2. 2.13.1 and used in IFAs to detect the 
presence of MAL13P1.94 in the parasite using specific rabbit polyclonal antibodies. 
Primary antibodies were detected by a fluorescently labelled secondary antibody 
(AlexaFluor 488 – green) and the nucleus is stained with DAPI (in blue). Compartments 
were identified using previously characterised antibodies to proteins of known location 
followed by secondary antibodies labelled with AlexaFluor 594 (red) and images were 
merged to determine comparative location (AMA-1 and EBA-175: micronemes; RON4: 
rhoptry neck; RhopH2: Rhoptry bulb [schizonts and merozoites] or PVM [ring]; MSP-1: 
surface). Antibodies and dilutions are listed in Table 2.4. Areas of co-localisation appear 
yellow. Scale bar on the bright-field image represents 5μm in schizont or 1μm in 
merozoite images. 
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7.5 Protein-specific polyclonal rabbit antibody precipitates a band of the 
correct size for MAL13P1.94 and co-precipitates other proteins of unknown 
identity. 
 
In order to determine the function of MAL13P1.94, it is desirable to establish which 
proteins it interacts with. Although conserved between apicomplexa, including T. gondii, 
there is no information regarding the function of MAL13P1.94’s orthologues in the 
literature. With the aim of identifying potential binding partners, MAL13P1.94-specific 
antibodies were used to immuno-precipitate protein from 35S-labelled schizonts 
(methods described in chapter 2.2.15). Resolution of this radio-labelled protein sample 
by SDS-PAGE and subsequent exposure to film revealed bands of approximately 18, 22, 
28, 35, 100, 150 and 200 kDa. The 18 or 22 kDa bands most likely correspond to 
MAL13P1.94 since its predicted size is 22 kDa and its apparent molecular weight 
determined in previous western blots is 17 kDa (figure 4.7 A and figure 7.3 A).  
 
In order to identify possible binding partners, a protein preparation from 3 ml of purified 
schizonts was passed over a column of MAL13P1.94 specific IgG bound to activated 
CNBr (methods described in section 2.2.16). Unbound proteins were washed off using a 
Tris buffer containing 300mM NaCl before eluting bound proteins in low pH buffer 
containing 100mM glycine. The elution was concentrated to 50 μl, of which 30μl was 
loaded onto a gel and eluted proteins were separated by SDS-PAGE. Staining the SDS-
PAGE gel either with Instant Blue™ or silverstain (Blum et al., 1996) resulted in no clear 
bands. This could be in part due to the low affinity of the antibodies used or due to low 
protein levels of MAP13P1.94 in parasites. Due to time constraints, no further 
immunoprecipitation experiments were attempted with MAL13P1.94 polyclonal 
antibodies. 
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Figure 7.4: Immunoprecipitation of radio-labelled schizonts with MAL13P1.94 polyclonal 
antibodies. MAL13P1.94 rabbit polyclonal antibodies were used to immuno-precipitate 
interacting proteins from 50 μl of pelleted 35S-labelled schizonts. Co-precipitating 
proteins were separated by SDS-PAGE and exposed to film. Two bands of the predicted 
size of MAL13P1.94, approximately 22kDa, were observed and highlighted with * and 
unique  additional precipitated bands are indicated with arrows.  
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7.6 Epitope tagging of the MAL13P1.94 locus by targeted homologous 
recombination 
 
As discussed in chapter 5.7, incorporating an epitope tag into the genomic locus of a 
gene is a useful tool for characterisation of the resulting protein. Due to the low affinity 
of the polyclonal antibodies raised as well as the problems of cross-reactivity of this 
antiserum with parasite and host proteins, incorporating an epitope tag into the 
MAL13P1.94 locus is required as a tool for characterisation. The small epitope tags 
3xFLAG and Ty1 were chosen and I attempted to introduce them onto the C-terminus of 
the protein since the protein contains a signal sequence that should not be interrupted 
at the N-terminus.   
 
In order to introduce these tags onto the C-terminus of the protein, a region of 
homology of 480 bp from the 3’ end of the MAL13P1.94 locus (minus the stop-codon) 
was amplified by PCR using primer combinations K/L and K/M (see Chapter 2, Table 2.1). 
Ty1 and FLAG epitope tag sequences (including a stop codon at the 3’ end) were 
included in reverse primers L and M respectively and used to amplify the region of 
homology, thereby incorporating the tag sequences. This region of homology plus tag 
sequence was cloned into the multiple cloning site of the pHH3 vector via the 
EcoRI/SacII restriction sites generating pHH3_MAL13P1.94_Ty1 and 
pHH3_MAL13P1.94_3xFLAG. An AvrII site was included between the gene and tag 
sequences to allow the use of these vectors to epitope tag other genes. The pHH3 
transfection vector which includes the Blasticidin resistance cassette as a selectable 
marker is depicted in Appendix D. The same region of homology of MAL13P1.94 was in 
addition cloned into the pHH3 vector via EcoRI/SacII without the presence of an epitope 
tag to serve as a 3’ replacement vector. 
 
Inserts were initially sub-cloned into the pGEM T-easy vector and transformed into E. coli 
TOP10 cells. Colonies were selected and sequenced before excising the correct inserts 
using EcoRI and SacII. Inserts were gel-purified and ligated into the pHH3 vector and 
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transformed into E. coli TOP10. Colonies were re-sequenced and one construct with 
correct DNA sequence was propagated and plasmid DNA purified for transfection. For 
analysis purposes the construct was subject to digestion with EcoRI and SacII to confirm 
the presence of the correct sized (480 bp) insert prior to transfection (figure 7.6 B) 
 
Unfortunately due to complications in preparation and time constraints, 
pHH3_MAL13P1.94_3xFLAG and pHH3_MAL13P1.94_3’ constructs were never 
completed or transfected. Complete and purified pHH3_MAL13P1.94TY was transfected 
into ring-stage parasites and selected for presence of episome by 2.5μg/ml of Blasticidin 
applied to cultures. Stock samples of these cultures were cryopreserved and genomic 
DNA was prepared. Transfected cultures were taken off drug for 3 weeks before re-
application of drug, which is required for enrichment of the parasite population that 
contains integrated versus episomal copies of the transfection vector. This was repeated 
for up to 4 cycles. A diagnostic PCR was designed to test for integration using a forward 
primer from the MAL13P1.94 5’UTR region (primer BB, table 2.1) and reverse primers 
from either the MAL13P1.94 3’UTR region (primer CC, table 2.1) to identify the wild type 
locus or from the HRP2 3’UTR contained within pHH3_MAL13P1.94_Ty1 construct 
(primer NN, table 2.1) to detect integrated plasmid (figure 7.6 A).  As shown in Figure 
7.6C integration occurred during drug cycle 2 however MAL13P1.94_Ty1 parasites were 
not detected by western blot, despite previous success using the αTy1 antibodies in 
western blot analysis of other Ty1-tagged lines. This discrepancy is perhaps due to only a 
small number of parasites in the population containing the epitope tag but might also 
be a problem with the batch of Ty1 antibody used. The western blot will be repeated 
with an alternative batch of Ty1 antibody, however this is out-with the time restrictions 
of the project. Additionally, a Southern blot of genomic DNA taken from each cycle 
would provide definitive evidence to support or deny the presence of integrated 
construct. If successful, attempts shall be made in introduce FLAG- or GFP- tag the 
protein for use in immunofluorescence assays and immunoprecipitation experiments.
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Figure 7.5:  Epitope tagging of the MAL13P1.94 locus with Ty1. A 480bp region of 
homology from the 3’ end of the MAL13P1.94 gene was amplified using primers K/L 
(sequence listed in chapter 2, table 2.1) and introduced into the pHH3 transfection 
vector along with a TY-1 epitope tag by way of EcoRI and SacII restriction sites. An AvrII 
site was included between the region of homology and the Ty1 tag sequence to enable 
the use of this vector in epitope-tagging other genes (A). pHH3 contains the Blasticidin 
resistance cassette and a copy of the P. falciparum hrp2 gene 3’ untranslated region 
(UTR). Restriction digest of the complete construct (5891bp) using EcoRI and SacII shows 
the 480bp insert and 5411bp vector backbone (B). The plasmid was transfected into P. 
falciparum 3D7 and drug cycled to promote loss of episomal copies of the construct. A 
diagnostic PCR was designed to test for integration events using a forward primer from 
the MAL13P1.94 5’UTR region (a: primer BB, table 2.1) and reverse primers from either the 
MAL13P1.94 3’UTR region (b: primer CC, table 2.1) to identify the wild type (WT) locus or 
from the HRP2 3’UTR from the pHH3_MAL13P1.94_TY construct (c: primer NN, table 2.1) 
to detect integrated plasmid. PCR revealed the presence of both WT and integrated DNA 
(C).  
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7.7 Unsuccessful attempts to knock out MAL13P1.94 by truncation suggests 
an essential role for this gene within blood stages. 
 
One way to uncover a protein’s function is to study the effect of the loss of protein by 
observing the phenotype of a knockout parasite line compared to the wildtype. As 
discussed previously, conditional knock-downs are not well established for P. falciparum 
therefore attempting a full knock out is the best alternative method available to analyse 
the effects of a protein’s absence or to establish whether or not it is essential. If the 
protein is essential during asexual blood stages then a knock out will not be possible 
and no integration will take place;  if not essential then there is potential for identifying 
the gene’s function through phenotypic analysis of the genetically modified parasites. 
 
Unfortunately, due to the small size of the gene and the AT rich nature of the 5’ and 3’ 
UTRs, a full knock out of MAL13P1.94 by double homologous recombination was not 
possible. Instead gene truncation was attempted using a construct designed to 
integrate into the 5’ end of the gene. If successful, the expressed protein would lack the 
last 43 amino acids from the C-terminus of MAL13P1.94 and a complete or partial 
reduction of expression can be expected due to the lack of a 3’ UTR and terminator 
sequence (see figure 7.7 for KO strategy). These 43 residues from the C-terminal end of 
the parasite represent the most significant portion of the protein not predicted to be 
incorporated into a membrane and it was therefore hoped that successful integration 
would disrupt function and exhibit a phenotype, or in the case that MAL13P1.94 is an 
essential gene, would result in non-viable parasites and therefore integration would not 
be possible. 
 
The integration transfection vector pHH3_MAL13P1.94_KO was manipulated to include 
474bp from the 5’ UTR and ORF of MAL13P1.94, amplified by PCR using primers I/J 
(sequences listed in table 2.1) and introduced into the construct’s multiple cloning site 
using the enzymes EcoRI and BamHI. The construct contains the blasticidin resistance 
cassette to be used as a selectable marker, conferring blasticidin resistance to 
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successfully transfected parasites. Inserts were initially sub-cloned into the pGEM T-easy 
vector and transformed into E. coli TOP10 cells. Colonies were selected and sequenced 
before excising the correct sequence inserts using EcoRI and BamII. Inserts were gel-
purified and ligated into the pHH3 vector and transformed into E. coli TOP10. Colony 
plasmid DNA was screened by restriction digest using EcoRI and BamII (figure 7.7 B) and 
re-sequenced before selecting one correct sequence vector to propagate and purify for 
transfection. 
 
As with the epitope TY-tag construct, complete and purified pHH3_MAL13P1.94_KO was 
transfected into ring-stage parasites. Selection for presence of episome was achieved by 
the addition of 2.5μg/ml of Blasticidin to transfection cultures. Stock samples of these 
cultures were cryopreserved and genomic DNA was prepared. Transfected cultures were 
taken off drug for 3 weeks before its re-application, which will enrich the proportion of 
the parasite population that contains integrated versus episomal copies of the 
transfection vector. This was repeated for 5 cycles. A diagnostic PCR was designed to test 
for integration events using a forward primer from the MAL13P1.94 5’UTR region (a: 
primer BB, table 2.1) and reverse primers from either the MAL13P1.94 3’UTR region (b: 
primer CC, table 2.1) to identify the wild type locus or from the hsp86 sequence of the 
pHH3_MAL13P1.94_KO vector back-bone (c: primer OO) to detect integrated plasmid 
(figure 7.7 A). No integration was detected by this method within 5 drug cycles (figure 
7.7 C). A Southern blot was designed which confirmed this negative result.  For this 
procedure, gDNA was subject to digestion by restriction enzymes SapI and PacI before 
separating the resulting fragments by gel electrophoresis and blotting onto a 
nitrocellulose membrane. In order to ascertain whether integration occurred, the 
membrane was probed with a radiolabelled DNA probe homologous to either 
blasticidin ORF or the 474 bp fragment of MAL13P1.94 cloned into the 
pHH3_MAL13P1.94_KO construct. The resulting banding pattern from exposure to film 
revealed the presence of wild type DNA with a band of 2739 bp (figure 7.7 E) and a band 
between 5 and 6 kb markers corresponding to the 5271 bp episome (figure 7.7 E+F) 
throughout the 5 cycles. In accordance with the diagnostic PCR (figure 7.7C), no bands 
of 4793 or 3217 bp, corresponding to an integration event, were detected. Instead, the 
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5.2kDa episome band disappears in cycle 5 when probed with the region of homology 
and a band of 5.5 kDa is detected by the blasticidin probe. Although similar to the 
episome band, there is a clear difference between the bands, suggesting the episome 
has integrated elsewhere in the genome. This attempted KO by truncation was repeated 
in duplicate however neither attempt was successful (data not shown).  
 
The data presented here suggests that MAL13P1.94 cannot be knocked-out and by 
implication, is an essential gene. 
 
 
 
 
 
 256
 
 
Figure 7.6: Attempted KO of MAL13P1.94 by truncation. A) A single cross-over strategy 
was employed for the KO of MAL13P1.94 which would result in a truncated version of the 
gene with no 3’UTR. Primers a (MAL13P1.94 5’UTR region), b (MAL13P1.94 3’UTR region), 
c (hsp86 sequence of pHH3_MAL13P1.94_KO back-bone) were designed to use for 
diagnosis of intergration versus the presence of wild type sequence. The transfection 
vector pHH3_MAL13P1.94_KO was manipulated to include 474bp from the 5’ UTR and 
ORF of MAL13P1.94, amplified by PCR and introduced into the construct’s multiple 
cloning site using the enzymes EcoRI and BamHI. Digestion with these enzymes from the 
completed plasmid excised a band of the correct size (B). After transfection, the positive 
parasites were drug cycled for 5 cycles, and a diagnostic PCR was designed to test for 
integration events using primer combinations a and b (detection of wild type) or a and c 
(to detect integration of plasmid). The PCR revealed presence of the wild type locus but 
not of any integration events (C). A Southern blot was designed to confirm this result (D). 
Genomic DNA taken each drug cycle was digested by SapI and PacI before separating 
resulting fragments by gel electrophoresis and blotting onto nitrocellulose membrane. 
The membrane was probed with either (E) a radiolabelled DNA probes corresponding to 
the 474 nucleotide fragment of the MAL13P1.94 region of homology (probe 1) or (F) the 
blasticidin ORF (probe 2). The resulting banding pattern from exposure to film revealed 
the presence of wild type DNA with a band of 2739 bp (WT) and a band between the 5 
and 6 kb markers corresponding to the 5271 bp episome (E) throughout the 5 cycles. 
Band X does not correspond to the size expected from intergration into the MAL13P1.94 
locus.  
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7.8 Discussion 
 
MAL13P1.94 is 22 kDa integral membrane protein expressed from 40 h p.i. in blood 
stage P. falciparum 3D7. This protein appears apical by immunofluorescence and co-
localises with known rhoptry neck protein RON4. Overlapping fluorescence is also seen 
with micronemal proteins however the pattern of fluorescence is different in schizont 
stages. Due to their close proximity within the merozoite and the fact that the limit of 
the resolution of light microscopy (diameter of light omitted by the fluorophore) is 
around 200-300nm, it is often difficult to distinguish between the rhoptry neck and 
micronemes. MAL13P1.94 does not co-localise with rhoptry bulb marker RhopH2 in 
schizonts, and is anterior to RhopH2 in merozoites. Rhoptry neck and bulb proteins are 
transferred into rings upon invasion, however by western blot MAL13P1.94 was not 
detected in ring stages. Indirect immunofluorescence revealed that MAL13P1.94 is in 
fact present in rings (figure 7.4 C) although it was necessary to use a higher 
concentration of antibody to stain ring stage parasites compared to late schizont and 
merozoite stages. This suggests that there is less protein present and perhaps this is why 
no band was not detected by western blot on ring stage lysates. Micronemal proteins 
are normally shed upon invasion and therefore antibodies to the extracellular portion of 
the proteins do not detect the newly invaded rings in IFAs. Given that MAL13P1.94 can 
be detected in ring stages gives weight to the hypothesis that this protein is present in 
the rhoptry neck, however the possibility that antibodies were raised against an 
intracellular region which would not be shed upon invasion cannot be ruled out since 
the topology of the protein has not been addressed in this study. RhopH2 was used as a 
marker for the PVM in ring stages and although MAL13P1.94 and RhopH2 did not 
completely co-localise, these proteins seem to be in close apposition. It is possible that 
MAL13P1.94 is maintained in the plasmalemma of the ring parasite or that its 
distribution along the PVM is not homogenous.  
 
Since beginning this study, a global transcriptome study analysing the effects of growth 
perturbations by a set of growth inhibiting compounds at schizonts stages assigned 
MAL13P1.94 as a protein with a putative role in invasion and episomal expression of a 
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GFP-tagged MAL13P1.94 also places this protein at the apex of merozoites by IFA 
although no colocalisation attempts were published (Hu et al., 2010). 
 
From the western blot of schizonts lysed in carbonate buffer, we saw that MAL13P1.94 
behaves like an integral membrane protein. This result was as expected due to the 
presence of 4 putative transmembrane domains within the protein. The antibodies 
raised against MAL13P1.94 cross-reacted with 2 additional proteins: an approximately 
30kDa protein that is also detected in erythrocytes (chapter 4, figure 4.7) and a parasite 
specific 50 kDa protein. The same antibodies were used in the IFAs and therefore caution 
should be taken when analysisng the results. Despite these cross-reacting bands, the 
pattern observed by IFA is consistent with a single, apical location. No rbc cross-
reactivity was observed by IFA and in fact no reactivity at all was observed in lifecycle 
stages other than segmented schizonts, merozoites and early rings.  The 50 kDa protein 
is present in the carbonate supernatant and was absent from the hypotonically lysed 
schizonts from the time-course westerns. Since completely soluble, it is possible that the 
50 kDa protein is lost during paraformaldehyde fixation, as is the case for haemoglobin. 
Antibodies recognise globular as well as linear epitopes and when proteins are 
separated by SDS-PAGE under reducing conditions, linear epitopes are exposed that are 
not necessarily available to the antibody when the protein is in its native state. This is 
perhaps responsible for the discrepancy between western blot and 
immunofluorescence assays. 
 
To definitively assign a sub-cellular location to MAL13P1.94 we tried to localise the 
protein using immuno-electron microscopy (IEM) on late schizont stages. Unfortunately, 
attempts to confirm location by IEM using MAL13P1.94 rabbit polyclonal antibodies 
were unsuccessful.  
 
In order to confirm the results obtained with the specific polyclonal antibody raised in 
this study we attempted to introduce an epitope tag at the C-terminus of MAL13P1.94. 
Epitope tags are designed to be immunogenic and commercial antibodies are available. 
GFP is a particularly attractive epitope tag, however thought unsuitable for MAL13P1.94 
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since its size of 27 kDa would more than double the size of the wild type protein and is 
therefore more likely to affect the protein’s function. Small epitope tags such as Ty1 and 
FLAG have previously been used in Plasmodium with some success (Treeck et al., 2009; 
Wider et al., 2009). At first glance, attempts to tag MAL13P1.94 with the Ty1 epitope tag 
seemed successful since the diagnostic PCR revealed the presence of integrated 
episome. Unfortunately, the anti-Ty1 antibodies failed to detect the presence of the 
tagged protein in purified late schizonts by western blot or IFA.  As discussed earlier this 
might be due to only a small subpopulation in the culture being actually tagged. 
However time constraints have not allowed further attempts to enrich for the integrated 
population and cloning of the tagged line. As seen with PF11_0443, epitope tags can 
also be useful tools in immunoprecipitation studies; unfortunately this was not possible 
here.  
 
The lack of identification of any binding partners makes it impossible to predict the 
function of this protein. A successful knock-out would have allowed the study of any 
phenotype and perhaps deduce the protein’s function. The data presented in section 7.7 
suggest that MAL13P1.94 cannot be knocked-out and by implication, is an essential 
gene. Caution should however be used here as it is possible that other factors influenced 
the ability of the construct to integrate. One such factor is accessibility of the locus to the 
construct – the gene may be silenced or subject to modification that obstructs cross-
over events. The fact that the pHH3_MAL13P1.94_Ty1 construct was able to integrate 
into the MAL13P1.94 genomic locus demonstrates however that the locus is accessible. 
The regions of homology in the case of the epitope tag and the truncation construct 
differ which may mean that the genomic region used in the KO strategy is incompatible 
with homologous recombination.  An alternative control could include the precise 
region of homology used, followed directly by a re-codonised copy of the remaining 
sequence of the gene, and a 3’UTR/terminator sequence to test if the region is 
compatible with recombination without altering the MAL13P1.94 gene product. Even 
with this approach there is still the somehow remote possibility that the re-codonised 
sequence is not compatible with P. falciparum and expression is consequently reduced 
or lost so no integration of the control would not necessarily equate to inaccessibility of 
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the region of homology; however this would be something to attempt in the future. 
Another limiting factor for this experiment was the size of the available region of 
homology. From work in the Division it has generally been noted that integration will 
not occur with regions of homology less than 400 bp and that although 500+ bp is what 
is generally used, longer regions integrate in an earlier drug cycle and have even been 
shown to integrate where shorter gene fragments have failed. Although 474bp is 
adequate, perhaps if a longer gene fragment was accessible then a different result 
would be had. Unfortunately this was not possible due to the 30 base stretch of poly-T 
and high AT percentage in the flanking UTRs which would prove difficult to maintain in 
bacterial culture and would increase the chance of random integration into one of the 
many other regions in the genome with over 90% AT content. 
 
In order to take work on this protein forward, it is essential that an epitope tag is 
integrated into the genomic locus. FLAG or GFP would be particularly beneficial due to 
the abundance of commercially available tools such as monoclonal antibodies and 
affinity columns which increase the experimental capacity of the protein and would aid 
functional studies. 
 
Proteomic data from Treeck & Sanders et al (2011) identified phosphorylated residues at 
the C-terminus of the protein, namely S179 and T182 (S*LGT* where *=phosphate 
addition). Interestingly phosphorylated residues are also present in the Toxoplasma 
homologue (TGME49_054070) in a similar motif at residues T178 and S181 (T*LGS*) with 
an additional phosphorylated threonine at position 185. Uncovering the purpose of this 
phosphorylation could reveal the function of the protein within both organisms. The 
fact that the C-terminus is phosphorylated suggests that it is on the cytoplasmic side of 
the membrane, therefore this protein has no real extracellular domain of sufficient 
stature characteristic of possible vaccine targets. Nevertheless the role of this protein 
may be mechanistic with phosphorylation/dephosphorylation acting in a regulatory 
capacity and therefore MAL13P1.94 may yet be interesting to study with regards to a 
role in the invasion process. 
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Although we did not characterize MAL13P1.94 fully this study has been able to locate 
this protein to the apical end of the parasite and therefore confirm the validity of the 
selection criteria laid out in section 1.8. Due to the protein’s size and the presence of 4 
membrane spanning regions, the only hydrophilic exposed stretches of amino acids 
available to raise antibodies against are very small.  For this reason generating an 
epitope tagged transgenic parasite line is highly desirable.  We have attempted with 
some success to generate a Ty-1 tagged line suggesting that such a line might be viable; 
laying the groundwork for future attempts to tag and characterize this protein. 
 263
8. Project summary 
 
The aim of this project was to uncover novel proteins that play a part in the invasion of 
red blood cells by merozoites. In order to identify such proteins, the Plasmodium 
falciparum genome was explored, using bioinformatic data that suggested expression in 
the late blood stages. Five proteins were initially selected for study based on 
conservation in the Plasmodium genus, the presence of a signal sequence and of one or 
more transmembrane domains and transcription data confirming expression of 
candidate genes in schizogony. The set of criteria used to search for these proteins was 
deemed successful due to the presence of previously identified invasion related proteins 
including AMA-1, MTRAP and multiple members of the EBA, Rh and MSP families. 
 
Although initially five proteins were selected for further study, characterisation of the full 
set was never intended. Starting with this number allowed room for experimental 
difficulty so that if one or two proteins were not compatible with being taken forward in 
some way, the other proteins would ensure the project’s success. The initial hurdle to 
overcome was protein solubility and it was at this stage that work on PF14_0325 was 
terminated due to difficulty in recombinant protein expression in E. coli. This protein was 
attractive due to the presence of transcripts in both schizonts and merozoites, implying 
the protein might have a conserved role in invasion. However PF14_0325 has a putative 
GPI-anchor and it would therefore not have been possible to integrate a tag onto the C- 
or N-terminus. Without protein- or epitope tag-antibodies, characterisation of this 
protein would be difficult. Perhaps this will be achieved in the future, particularly if a 
usable conditional knock-out method can be established for P. falciparum.  
 
The protein PF14_0045 was also selected for further study and although recombinant 
protein was expressed and antibodies were raised, the antibodies did not recognise a 
band of the correct size in merozoites. Consequently the protein remains 
uncharacterised. Perhaps if the initial strategy used had focused on genetic 
manipulation to tag the protein instead of production of specific polyclonal antibodies 
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as tools for characterisation then this protein may have featured more heavily in this 
thesis. However this could be something to focus on in the future.  
 
Having discounted two selected proteins, three remained to be characterised. 
MAL13P1.94 was found to be an integral membrane protein present at the apex of 
merozoites and found in early rings. Colocalisation by IFA strongly suggested this 
protein is present in the rhoptry neck, however confirmation by IEM was not successful. 
Antibodies to a protein are an extremely important tool in characterisation studies but 
unfortunately the antibodies raised against MAL13P1.94 recognised additional, 
apparently non-specific bands. Although an alternative set of antibodies was raised 
against a slightly different protein sequence, the same contamination problem 
persisted. Due to the presence of three transmembrane domains and a signal anchor in 
this protein, only a small region at the C-terminus was suitable for protein expression in 
terms of size and hydrophilicity, therefore antibody options were limited. Integrating an 
epitope tag into the locus of MAL13P1.94 would go some way to solving this problem. 
Attempts to tag MAL13P1.94 with the Ty1 epitope tag seemed successful since the 
diagnostic PCR revealed the presence of integrated DNA. Unfortunately, the anti-Ty1 
antibodies failed to detect the tagged protein in purified late schizonts by western blot 
or IFA.  This might be due to only a small subpopulation in the culture expressing tagged 
protein or low levels of tagged protein in each cell, however time constraints have not 
allowed further attempts to enrich for the integrated population. Cloning of the tagged 
line is something that will be attempted in the future. Integration into the locus proves it 
is accessible and therefore the fact that a construct designed to knock-out MAL13P1.94 
failed to integrate over 5 drug cycles in 3 attempts suggests the protein is essential. 
Although this provides little insight into function, as Plasmodium genetics advances a 
conditional knock-out method may become available that will allow the role of 
MAL13P1.94 to be uncovered. A study by Hu et al (2010) that was published during the 
course of this project analysed the effects of growth perturbations by a set of growth 
inhibiting compounds on schizonts stage transcript levels and assigned MAL13P1.94 as 
a protein with a putative role in invasion. Also, episomal expression of a GFP-tagged 
MAL13P1.94 places this protein at the apex of merozoites by IFA although no 
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colocalisation attempts were published (Hu et al., 2010). These data confirm what was 
already observed by IFA using anti-MAL13P1.94 polyclonal antibodies, and further 
validate the selection criteria since MAL13P1.94 appears to be a novel protein with a role 
in invasion, even if the precise role remains elusive. 
 
Uncovering the function of a protein without conserved domains is an arduous 
undertaking. Plasmodium is relatively well studied in comparison to other pathogens 
due to the funding it attracts from its medical relevance [Toxoplasma is also relatively 
well studied however more so in cellular processes important for virulence and host cell 
invasion than more general molecular cell biology]; therefore little can be learned from 
bioinformatics unless the protein has orthologues of known function. This was certainly 
the case for MAL13P1.94, but in the beginning PF02_0040 appeared to have no known 
orthologues other than in eukaryotic pathogens, particularly if the data from OrthoMCL 
(available on plasmodb.org). PF02_0040 was discovered to contain a Sec66 domain 2 
years into the project by BLAST search using the protein sequence of the T. gondii 
orthologue. Due to the increased power of protein domain prediction algorithms, this 
domain is now predicted by Pfam with an e-value of 0.00011 which is significant but 
lower than normally observed between protein family members . For example the J 
domain of PF11_0443 has an e-value of 1.5x10 8−  (Finn et al., 2008) and this information 
has been added to PlasmoDB following its latest update from May of this year. Due to 
the AT rich nature of the P. falciparum genome, amino acids which are coded for by A- or 
T-rich codons are preferentially utilised and this could contribute to the lack of 
detectable sequence identity between P. falciparum and, for example, yeast proteins. 
 
The identification of the Sec66 domain implies PF02_0040 is a homologue of ER resident 
protein Sec66 (aka Sec71) of Saccharomyces. If this protein feature had been detectable 
at the beginning of the project then perhaps PF02_0040 would not have made the 
shortlist of protein for further study, because any protein selected by the criteria 
containing an obvious ER retention signal, such as an XDEL motif, was discounted. At the 
start of the project it was assumed that only receptor/ligand interaction at the surface 
are important for invasion, a fact which is now clear not to be the case. 
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Specific antibodies raised against PF02_0040 revealed this protein is an integral 
membrane protein present throughout the intra-erythrocytic lifecycle of P. falciparum, 
where is resides within the ER, as shown by colocalisation with parasite ER resident BiP. 
Unfortunately these antibodies were unable to immuno-precipitate other members of 
the ER translocase therefore an equivalent role for this protein between Plasmodium and 
yeast was not verified. An IP using antibodies to an epitope tag may have improved 
upon this result however this was not possible as the 3xFLAG integration construct for 
this protein did not integrate. Targeted genetic deletion attempts of PF02_0040 were 
unsuccessful over 5 drug cycles, which would suggest this protein is essential. However 
the possibility that failure to integrate an epitope tag into the locus may represent a 
technical difficulty in recombination and gene accessibility cannot be ruled out. This 
issue of accessibility will be addressed in the near future by attempted integration of a 3’ 
replacement construct containing genomic sequence from PF02_0040 without the 
presence of a C-terminal tag. The issue of ER retention will also be addressed since 
PF02_0040 contains no obvious retention sequence such an XDEL motif which is present 
in other ER resident proteins.  
 
Despite PF02_0040’s presence in the ER, the protein may still have an impact on 
invasion. Targeting of RhopH2 appears to involve specific recognition of its signal 
peptide for correct targeting to the rhoptries (Ghoneim et al., 2007), and given the role 
of Sec71 in the post-translational translocation of proteins into the ER in other species, a 
role in recognition of a specific set of signal peptides is possible. Since rhoptry proteins 
are important in these invasion organelles, a role here would also present PF02_0040 as 
an attractive drug target. Sec71 of T. brucei is already being developed as a drug target 
due to its indispensible role in translocating GPI-anchored proteins into the secretory 
pathway (Ghoneim et al., 2007). Since Sec71 is absent in humans, PF02_0040 would also 
be an attractive drug target if the proteins share similar role. However in the absence of 
any conditional knock-down, this is impossible to predict.  Nonetheless there is definite 
potential for this protein to impact upon erythrocyte invasion by merozoites, despite 
residence in the ER and homology to conserved eukaryotic secretory components. 
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The final protein selected is also conserved in other eukaryotes. PF11_0443 is a putative 
type IV J domain-containing protein or Hsp40. Although a role in invasion for this 
protein would not necessarily be predicted, transcript data revealed this protein is only 
expressed in blood stage schizonts (Bozdech et al., 2003) and there are other J proteins 
present in dense granules [such as ring-expressed surface antigen (RESA) (Culvenor et 
al., 1991)] and P. berghei ookinete micronemes (Lal et al., 2009). PF11_0443 was found to 
be an integral membrane protein expressed from 36 h pi. The protein is present in the 
ER of early schizonts where it remains until segregation of daughter merozoites in what 
is termed late schizonts or segmenters. At this stage it appears to translocate to the 
apex, but it is not clear whether it is present in rhoptries or micronemes. A rhoptry 
location is more likely as it is transferred into the early ring stage, albeit at a lower level 
than seen in schizonts and merozoites and it appears to be degraded at this stage as it is 
not visible until the commencement of the next round of schizogony. IFAs using 3xFLAG 
epitope-tagged PF11_0443 also supported a rhoptry location although only IEM would 
provide a definitive answer to the question of subcellular location. Unfortunately this 
approach was unsuccessful and so far attempting to repeat it using the 3xFLAG tagged 
line and anti-FLAG antibodies has not been possible.  Immunoprecipitation studies 
pulled-down a number of potential binding partners including a number of chaperones, 
however reciprocal immunoprecipitation is required to confirm these interactions as 
real. As with the other two proteins, targeted genetic deletion of PF11_0443 was not 
possible over 5 drug cycles in 3 attempts. On this occasion a double homologous 
recombination strategy was employed and the 3’ region of homology (flank 2) did 
integrate into the PF11_0443 locus, but this expression had little effect since the protein 
was still expressed at 90% of WT levels. The PF11_0443 locus is clearly accessible, 
however without a control for integration into the exact region used in flank 1, the 
possibility that the lack of integration is due to a technical difficulty in homologous 
recombination cannot be ruled out.  
 
The apical organelles have specifically evolved to facilitate invasion and the presence of 
PF11_0443 in these organelles implies this protein has a role in erythrocyte invasion. 
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Since there is a clear distinction between the subcellular location of PF11_0443 in early 
schizonts and PF11_0443 in late schizonts, perhaps the protein has a role in the 
trafficking of late-expressed blood stage proteins of the secretory pathway out to the 
apical organelles. From IFA and IP data, the organelles in question are most likely the 
rhoptries. Experimental validation of this putative function is required and will be 
undertaken in the future. If PF11_0443 has an essential role in this process then it could 
also represent an attractive anti-malarial drug target. 
 
 
8.1 Concluding remarks 
 
Invasion of erythrocytes involves a multitude of molecular processes: from signal 
peptide recognition which appears important in rhoptry protein targeting (Ghoneim et 
al., 2007); to signalling pathways involving kinases and phosphatases; extensive 
proteolytic processing of protein precursors (Blackman, 2004); and cell motility by way of 
an actin myosin motor (Baum et al., 2006). Receptor/ligand interactions at the 
host/parasite interface represent only a small subset of these processes, yet are the most 
studied due to their vaccine antigen potential. Blocking the processes involved in 
erythrocyte invasion will result in a block in the parasite’s lifecycle and therefore they are 
also attractive drug targets. Although none of the proteins detailed in this study appears 
to function via direct interaction with the host, they have shown potential involvement 
in other processes important for invasion and could represent desperately needed new 
drug targets. 
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 Appendix A: PF11_0443rabbit polyclonal antibody immunoprecipitation LcMS/MS results 
Band Gene ID Protein kDa (gel) kDa (MS) Score % coverage Comments
1 PFI1475w MSP-1 25-37 197217 1049 16.27 N and C terminus
PFB0340c SERA 5 113294 786 26.18
PF11_0443 39678 711 48.6
PF14_0102 RAP1 90467 588 35.68
PF08_0054 hsp70 74754 546 15.81 C terminus only
PFF0435w ornithine aminotransferase 46938 519 26.81
PF11_0351 hsp70 71945 515 16.44 C terminus only
PF11_0099 Pfj2 62747 499 24.26 C terminal half
PF11_0344 AMA-1 61606 478 21.22 N terminal half
PF10_0348 MSPDBL1 80997 426 15.93
PFI0265c RhopH3 105587 422 14.83
PFD0240c 6-cysteine protein 43802 399 30.42
hyp17 144218 344 11.88
PF14_0077 plasmepsin II 51847 332 24.94
PF10_0115 QF122 antigen 132002 330 10.1
PFD1130w conserved protein 43432 306 26.24
MAL13P1.336conserved protein 78582 268 11.09
PFL2275c FKBP-type isomerase 35147 258 25.33
PFF1025c SNO glutamine amidotransferase 33391 238 23.26
PF14_0567 conserved protein 40556 226 21.18
PFL0300c protein phosphatase 36120 217 15.46
PF14_0660 protein phosphatase 42697 217 23.46
2 PF14_0425 fructose-1,6-bisphosphate aldolase 37kDa 40348 1123 62.33
PFI1475w MSP-1 197217 715 13.72 N and C terminus only
PF11_0099 Pfj2 62747 714 31.48 C terminal half
PFD0240c 6-cysteine protein 43802 597 42.33
PFF0435w ornithine aminotransferase 46938 455 25.12
PF10_0348 MSPDBL1 80997 432 19.51
PF11_0443 39678 423 42.37
PFE0080c RhopH2 47017 348 22.11
PFI0265c RhopH3 105587 342 13.15 N terminus only
PF11_0175 hsp101 103038 327 12.47 N terminus only
PF11_0086 MIF4G domain containing protein 383293 320
PFE0075c RAP3 47232 318 16.25
PFF1415c DNAJ domain protein 45040 287 25.53
PF07_0129 acyl-coA synthase 93624 283 9.49
PF14_0281 Plasmepsin IX 74820 259 15.15
PF14_0075 Plasmepsin IV 37159 253 20.71
PF13_0272 Thioredoxin-related protein 24314 193 31.25
PFI0880c GAP50 44804 179 15.15
3 PFI1475w MSP-1 50kDa 196746 660 9.71 N- terminus only
hyp17 144218 507 10.37
PF11_0344 AMA-1 69741 504 22.51
MAL8P1.17 disulphide isomerase 55808 379 26.71
PF14_0694 disulphide isomerase 66989 194 10.67
PF11_0443 39678 168 15.26
4 PFI1475w MSP-1 60kDa 197217 545 10.06 N-terminus only
PF14_0102 RAP-1 90467 536 22.51
PFA0125c EBA-181 183259 361 7.34 aa's 180-720
PF11_0443 39678 271 21.5
PF11_0465 dynamin-like protein 96712 192 8
PF10_0153 hsp-60 62911 167 16.03
5 PFI1445w RhopH2 150kDa 163587 1573 27
6 PFI0875w BiP 15-20kDa 30696 227 9.2 C terminus only
7 No significant hits
 292
Appendix B: PF11_0443-FLAG immunoprecipitation attempt 1 LcMS/MS results. Proteins 
are listed according to peptide matches in descending MOWSE score. PF11_0443 is 
highlighted in blus, the next hightest scoring hit in pink, rhoptry proteins in yellow and 
DnaJ domain containing proteins in purple. 
Results of FLAG IP attempt 1
Accession Description MW (kDa) Coverage (%) # Peptides Band Score
PF11_0443 DnaJ protein, putative 39.3 44.24 27 9 2,116.20
PF10_0153 heat shock protein 60 62.5 48.97 29 5 1,188.61
MAL7P1.38 regulator of chromosome condensation 79.0 22.13 12 3 321.60
PFL1875w conserved Plasmodium protein 61.3 15.09 6 5 307.46
PF14_0407 guanine nucleotide exchange factor 404.3 2.98 8 1 279.49
PF13_0357 conserved Plasmodium protein 100.0 10.00 7 3 272.61
PFB0095c erythrocyte membrane protein 3 273.5 39.57 10 1 262.21
MAL13P1.352 conserved Plasmodium protein 131.3 5.15 5 3 251.05
PF11_0168 RON4 135.5 7.33 8 5 206.15
Proteins with lower scores absent fromWT control IP
Accession Description MW (kDa) Coverage (%) # Peptides Band Score
PF11_0084 conserved Plasmodium protein 84.2 7.57 4 3 184.93
MAL7P1.108 phosphoinositide-binding protein 258.3 3.55 7 1 182.36
MAL7P1.204 conserved Plasmodium protein 196.4 3.17 5 3 172.82
PFF1030w mRNA binding Pumilio-homology domain protein 94.2 6.05 4 3 166.45
PF13_0061 ATP synthase gamma chain, mitochondrial precursor 35.7 14.15 3 11 159.41
PFI0265c RhopH3 104.8 6.02 5 3 150.41
PFL1385c MSP-9 86.6 4.85 3 3 149.80
PF14_0386 adaptor complexes medium subunit family 87.1 7.09 4 3 126.68
PF08_0067 ubiquitin 44.9 13.40 4 11 126.44
PFL1545c chaperonin, cpn60 81.4 6.96 4 3 113.21
PFL1070c endoplasmin homolog precursor (Hsp90) 95.0 4.14 3 3 111.43
PF14_0350 N-acetyltransferase, putative 64.1 3.86 2 5 107.91
PF11_0380 DnaJ protein, putative 44.5 6.50 2 11 95.59
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Appendix C: PF11_0443-FLAG immunoprecipitation attempt 2 LcMS/MS results. Proteins 
are listed according to peptide matches in descending MOWSE score. PF11_0443 is 
highlighted in blue, the next hightest scoring hit in pink, rhoptry proteins in yellow and 
DnaJ domain containing proteins in purple. 
 
 
 
 
 
 
Results of FLAG IP attempt 2
Accession Description MW (kDa) Coverage (%) # Peptides Band Score
PF3D7_1143200 DnaJ protein, putative 39.3 30.84 18 11 440.92
PF3D7_0804800 peptidyl-prolyl cis-trans isomerase (CYP24) 24.9 33.64 9 12 421.56
PF3D7_1341200 60S ribosomal protein L18, putative 21.7 40.76 9 12 262.2
PF3D7_0503400 actin-depolymerizing factor 1 (ADF1) 13.7 22.95 2 12 246.54
PF3D7_1004000 60S ribosomal protein L13, putative 23.7 39.60 10 12 220.66
PF3D7_0322900 40S ribosomal protein S3A, putative 30.0 39.31 10 12 215.41
PF3D7_1452000 rhoptry neck protein 2 (RON2) 249.3 4.61 10 9 210.84
PF3D7_0823800 DnaJ protein, putative 76.6 13.13 9 11 202.49
PF3D7_1361900 proliferating cell nuclear antigen (PCNA) 30.6 12.04 3 12 177.29
PF3D7_0706000 conserved Plasmodium protein 145.4 4.31 6 9 176.65
PF3D7_1331800 60S ribosomal protein L23, putative 15.0 11.51 2 12 164.28
PF3D7_1455200 conserved Plasmodium protein 24.0 29.76 5 12 164.2
PF3D7_0513300 purine nucleoside phosphorylase (PNP) 26.8 16.73 3 12 137.53
PF3D7_0711400 sin3 associated polypeptide p18-like protein 88.4 8.10 6 12 135.19
PF3D7_1438900 thioredoxin peroxidase 1 (Trx-Px1) 21.8 40.00 6 12 132.69
PF3D7_0415900 60S ribosomal protein L15, putative 24.1 27.32 5 12 131.91
PF3D7_0627700 transportin 132.8 4.80 5 9 119.28
PF3D7_1120100 phosphoglycerate mutase, putative (PGM1) 28.8 8.00 2 12 117.53
PF3D7_1238100 calcyclin binding protein, putative 26.6 18.86 4 12 113.16
PF3D7_1211400 heat shock protein DNAJ homologue Pfj4  28.0 16.80 5 12 112.56
PF3D7_1451800 sortilin, putative 102.2 3.35 3 10 107.53
Proteins of interest with low scores
Accession Description MW (kDa) Coverage (%) # Peptides Band Score
PF3D7_0817700 rhoptry neck protein 5 (RON5) 133.6 5.71 6 9,10,11,12 73,79,60,57
Protein with high score but WT presence
Accession Description MW (kDa) Coverage (%) # Peptides Bands Score WT Band WT Score
PF3D7_0720900 conserved Plasmodium protein 31.1 30.94 12 11,12 411,245 5 270.9
PF3D7_1252100 rhoptry neck protein 3 (RON3) 263.0 11.11 27 9,10,11 449,68,88 3 381.44
PF3D7_0935800 CLAG9 160.3 7.69 11 9,10,11 157,140,85 3 124
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Appendix D: Vector map for the epitope-tagging construct pHH3. The diagram shows a 
vector map of an example pHH3 construct used to epitope tag genes presented in this 
thesis. All unique restriction sites and important features are indicated, the pink arrow 
hightlights the region containing either the Ty1 or 3xFLAG epitope tag. For KO by 
truncation, the tag and 3’ UTR were removed and the region of homology for 
MAL13P1.94 and PF02_0040 was cloned in between EcoRI and BamHI restriction sites. 
 295
Appendix E: Vector map of pHTK_PF11_0443_KO. The diagram shows the vector map of 
the construct used in an attempt to KO PF11_0443 by double homologous 
recombination. All unique restriction sites and important features are indicated. 
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Appendix F: Localisation of DNAJC25 in human skin cell line A-431. Image taken from The 
Human Protein Atlas website: www.proteinatlas.org (Uhlen et al., 2010). DNAJC25 from 
the skin cell line A-431 is stained with antibody HPA019122 (green), microtubules are 
probed with anti-tubulin in red and the nucleus is stained with DAPI and shown in blue. 
The confocal image presented represents a single optical section of the cells. 
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      Appendix G: Protien selected by the project criteria before choosing five for further study. 
Gene Product Description TM Molecular Weight Orthologues Contender? Comments
PFA0125c erythrocyte binding antigen-181 2 181151 6 No Already characterised
PFA0265c conserved Plasmodium protein, unknown 
function 
2 16856 4 No No vivax, small
PFB0060w rifin 1 39920 0 No Already characterised
PFB0194w conserved Plasmodium protein, unknown 
function 
1 33415 4 Yes CANDIDATE
PFB0305c-a merozoite surface protein 5 2 30974 2 No Already characterised
PFC0581w co-chaperone p23, putative 1 32611 5 No wrong function
PFD0110w reticulocyte-binding protein homologue 1 1 357784 0 No Already characterised
PFD0295c apical sushi protein, ASP 1 85461 5 No Already characterised
PFD0930w 
CGI-141 protein homolog, putative 
3 15891 5 No too many TMs for a small protein
PFD1100c conserved Plasmodium protein, unknown 
function 
1 58351 5 No In gamaetocytes
PFD1150c reticulocyte binding protein homolog 4, Rh4 2 205850 0 No Already characterised
PFD1155w erythrocyte binding antigen-165 1 160266 6 No Already characterised
PFE1130w conserved protein, unknown function 8 55565 5 No too many TMs 
PFE1445c conserved Plasmodium protein, unknown 
function 
2 82906 5 No Poor expression
PFE1515w conserved Plasmodium membrane protein, 
unknown function 
11 173268 5 No Large with too many TMs (hard 
to work with)
PFF0615c 6-cysteine protein, putative 1 39435 5 ?
PFF0995c Merozoite surface protein 10, MSP10 2 61381 6 No Already characterised
MAL7P1.119 conserved Plasmodium protein, unknown 
function 
1 87880 6 No RALP1 (Gilberger lab), low 
expression
MAL7P1.176 erythrocyte binding antigen 175 1 174589 6 No Already characterised
MAL8P1.135 conserved Plasmodium membrane protein, 
unknown function 
9 122107 5 No too many TMs for a small protein
PF08_0104 rifin 2 37838 0 No Already characterised
PF08_0057 conserved Plasmodium protein, unknown 
function 
1 6159 5 No too small
PF08_0008 conserved Plasmodium protein, unknown 
function 
2 85251 5 No GAMA (Holder lab)
PFI1475w merozoite surface protein 1 precursor 1 195728 6 No Already characterised
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             Appendix G continued 
Gene Product Description TM Molecular Weight Orthologues Contender? Comments
PFI1560c conserved Plasmodium membrane protein, 
unknown function 
4 147394 6 No No longer appears in search 
results
PF10_0082 conserved Plasmodium membrane protein, 
unknown function 
10 154751 5 No too many TMs 
PF10_0166 conserved Plasmodium protein, unknown 
function 
1 36405 5 Yes low expression
PF10_0168-a golgi re-assembly stacking protein 2 1 68411 5 No Already characterised
PF10_0177b conserved Plasmodium protein, unknown 
function 
2 118420 5 Yes
PF10_0281 merozoite TRAP-like protein, MTRAP 1 58085 4 No Already characterised
PF10_0295 conserved Plasmodium protein, unknown 
function 
4 51393 5 Yes
PF10_0399 rifin 1 36463 0 No Already characterised
PF11_0035 Plasmodium exported protein, unknown 
function 
1 53488 0 No Its exported into rbc therefore not 
a role in invasion
PF11_0040 early transcribed membrane protein 11.2, 
etramp11.2 
2 10231 3 No Already characterised
PF11_0261 conserved Plasmodium protein, unknown 
function 
1 34708 5 Yes low expression
PF11_0286 conserved Plasmodium protein, unknown 
function 
1 51186 6 Yes low expression
PF11_0344 apical membrane antigen 1, AMA1 1 72042 5 No Already characterised
PF11_0381 subtilisin-like protease 2 1 154801 6 No Already characterised
PF11_0443 DNAJ protein, putative 2 39362 6 Yes CANDIDATE
PF11_0466 transporter, putative 6 99350 5 No
PFL0065w conserved Plasmodium protein, unknown 
function 
2 12268 2 No too small
PFL0870w Thrombospondin-related apical membrane 
protein 
1 41261 5 No Already characterised
PFL1945c early transcribed membrane protein 12, 
ETRAMP12 
2 11729 0 No Already characterised
PFL2205w conserved Plasmodium protein, unknown 
function 
2 57944 5 Yes very low expression
PFL2410w conserved Plasmodium membrane protein, 
unknown function 
9 121332 5 No too many TMs
PFL2510w chitinase 1 42787 6 No Already characterised
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                 Appendix G continued 
Gene Product Description TM Molecular Weight Orthologues Contender? Comments
MAL13P1.60 erythrocyte binding antigen-140 1 140597 6 No Already characterised
MAL13P1.49 conserved Plasmodium protein, unknown 
function 
2 16746 5 Yes Dubious expression data
MAL13P1.94 conserved Plasmodium membrane protein, 
unknown function 
4 22051 5 Yes CANDIDATE
PF13_0223 conserved protein, unknown function 1 12259 5 No too small
MAL13P1.206 Na+ -dependent Pi transporter, sodium-
dependent phosphate transporter 
10 75296 7 No Already characterised
PF13_0247 
transmission blocking target antigen precursor 
1 51487 5 No Already characterised
PF13_0265 conserved Plasmodium protein, unknown 
function 
1 133582 5 No Higher expression in rings than 
schizonts
MAL13P1.342 conserved Plasmodium protein, unknown 
function 
1 77875 5 Yes low expression
PF14_0016 early transcribed membrane protein 14.1, 
etramp14.1 
2 11427 0 No Already characterised
PF14_0211 Ctr copper transporter domain containing 
protein, putative 
4 18752 5 No wrong function
PF14_0369 copper transporter putative 2 27151 5 No wrong function
PF14_0372 conserved Plasmodium protein, unknown 
function 
3 220749 8 Yes low expression
PF14_0440 conserved Plasmodium membrane protein, 
unknown function 
8 143163 7 No too many TMs
PF14_0495 rhoptry neck protein 2 1 249490 5 No Already characterised
PF14_0572 conserved Plasmodium membrane protein, 
unknown function 
4 23055 5 Yes
PF14_0607 conserved Plasmodium membrane protein, 
unknown function 
7 127138 6 No too many TMs
PF14_0691 conserved Plasmodium membrane protein, 
unknown function 
7 64421 6 No too many TMs
PF14_0735 probable protein, unknown function 1 38449 0 Yes low expression
